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5-LO 
-/
-  
mouse 
5-LO double knock-out  mouse 
5-LO-3W  triple W 5-LO mutant 
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5xLB  5 x loading buffer 
A23187  calcium ionophore or ionomycin 
AA  arachidonic acid 
Ala  alanine, amino acid 
Alox-5  arachidonate 5-lipoxygenase 
ASA  aspirin, acetylic salicylic acid 
BWA4C  non chelating 5-LO inhibitor 
cAMP  cyclic adenosine monophosphate 
ChIP  chromatin immunoprecipitation assay 
CLP  coactosin-like protein 
CML  chronic myeloic leukemia 
COX  cyclooxygenase 
cPLA2  cytosolic phosphilipase A2 
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ERK 1/2   p42/44 MAP-kinase  or extracellular regulated kinase 
FLAP  5-lipoxygenase activating protein 
fMLP  N-formyl-methionyl-leucyl-phenylalanine 
GPCR  G-protein coupled receptor 
GPx  glutathione peroxidase 
HDAC  histone deacetylases 
HeLa  cervix carcinoma cell line 
HPLC  high pressure liquid chromatography 
iNOS  inducible nitric oxide synthase 
LPS  lipopolysaccharide 
LT  leukotriene 
LTB4  leukotriene B4 
LTC4 
LTD4 
LTE4 
leukotriene C4 
leukotriene D4 
leukotriene E4 
MAPEG  membrane-associated proteins in eicosanoid and glutathione metabo-
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MAPK  mitogen-activated protein kinase 
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NO-ASA 
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NO-aspirin, NO-acetylic salicylic acid 
non-steroidal antiinflammatory drug 
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OAG 
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phosphatidic acid 
PBS  phosphate buffered saline 
PC  phosphatidylcholine 
PE  phosphatidylethanolamine 
PG  prostaglandin 
PGC buffer  PBS containing glucose and CaCl2 
PGE2  prostaglandin E2 
PIP  posphatidylinositol-bisphosphate 
PMNL  polymorphonuclear leukocytes 
PMSF  phenylmethanesulfonylfluoride 
PPARα  peroxisome proliferator-activated receptor 
PS  phosphatidylserine 
ROS 
S100 
reactive oxygen species 
100.000xg supernatant 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ssi  sulindac sulfide 
Sso   sulindac sulfone 
STI  soybean-trypsin-inhibitor 
Sul  sulindac Abbreviations 
 
TFA  trifluoroacetic acid 
TGF-ß  transforming growth factor beta 
Tris  tris(hydroxymethyl)aminomethane 
Trp  tryptophan, aromatic amino acid 
ZD-2138  non-redox type 5-LO inhibitor 
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1  INTRODUCTION 
1.1  Non-steroidal anti-inflammatory drugs 
1.1.1 Classification of NSAIDs 
Non-steroidal  anti-inflammatory  drugs ( NSAIDs)  display  a  wide  spread  group  of 
drugs used to treat a variety of diseases related to inflammatory and painful proc-
esses in acute and chronic conditions. Several compounds are on today’s drug mar-
ket differing in their therapeutic potential and mainly in their adverse side effect pro-
files. The origin of anti-inflammatory drugs was found in the salicylates, a familly of 
carboxylic acids, discovered in the middle of the 19
th century were aspirin® becomes 
the progenitor of the NSAIDs. Followed by the development of phenylbutazone and 
later  indomethacin,  more  drugs  reached  the  market  and  ibuprofen  was  the  first 
NSAID available without prescription. Classification of the drugs is typically carried 
out by means of their chemical structures and properties. Today, therefore still the 
carboxylic acids exist, including subgroups like the salicylates, the fenamates, the 
indole/indene actetates, the phenylacetates and the propionates. Another group dis-
play the oxicames with piroxicam and meloxicam as prominent agents (refer to Fig.1) 
[1]. High efforts were made to gain more knowledge about the molecular mecha-
nisms of NSAIDs and in may 1999, the COX-2 selective inhibitor rofecoxib, was re-
leased  to  the  market  displaying  the  first  drug  of  a  novel  group  of  NSAIDs.  The 
coxibes, which are indicated for treatment of rheumatoid arthritis, osteo-arthritis and 
other arthritic diseases, dental and surgical pain in postoperative seetings  and acute 
injuries were developed [2]. Structural variations of coxibs followed, but unfortunately 
rofecoxib had to be withdrawn by Merck from the market only a short period later due 
to severe cardiovascular side effects [3].  
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Fig.1: Classification of NSAIDs due to their structural properties according to Rainsford et al. 2007.  
 
1.1.2 Chemoprevention by the use of NSAIDs 
Since several years, it is known, that a regular intake of NSAIDs accounts for a bene-
ficial prognosis related to a variety of cancer indispositions by interference with the 
arachidonic acid (AA) pathway. These class of drugs are shown to reduce the risk for 
certain  cancer  types  as  their  target,  the  prostaglandin  (PG)  producing  cyclooxy-
genases (COX), are upregulated and PG biosynthesis is increased in the tumor mi-
croenvironment [4]. As promotion of cancer progression is described in literature by 
the regulation of tumor-associated angiogenesis, modulation of the immune system, 
the regulation of cell migration and cell invasion and the inhibition of apoptosis trig-
gered by the COX-2 produced PG, inhibition of both COX-1 and COX-2 was a possi-
ble strategy for chemopreventive therapies [5]. An increasing body of evidence linked 
the AA metabolism pathways and PG biosynthesis, in particularly elevated COX-2 
levels, to the promotion and progression of many different cancers, such as lung, 
breast, colorectal and bladder cancer [6-9]. There is growing experimental and clini-
cal evidence indicating that regular use of aspirin® and NSAIDs reduced the risk of 
developing cancer, in particularly of colon cancer [10]. Since the 1970s work in sev-
eral disciplines increasingly has suggested that aspirin® or other NSAIDs may re-
duce the occurence or progression of colorectal cancers and polyps [11]. In literature, Introduction 
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miscellaneous reports are found about colon cancer and its prevention by the use of 
NSAIDSs due to COX inhibition [12-14]. Thus, with the current therapy, progressive 
results are achieved but, like most medications, NSAIDs are not risk-free. Dyspepsia, 
gastritis, peptic ulcer, gastrointestinal bleeding, hemorrhagic stroke and perforation of 
gastroduodenal ulcers are thought to be responsible for an imbalance in the mainte-
nance of the intestinal mucosa due to unselective COX inhibition as COX-1 was pre-
sumed to be the cause for the undesirable effects [15-18]. In 1991, COX-2, an iso-
form  expressed  in  inflamed  tissues  by  induction  of  various  factors  like  cytokines, 
tumor promotors and inflammatory stimuli, was discovered and hypothesized to be 
only  present  under  inflammatory  and  painful  conditions  [19-21].  Following  studies 
indicated that inducible COX-2 was largely responsible for PG production associated 
with inflammation in contrast to the housekeeping gene COX-1, whose inhibition ap-
peared to cause more gastrointestinal damage [22, 23]. This provided the rationale 
for the development of selective COX-2 inhibitors. In a relatively short period several 
substances entered the market in order to circumvent the mentioned side effects. 
Rofecoxib  (Vioxx®),  celexocib  (Celebrex  ®), valdecoxib  (Bextra  ®)  and  parecoxib 
display a range of agents with chemically different structures of COX-2 selective in-
hibitors. Etoricoxib (Arcoxia®) failed to enter the US market because of refused ap-
proval by the FDA in 2007 [20, 24, 25]. Etoricoxib was approved on the german mar-
ket in 2004 [26]. Unfortunately, rofecoxib had to be withdrawn from the market due to 
observed  elevated  cardiovascular  risks  [27-29].  Experiments  and  clinical  studies 
showed  decreased  vascular  prostacyclin  production,  which  is  a  potent  platelet-
aggregation  inhibitor  synthesized  by  human  arteriell  and  venous  tissues  from  AA 
[30]. Despite COX-2 inhibitor mediated decreased prostacyclin production there was 
no concomittant change in thromboxane (TX) levels, a potent platelet-aggregating 
agent synthesized within the platelets. Inhibition of prostacyclin activity can lead to a 
predisposition state of thrombosis, hypertension and artherosclerosis. Human studies 
revealed, that the mentioned cardiovascular events due to decreased prostacyclin 
levels maybe diminished under coxib therapy [25, 31-35]. In pathophysiological con-
ditions, COX-derived vasoconstrictors such as TXA2 may act as mediators of myo-
cardial infarction and thrombotic strocke [35]. The role of COX-2 evoked in tumori-
genesis in the 1990s. An association between regular consumption of NSAIDs and 
cancer was made. The reason for the observed effect of reduced incidence of colon 
cancer was not entirely clear, but it was argued that the protection was exerted via Introduction 
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the COX-2 pathway. Mainly, aspirin® and sulindac were observed to act beneficial on 
tumor  incidence  [23,  36].  Further  elucidation  of  the  underlying  chemopreventive 
mechanisms by the use of NSAIDs pointed out that not only COX-derived AA me-
tabolites are involved but products formed via the lipoxygenase (LO) pathway named 
leukotrienes (LTs). Increasing evidence suggested moreover either intervention with 
the 5-lipoxygenase (5-LO) or LT antagonism. More importantly, a few studies in ani-
mal carcinogenesis models showed that inhibition of the 5-LO pathway also may in-
hibit carcinogenesis.[37]. Investigations made over the past years showed 5-LO in-
hibitors  to  act  chemopreventively  in  carcinogenesis  of  lung,  prostate,  breast,  skin 
and, extensively studied, in colon cancer and as well in both acute and chronic leu-
kemia [38]. As the AA cascade provides two distinct pathways for intervention, target-
ing the major enzymes producing metabolites, either PGs or LTs, in a dual manner 
seems to be a reasonable basic approach as COX and 5-LO pathway  appear to act 
synergistically in the regulation of cell proliferation and neoangiogenesis  and all the 
enzymatically AA-derived metabolites are blocked [39]. Licofelone, former known as 
ML-3000, is the most prominent candidate in an advanced phase of clinical develop-
ment, but investigations were currently interrupted [40]. However, molecular mecha-
nisms responsible for chemopreventive properties of NSAIDs, which are still matter of 
intensive research, are needed to elucidate the effect more detailed. This would con-
tribute  to  the  development  of further  strategies  for  inhibitors  of  involved  enzymes 
lacking typical severe side effects.  
 
1.1.3 Prostaglandin biosynthesis 
PGs are biologically active lipid mediators which, together with  LT’s, prostacyclins 
and thromboxanes belong to the group of eicosanoids. PGs were discovered early in 
the 1930’s and continuing research led to isolation and characterisation of the bio-
logically  active  endoperoxide  intermediates  PGE2,  PGH2,  thromboxane  A2  (TXA2) 
and prostacyclin by Bergström, Samuelsson and Vane [32, 41]. All mediators consti-
tute fatty acids with 20 carbon atoms and include a cyclopentane ring, except TXA2. 
Substitutions in this ring confer differences in the major PG groups which are classi-
fied by letters [42]. PGs are involved in a variety of inflammatory conditions; in par-
ticularly in inflammatory conditions of the skin, arthritis, asthma and certain types of 
cancer [43-45]. They are derived from the precursor AA released from phospholipids Introduction 
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from cellular membranes by enzymes of the phospholipase A2 superfamily upon acti-
vation of various inflammatory stimuli via G-protein coupled receptors [46]. All cells 
with exception of red blood cells show the capability to synthesize PGs. Previously 
mentioned, COX enzymes were discovered to exist in two different isosforms. Each 
isoform catalyzes two reactions and posseses two different activities. The cyclooxy-
genase activity is used to catalyze the addition of molecular oxygen into the substrate 
AA resulting in the endperoxide intermediate compound prostaglandin G2 (PGG2). 
Secondly, a peroxidase activity of the COX enzyme catalyzes the reaction of conver-
sion of PGG2 to PGH2. PGH2 is an unstable intermediate for all further steps in the 
COX pathway which are catalyzed by a number of cell-specific isomerases and lead 
to the formation of prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin 
F2α(PGF2α), prostaglandin I2 (PGI2 = prostacyclin) and TXA2 [47, 48].  
 
Fig. 2: COX pathway with main intermediates and products catalyzed by COX and its isomerases 
including chemical structures. According to Hyde et al. 2009.  Introduction 
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1.1.4 Sulindac - a well established NSAID 
The following section provides an overview about the pharmakodynamic and phar-
makokinetic properties of the drug sulindac ending with a short description of invest-
gations on gene regulatory functions related to the drug’s chemopreventive activity. 
Pharmakodynamics 
Sulindac  is  a  well-characterized  compound and  can  be  classified  to  the  group  of 
NSAIDs. So far, the mode of action for the active metabolite of sulindac, sulindac sul-
fide (Ssi) comprises inhibition of PG biosynthesis by interfering with both COX en-
zymes with only a slight preference for COX-1 [49]. In several countries sulindac is 
approved for the treatment of painful and inflammatory conditions (e.g. USA, spain, 
france)  as  it  has  anti-inflammatory,  analgesic  and  antipyretic  properties.  Studies 
evoke participation of sulindac in artherosclerotic processes as experiments in Apo E 
-/- mice demonstrated reduced neointima formation under sulindac therapy after in-
jury in both hyperlipidemic and normolipidemic mouse model [50]. Furthermore, a 
role of sulindac in the genesis of Alzheimer’s disease is proposed as sulindac may 
modifiy γ-secretase, a membrane-bound multi protein complex catalyzing the final cut 
of  the  Alzheimers’s  disease  related  amyloid  precursor  protein  [51].  Among  these 
properties, sulindac is an extensively studied low-ulcerogenic drug with chemopre-
ventive activities. In 1983, observations noting regression of large bowel polyps in 
patients with Gardner’s syndrome (familial colonic adenomas, bone tumors and soft 
tissues) treated by the NSAID sulindac were made [52]. Additionally, long term effec-
tiveness  of  sulindac  in  colorectal  adenomas  was  determined  in  patients  suffering 
from familial adenomatous polyposis (FAP) and long term use of sulindacseems to 
effectively reduce dysplasia grade of colorectal adenoma [53]. Further, Ssi was ob-
served to induce cell cycle arrest and apoptosis in mammalian cell lines and targeting 
of cell cycle check-points is presumed in premalignant cells [54, 55]. Recent work 
reported that the inhibition of colon tumor cell growth by Ssi is associated with phos-
phodiesterase-5 (PDE) inhibition in breast cancer [56]. These effects seems to be 
concomitant with suppression of the ß-catenin signalling in prostate cancer cells [57]. 
The  anti-inflammatory  action  of  NSAIDs  is  mainly  related  to  inhibition  of  COX-2 
whereas unwanted effects are due largely to their inhibition of COX-1 [58]. Interest-
ingly, the prevention of colorectal polyps in humans by sulindac materializes by inter-Introduction 
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acting with COX-independent targets [59]. However, mechanisms behind the chemo-
preventive action of this drug still remain unclear and need to be further elucidated.  
Pharmakokinetics 
Sulindac is an indene acetic analogue of the NSAID indomethacin [60]. As addressed 
before, the prodrug sulindac is devoid of COX inhibition. After oral administaton, 90% 
of the drug is absorbed and a two-step biotransformation follows. First, sulindac is 
oxidized to the metabolite sulindac sulfone, which exerts no COX inhibitory activity, 
and is then reversibly reduced to the active metabolite sulindac sulfide (Ssi). Ssi has 
a selective COX-1 inhibitory activity [49]. Plasma half life of sulindac sulfone is about 
7 hrs while Ssi has a half life of 18 hrs. Plasma protein binding of Ssi occurs up to 95 
% [60]. The usual dose of sulindac is to 200 mg – 400 mg bid (bis intake daily, treat-
ment of rheumatoid arthritis)[59].  
 
          sulindac          sulindac sulfone          sulindac sulfide 
Fig. 3: Metabolism of sulindac to the active metabolite sulindac sulfide via the sulindac csulfone, an 
inactive metabolite. 
Regulation of gene expression by Ssi  
Lastly,  as  the  chemopreventive  effects  of  NSAIDs  seem  to  be  partly  COX-
independent, it was demonstrated that NSAIDs alter the gene expression patterns 
which are involved in cancer development, such as NSAID-activated gene-1 (NAG-
1),  a  critical  gene  regulated  by a  number  of  COX-inhibitors  and  chemopreventive 
agents [61]. Approaches to elucidate Ssi’s chemopreventive molecular mechanisms 
were undertaken and it was determined that Ssi induces the NAG-1, a gene belong-Introduction 
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ing to the transforming growth factor-beta (TGF-ß) superfamily, resulting in tumor cell 
growth suppression of ovarian cancer cells [62].  
 
1.1.5  NO-releasing NSAIDs 
Nitric  oxide-donating  NSAIDs  (NO-NSAIDs)  constitute  conventional  NSAIDs  cova-
lently  attached to  a  NO-releasing  moiety,  often  linked  via  a  spacer  molecule.  As 
NSAIDs damage the gastrointestinal mucosa due to inhibition of cytoprotective PGs 
the strategy of an NSAID locally providing NO was born as nitric oxide (NO) can 
mimic the PG action. NO-NSAIDs indeed could fulfill protection of the gastric mucosa 
in contrast to their given parent NSAIDs [63-65]. So far, several molecules with NO-
releasing moietys have been synthesized and are currently under investigations in 
different scopes [66]. NO-donating drugs are promising agents for treatment of car-
diovascular  diseases,  asthma,  hypoxic-ischemic  brain  injury,  glaucoma  and  Alz-
heimer’s disease which is underscored by existing preclinical models and clinical tri-
als [67-71]. The most prominent NO-releasing drug displays NO-aspirin (NO-ASA) 
which provides the strongest evidence that NO is not responsible for the cytoprotec-
tive mechanism of NO-releasing drugs in the stomach as pharmacokinetic studies 
have shown that NO-ASA traverses the stomach structurally intact [72, 73]. Further-
more, potent esophageal protection was recently shown by NO-ASA which seems to 
be due to induced enhancement of esophageal microcirculation and inhibition of ex-
pression and release of proinflammatory cytokines [74]. Nevertheless, a lot of other 
compounds  were  tested.  NO-naproxen  (naproxcinod)    is  one  candidate,  which 
reached the market so far among the current investigated NO-releasing drugs and an 
improved safety on the gastrointestinal mucosa was assessed in human studies [75]. 
Further evaluation led to a beneficial impact of naproxcionod in osteoarthritis of the 
knee in clinical trials [76]. NO-NSAIDs are  an emerging class of compounds with 
chemopreventive  properties  in  various  cancers  demonstrated  by  either  pre-clinical 
models including cell culture models or animal tumor models. NO-ASA, NO-sulindac 
and NO-ibuprofen were shown to reduce the growth of cultured HT-29 human colon 
adenocarcinoma cells much more potently than their corresponding NSAIDs provid-
ing evidence for anticancer effects of NO-donating drugs [77-80]. Even though the 
mechanisms  behind  these  effects  have  been  pursued  from different  perspectives, 
their complex mode of action possibly involves cell kinetic effects, effects on cell sig-Introduction 
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nalling pathways and on detoxifying enzymes [66]. Mechanistic studies on NO-ASA 
report a large array of molecular targets such as involvement of mitogen-activated 
protein kinases (MAPK) signalling, inhibiton of expression and catalytic activity of in-
ducible nitric-oxide synthase (iNOS) and inhibition of the transcriptional factor NF-kB 
and  interference  with  drug  metabolizing  enzymes  [81-84].  COX-2  effects  of  NO-
NSAIDs are still unclear. However, despite these wide spectra of molecular targets, 
the defined mechanisms of NO-releasing NSAIDs are still a matter of research. 
 
 
Fig. 4: Chemical structures of prominent NO-releasing drugs  Introduction   
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1.2  Leukotrienes 
In 1976, certain lipid mediators converted from AA by the catalytic activity of the 5-LO 
enzyme were discovered and named leukotrienes (LTs) [85]. LTs belong to the family 
of eicosanoids [86]. The following section gives an overview about their biological 
role in the pathogenesis of different types of diseases, about the restricted cellular LT 
biosynthesis and about the major enzyme primarily involved in the catalysis of the AA 
cascade, the 5-LO. Following a detailed description of structure and function of the 5-
LO protein, the section ends with a summary of the current existing inhibitor com-
pounds of 5-LO. 
 
1.2.1 Leukotrienes – key players in inflammation and immune reactions 
Physiological role of leukotrienes 
The word leukotriene comprises „leuko“, from white blood cells and „triene“ meaning 
three conjugated double bonds. LTs derive from the metabolism of AA, a twenty car-
bon  polyunsaturated  fatty  acid  and  constitute  a  subgroup  of  potent  inflammatory, 
oxygenated mediators [87] within the field of eicosanoids  with several physiological 
functions in a receptor-mediated fashion [88]. The primary sources of LTs are mature 
leukocytes  but  the  pattern  of  lipid  mediators  produced  varies  within  different  cell 
types. In humans, leukotriene B4 (LTB4) is produced in neutrophils, dendritic cells and 
B-lymphocytes whereas leukotriene C4 (LTC4) is mainly found in eosinophils and hu-
man  mast  cells.  Monocytes and  macrophages  are  found  to  form  more  LTB4  than 
LTC4  [89].  Leukocytes  release  LTs  displaying  hormone-analogue  properties  and 
show  local  actions  which  result  in  paracrine  communication  affecting  neighboring 
cells. However, LTs  can show autocrine actions as well when they immediately af-
fect  the  source  cell they  derive  from  [89].  Target  cells  of  LTs  can  be  leukocytes, 
epithelial cells or smooth muscle cells. The first step in LT biosynthesis using AA as 
subtrate mediated by the enzyme 5-LO,  generates the unstable [90]  epoxid leukot-
riene A4 (LTA4) as major product [91]. Further transformation by LTA4 hydrolase pro-
duces LTB4 which can be processed to the cysteinyl-leukotrienes (cys LTs) C 4, D4 
and E4, also formerly known as slow-reacting substances of anaphylaxis [92]. When 
inflammation is initiated upon stimulation by stress or infection, LTB4 known as a po-
tent chemotactic agent, stimulates cell adhesion of leukocytes to the endothelial cell Introduction 
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surface [93] and is responsible for the recruitment of further leukocytes or neutrophils 
displaying several important functions for the ongoing process of inflammation like 
additional  LTB4  synthesis  by  the  recruited  cells  [89].  In  consequence,  increased 
phagocytosis of neutrophils and macrophages occurs in addition to neutrophil de-
granulation [94], liberation of reactive oxygene species and lysosomal enzymes [95] 
and  aggregation [96].  Taken  together,  LTB4-driven  leukocyte recruitment  from the 
bloodstream into tissues causes a dramatic increase in tissue cellularity, an important 
factor of inflammation [89]. LTB4 was also found to activate the peroxisome prolifera-
tor-activated receptor α (PPAR α), one of the key players in carbohydrate, lipid and 
protein metabolism [89, 97]. Beside  LTB4, also the cys-LTs  LTC4,  LTD4 and  LTE4 
possess  biological  activities.  Their  actions  lead  to  contradiction  of  airway  smooth 
muscle cells resulting in bronchioconstriction [98].  Further effects promoted by cys-
LTs constitute the induction of mucus secretion by bronchial mucosa [99], constric-
tion of both venous and arterial vascular smooth muscle cells, thus representing a 
regulatory function of cys-LTs in vasoconstriction [100, 101]. The involvement of cys-
LTs in allergic reactions is due to the mediated vascular penetration of plasma into 
tissues while affecting endothelial cells and resulting in edema [102, 103]. Another 
contribution to inflammation by cys-LTs is the attraction of other blood cells like leu-
kocytes, especially monocytes and eosinophils [89]. All LT effects are mediated by 
the interaction with specific receptors. The LT receptors can be classified into the 
group of G-protein coupled receptors (GPCRs) mediating their downstream signaling 
either  via  the  activation  of G i  proteins  resulting  in  decreased  formation  of  cyclic 
adenosine-monophopshat (cAMP) or via  Gq proteins resulting in the activation of 
phospholipase C (PLC) [89, 104]. These triggers promote downstream signalling by 
means of kinase activation, involved in cellular and tissue responses [92]. LTB4 ad-
ministers its functions by two receptor types, including the high affinity BLT1 (maximal 
effect at 1-100 nM) and the low affinity BLT2 receptor modulated by concentrations of 
0.1 - 1.0 µM [92, 105, 106]. For the cys-LTs two G-protein coupled receptors could 
also be identified which are named cys-LT1 and cys-LT2. Differences between cys-LT 
receptors occur in ligand affinities to LTC4, LTD4 and LTE4 and the type of G protein 
recruited (Gq) and by the ability of the cys-LT receptors to modulate cellular Ca
2+-
signalling [89].  
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Pathophysiological processes associated  with enhanced leukotriene 
formation 
It is well known that lipid mediators such as LTs participate in a variety of diseases 
related to inflammation and allergic processes. It became clear that bronchial asthma 
is one of the major LT-driven disorders. As mainly cys-LTs were discovered playing a 
regulatory role in the pathogenesis of asthma enforcing airway hyperreactivity and 
the frequency of bronchospasms, the focus was set on the development of anti-LT 
drugs, particularly on cys-LT antagonists [92, 107, 108]. Currently, the cys-LT1 recep-
tor antagonists montelukast, zafirlukast and pranulukast are approved for the treat-
ment of asthma whereas zileuton was the first direct inhibitor of the 5-LO enzyme 
which reached the market. Although therapy focuses on cys-LTs, recent studies pro-
pose LTB4 to exert an important regulatory role in models of asthma [109]. Other dis-
eases where LTs are involved are rheumatoid arthritis, allergic rhinitis, psoriasis and 
inflammatory bowel disease [110, 111]. Ongoing research suggested a role of LTs in 
the pathogenesis of cardiovascular disorders [92]. The pathogenesis of artheroscle-
rosis,  stroke,  myocardial  infarction  and  aortic  aneurisms  is  considered to  be  con-
nected to significantly elevated expression of the participating LT-forming enzymes 
and increased LT formation was correlated with the mentioned diseases [112-115]. 
Animal models and even human studies support this hypothesis [116]. Genetic stud-
ies on a possible link between the LT / 5-LO pathway and cardiovascular diseases in 
knockout  mice  revealed  that  5-LO  and  other  enzymes  producing  LTs  are  crucial 
players in cardiovascular diseases. Subsequently,  human population genetic studies 
associated enyzmes involved in LT biosynthesis with cardiovascular disorders. Stud-
ies  have  also  identified  variants  of  the  5-LO  gene  promotor  and  the  five-
lipoxygenase-activating  protein  (FLAP)  as  risk  factors    in  human  artherosclerosis 
[117-124]. Recent reports provide evidence that excess amounts of LTs could con-
tribute to impaired fracture healing and a 5-LO 
-/
-  mouse model showed enhanced 
and accelerated healing concomitantly by decreased  LT levels [125]. Moreover, a 
role of eicosanoids, especially 5-LO products, in the formation of amyloid beta pro-
tein, a major player in Alzheimer’s disease was reported [126]. A role of LT’s in the 
pathogenesis of renal disease and an immunoregulatory role in kidney transplanta-
tion is currently debated [127]. Another novel indication of anti-LT therapy could be 
demonstrated with the treatment of osteoporosis as certain 5-LO metabolites seem to Introduction 
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modify bone resorbing osteoclasts, but show disadvantages on the bone providing 
osteoblasts [110].  
                                    
Fig.5: Summary of physiological and pathophysiological effects of leukotrienes. 
 
1.2.2 The role of 5-lipoxygenase in cancer and tumorigenesis 
An  increasing  body of  evidence  suggest a participation producing enzymes  in  tu-
morigenesis and the role of 5-LO and its metabolites, mainly LTB4, are widely dis-
cussed to participate in the neoplastic progression in certain types of cancer, as was 
found in animal models [37, 38, 128, 129]. In 2002, data from lung tumors in mice 
suggested a role of 5-LO, since the 5-LO inhibitior zileuton and the FLAP inhibitor 
MK-886 were able to reduce tumor multiplicity in mice [130]. A variety of different ma-
lignant tumors are thought to be affected in their development already during the ear-
liest  stage  of  carcinogenesis  by  5-LO  products,  namely  prostate,  pancreas  and 
breast cancer [110, 131, 132]. The 5-LO metabolite LTB4 seems to be involved in 
murine melanoma growth [133]. Also, 5-LO is proposed to play a major role in pro-
moting cell proliferation and therefore tumorigenesis in human brain cancer [134]. 
Current investigations revealed evidence indicating that 5-LO and  LT biosynthesis Introduction 
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are related to malignant diseases not only because of 5-LO overexpression in pri-
mary tumor cells and tissues, but also because the addition of 5-LO products to cul-
tured cells led to increased proliferation, cell viability and activation of antiapoptotic 
signalling  pathways  [135,  136].  Notably,  enzymes  related  to  AA  metabolism  and 
linked to 5-LO binding were shown to be overexpressed [137]. Involvement of 5-LO 
and LTs in the growth and viability of malignant cells were documented first with an 
antisense approach [138]. Further studies using si-RNA approaches revealed a role 
for the 5-LO product 5-oxo-(6E, 8Z, 11Z, 14Z)-6, 8, 11, 14-eicosatetraenoic acid (5-
oxo-ETE) as reduced 5-LO expression significantly impaired prostate cancer cell vi-
ability and  LT receptor silencing was capable to suppress growth of human colon 
cancer and neuroblastoma cells [139-141]. Very recently, the 5-LO gene (Alox5) was 
identified to be crucial in leukemia stem cell proliferation and studies with 5-LO 
-/
- 
mice  underline  previous  findings by  explaining impaired  chronic myeloid  leukemia 
(CML)  cell  proliferation  evolved  by  5-LO  loss  [142].  Additionally,  the  Alox5  gene 
seems  to  display  a  target  structure  in  the  specific  treatment  of  tyrosine-kinase-
inhibitor-resistant CML as alox5-deficient stem cells show defective ability to develop 
CML and the approved 5-LO inhibitor zileuton as well as the tyrosine-kinase-inhibitor 
imatinib led to improved survival of CML-affected mice [143, 144].  
 
1.2.3 Cellular leukotriene biosynthesis 
5-LO as the main enzyme responsible for LT formation catalyzes the first two steps in 
LT biosynthesis and participates in the first enzymatic reaction by its oxygenase ac-
tivity. It metabolizes AA by abstraction of one hydrogen atom at C-7. After oxygena-
tion at C-5 an intermediate product termed 5-hydroxyperoxyeicosatetraeonic acid (5-
HpETE) is formed [145, 146]. As 5-LO possesses another enyzmatic activity, namely 
the  leukotriene  A4  synthase  activity,  the  second  metabolic reaction  composes  the 
abstraction of a hydrogen bond at C-10 and dehydration lead to the allylic epoxide 
(conjugated  triene  C-5,6  epoxide)  leukotriene A4  (LTA4) [147-149].  5-HpETE  as  a 
catalytic product of 5-LO can alternatively rapidly be reduced to the corresponding 
alcohol  5-hydroxyeicosatetraenoic  acid  (5-HETE).  Intracellular  conditions  influence 
the  pattern  of  the  produced  metabolites.  Cellular  glutathione peroxidases  (GP-x1) 
play a decisive role for the reduction of 5-HpETE but also a pseudoperoxidase activ-
ity of 5-LO seems to be involved [150]. Subsequently, 5-HETE can be oxidized by 5-Introduction 
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hydroxy-eicosanoid dehydrogenase which is the case in the presence of oxidative 
stress and reactive oxygen species (ROS) resulting in the synthesis of 5-oxo-ETE. 
This intermediate displays a precursor structure for several additional eicosanoids via 
enzymatic linked catalysis or nonenzymatic pathways [151-153]. The unstable LTA4 
intermediate can be enymatically hydrolyzed by LTA4-hydrolase leading to the dihy-
droxyacid LTB4 but this reaction is cell type-specific and depends on the enzymatic 
equipment of the cell. Furthermore, the conversion of LTA4 to the LTC4 is catalyzed 
by leukotriene C4 synthase (LTC4 synthase) or LTC4 synthase isoenzymes microso-
mal glutathione S transferase typ 2 (MGST2) and type 3 (MGST3) [110, 146]. Cys-
LTs,  such  as  LTD4  are  produced  by  a  subsequent  enzymatic  elimination  of  the 
gamma glutamoyl portion of glutathione of LTC4. Cleavage of the amino aicd residue 
glycine in LTD4 finally yields LTE4 [92].  
 
Fig. 6: Cellular leukotriene biosynthesis based on the conversion of from cell membrane released AA. 
5-LO catalyzes in a dioxygenation reaction the formation of 5-HpETE and LTA4. 5-HpETE is reduced 
to 5-HETE and LTA4 is either converted by LTA4 hydrolase leading to LTB4 or by LTC4 synthase to the 
cys-LTs LTC4, LTD4 and LTE4. Figure according to Radmark et al., 2007. Introduction 
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1.2.4  The 5-lipoxygenase protein – master enzyme in leukotriene formation 
The expression pattern of 5-LO protein varies between different cell types and the 
capability of 5-LO protein expression was found to be restricted to cells with myeloid 
origin underlining a pivotal role of 5-LO during cell maturation. 5-LO is mainly ex-
pressed  in  leukocytes  which  is  in  line  with  its  discussed  functions  in  immune  re-
sponses. Also 5-LO is found in granulocytes, macrophages, mast cells, dendritic cells 
and B-lymphocytes whereas platelets, endothelial cells and T-cells obviously do not 
express 5-LO [145]. In contrast, a recent publication points out T-cells as a source of 
5-LO  expressing  cells  [154].  Further  observations  revealed  an  increase  in 5 -LO 
mRNA and protein level in differentiated myeloid cells compared to undifferentiated 
cells using differentiation inducers like dimethylsulfoxide (DMSO), retinoic acid, cal-
citriol and transforming growth factor ß (TGF-ß) [155]. During cell differentiation in the 
bone marrow the increase in 5-LO mRNA is thought to reflect the upregulation of 5-
LO expression. This is also the case for granulocyte-macrophage colony-stimulating 
factor (GM-CSF), which is able to augment 5-LO expression in human granulocytes. 
Further, high levels of 5-LO mRNA occur in peripheral blood leukocytes from asth-
matics as well as in macrophage-derived foam cells in the human vessel wall, which 
has been linked to the involvement of  LT biosynthesis in cardiovascular diseases 
[112, 156]. It has additionally been reported that in lung macrophages accelerated 
levels of 5-LO protein were examined during the immigration of blood monocytes into 
tissues affiliated with their differentiation into macrophages [157, 158].  
 
1.2.5 Related lipoxygenases 
LOs form a familiy of lipid peroxidizing enzymes found in animals as well as in plants.  
So far, 18 different mammalian LO sequences have been published [159]. Apart from 
5-LO, two other subfamilies of mammalian LOs exist: 12- and 15-LO, which exert 
functional lipid mediators with distinct profiles of action [159, 160]. The complex array 
of formed metabolites gained by these LOs are tissue- and species- specific and can 
result in pro- and anti-inflammatory effects [161]. One lipid mediator derived from the 
AA cascade by catalytic activity of 12-Lipoxygenase (12-LO) via stereospecific oxy-
gen insertion to AA is 12-(S)-hydroperoxyeicosatetraenoic acid (12-HpETE) which is 
rapidly  reduced  to  12-(S)-hydroxyeicosatetraenoicacid  (12-HETE)  seemingly  func-Introduction 
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tioning as a stop signal for inflammatory processes [162].12-LO isoformes are dis-
covered in platelets (platelet-12-LO), in leukyocytes and in the epidermis and are of-
ten termed after the cells they were first identified in [163]. 12-LO is widely discussed 
as a potential pathogenic enzyme which is thought to be involved in a great number 
of  diseases,  namely  diabetes,  cardiovascular  dysfunctions  such  as  atherogenesis 
and angiogenesis, hypertension, renal disorders, sickness of the central nervous sys-
tems, circumstantial Alzheimer’s and Parkinson’s disease [164]. Other recent publi-
cations claim a prominent role of 12-LO as a potential new therapeutic target in the 
regulation of epithelial ovarian cancer cells since decreased cell growth and survival 
was observed after silencing 12-LO gene [160]. Additionally, a possibility of 12-LO 
serving as a unique marker and target in prostate cancer stem cells raised lately 
[165]. 15-hydroxyeicosatetraenoic acid (15-HETE) represents another lipid signalling 
molecule derived from the subgroup of LOs which is assumed to exhibit opposed 
properties than the 12-LO metabolite 12-HETE [161]. Antiatherogenic characteristics 
by inhibition of oxidative stress are attributed to 15-LO and studies in rabbits revealed 
that overexpression of 15-LO protein showed protective mechanisms against arthe-
rosclerosis. One isoform, 15-LO-1 was thought to play a role in the oxidative modifi-
cation of low-density lipoproteins and foam cell formation and a proatherogenic role 
in mice models was established [166]. Further, 15-LO-1 seemed to display a key 
component  in  the  cell  proliferation  process  in  epithelial  cancer  cells,  in  particular 
prostate, colorectal and breast cancer [167]. In 2008, another pathophysiological role 
for 15-LO-1 was proposed argueing for an involvement of 15-LO-1 in allergic airway 
inflammation such as asthma. These findings were supported by 15-LO-1 deficient 
mice models and underline a putative therapeutic implication of 15-LO-1 inhibitors in 
the treatment in airway inflammation [168]. In the same year, anti-carcinogenic ef-
fects, reflected in enhanced apoptosis and a decreased proliferation rate were re-
ported and a role for 15-LO-1 in survival of colorectal cancer cells was demonstrated 
[169]. As 12- and 15-LO enzymes are expressed in a variety of tissues in the human 
body and their metabolites contribute to certain diseases, the development of iso-
form-specific inhibitors will be of great interest as these enzymes represent promising 
drug targets [164]. 15-LO-2, mainly expressed in normal human prostate epithelial 
cancer cells, additionally, has a physiologic tumor suppressor function [170]. 
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1.2.6  The 5-lipoxygenase gene and promoter region 
Discovered in 1989, the 5-LO gene consists of 14 exons divided by 13 introns with a 
total length of 79 kilobases (kb). Exons 4 - 8 comprise five conserved histidin resi-
dues and six more conserved acidic and basic residues followed by the latter region. 
This region is supposed to be involved in the iron binding and a short sequence dis-
playing homology to the interface binding domain of lipases is located in this region. 
Therefore, it was concluded that AA binding occurs in this region and it is encoded in 
exon 8 and part of exon 9 [171]. The putative promotor region was characterized in 
1990 and is located 5.9 kb upstream from the ATG transcriptional initiation site. It is 
lacking the typical TATA and CCAAT boxes near the transcription initiation site and 
thus shows properties of a housekeeping gene [171-173]. Sp1, a wide spread tran-
scriptional activating factor, is thought to be able to bind to a sequence of five from 
eight  existing  repeated  GC-boxes  designated  by  Hoshiko  and  co-workers  as  the 
transcription factor binding region. The transcriptional factor Egr1 is also recognized 
at this binding site [173, 174]. These GC-rich sequences were discovered as essen-
tial regions in the 5-LO promotor for expression of native 5-LO in Mono-Mac-6 (MM6) 
cells and also a novel Sp1 binding site 20 base pairs upstream from the transcrip-
tional initiation site was detected [175]. Sp1 is an ubiquous zinc-finger containing pro-
tein shown to crosstalk with numerous other proteins. High expression levels of Sp1 
are correlated with cells undergoing differentiation and high amounts of Sp1 seem to 
be needed for the induction of tissue-specific genes [176]. Sp1 is modified by a vari-
ety of posttranscriptional events such as sumoylation, acetylation, phosphorylation or 
glycosylation for example, resulting in augmented target promotor binding and tran-
scriptional activity [177, 178]. Basal regulation of 5-LO transcription is influenced by 
Sp1 via binding to the GC-4 boxes [179]. Beside Sp1 and Egr1, other consensus 
sites for promoter regulating proteins are characterized, namely Sp3, Egr2, GATA or 
NF-kB, but only Sp1, Sp3 and Egr1 show functional effects on the 5-LO promoter 
[180].  Further  upstream  in  the  promoter  region,  in  intron 4   and  M,  calcitriol-
responsive  elements  were  recognized  [181].  Very  recently,  5-LO  mRNA  isoforms 
were detected in human leukocytes lacking catalytic activity and therefore possibly 
representing a novel regulation mechanism of the 5-LO pathway [182]. 
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1.2.7  The 5-lipoxygenase protein – structure and function 
The next section deals with the three-dimensional structure of the 5-LO enzyme and 
its properties. So far, for structural elucidation efforts where made on modeling the 5-
LO structure on the basis of the rabbit reticulozyte 15-LO crystal structure and these 
studies emerged that a two-domain structure appears to be present, that is a catalyti-
cally active domain and a small regulatory C2-like domain (C2ld). This C2ld is re-
sponsible for binding several factors and adjusting biological functions of 5-LO, simi-
lar to the C2 domain of cPLA2α [148, 183]. Very recently, the group of Newcomer et 
al. reported the crystal structure of human 5-LO where a newly discovered 5-LO de-
stabilizing sequence was mutated [184]. The human enzyme is a monomeric 78 kDa 
protein [185]. As the enzyme can be divided into two structural different domains, 
these will be handled separately in the following.  
The catalytic domain of 5-lipoxygenase 
For studies on the catalytic domain of 5-LO the published structure of rabbit 15-LO 
was used as a template due to existence of high similarity between the two catalytic 
domains of the two proteins [183]. The C-terminal catalytic domain (amino acid resi-
dues 121-673) of 5-LO contains a non-heme-iron atom which cycles between the 
ferric and the ferrous state during enzyme catalysis and is chelated by three histidine 
residues (His-367, His-372, His-550), an asparagine (Asn-554) and the C-terminal 
isoleucine carboxy group (Ile-673) [85]. The sixth ligand of the coordination sphere 
can be proposed as water. The iron functions as the prosthetic group of the enzyme 
and stays in the ferrous state (Fe
2+) while the enzyme is resting in the cytosol. Mono-
nuclear non-heme Fe
2+- containing enzymes present this feature typically, called the 
2-His-1-carboxylaed facial triad [186]. The aforementioned peroxidase activity of 5-
LO is able to reduce lipid hydroperoxides generating Fe
3+ in the active site. An origi-
nated AA radical at C-7 can then be attacked by molecular oxygen resulting in a 5-
hydroperoxy radical intermediate. The resulting Fe
2+ can now donate an electron to 
the radical and form the 5-hydroperoxy anion from which 5-HpETE is released after 
regenerating the active Fe
3+ [148]. Fatty acid hydroperoxides are required to activate 
enzyme activity in a cell-free system turning the non-heme-coordinated iron into the 
ferric state. 5-, 12- and 15-HpETE as well as 13-hydroperoxylinoleic acid were all 
shown to be similar in their capacity to stimulate 5-LO in crude leukocyte homogen-
ates. In contrast, the corresponding HETEs were totally inactive as stimulators of 5-Introduction 
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LO, indicating that an intact hydroperoxy function is necessary for enzyme activation. 
Other  standard  hydroperoxides,  e.g.  hydrogene  peroxide  or  t-butyl  hydroperoxide 
were inactive, as they do not contain a long chain fatty acid part [187]. The perform-
ance of the enzyme, once switched to the active form, is characterized by a linear 
propagation phase with maximal conversion rates followed by an irreversible turnover 
dependent inactivation (suicide inactivation) [188]. The catalytic domain further fea-
tures  three  phosphorylation  sites,  at  Ser-271  for  mitogen-activated  protein  kinase 
activated protein kinase-2 (MAPKAP-2), at Ser-663 for extracellular regulated kinase-
2 (ERK-2) and at ser-523 for PKA. Phosphorylation or dephosphorylatione events 
regulate 5-LO enzyme activity [189-191]. Additionaly the specific phosphorylation at 
Ser-271 serves to inhibit nuclear export of 5-LO which is consistent with the nuclear 
import action induced by phosphorylation of Ser-532 [192]. Using photoaffinity label-
ling, a general nucleotide binding site was discovered and utilized for affinity chroma-
tography in terms of protein purification as ATP appears to interact specifically at this 
sequence [193, 194]. In the same way, the binding site of the natural substrate of 5-
LO  enzyme,  AA,  was  proposed  [195]. The carboxyterminal domain  predominantly 
contains α-helices [196]. 
The regulatory C2-like domain of 5-lipoxygenase 
C2-domains generally are known as Ca
2+ binding proteins and display a conserved 
structural motif forming an eight-stranded antiparallel ß-sandwhich mediating binding 
to a variety of ligands including divalent cations, phospholipids and other proteins 
[197, 198]. Sequences involved in the core ß-sandwhich are highly conserved be-
tween C2-domains whereas the sequences of the loops are not [199]. C2-domains 
have  been  identified  in membrane-interacting  proteins, e.g.  cPLA2,  synaptotagmin 
and protein kinase C (PKC) [200]. The N-terminal regulatory domain of human 5-LO 
is composed of two four-stranded antiparallel beta-sheets (ß-sandwhich) and can be 
categorized into the PLAT (polycystin-1, lipoxygenase, α-toxin) family which do have 
structural features similar to C2-domains [196, 201]. In a model of the 5-LO structure 
based on the crystal structure of the ferrous form of rabbit reticulocyte 15-LO, amino 
acid residues 1-121 are assigned to the small regulatory domain [202]. Within the 
emerged homology model of 5-LO the regulatory domain is termed “C2-like-domain” 
in comparison to other proteins as differences exist in the constitution of the ß-sheets 
[203]. For human 5-LO, several functionalities are ascribed to locations within the 
C2ld suggesting the small domain as a possible target for enzyme inhibition.  Introduction 
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Divalent cation binding 
C2-domains are often refered to as Ca
2+-dependent lipid binding domains but are not 
obligatory Ca
2+ binding as they display a family of versatile protein modules with di-
verse functions. Ca
2+ ususally binds to negatively charged amino acid residues such 
as aspartate (asp) side chains and glutamine (glu) which can serve as ligands for two 
or three Ca
2+ ions and are conserved as well [199]. First, the C2ld of 5-LO possesses 
the ability to associate two Ca
2+ ions shown in Ca
2+-overlay studies, electrophoretic 
mobility shift assay, gel filtration and equilibrium dialysis. Mutagenesis studies of the 
loops between the ß-strands (ligand binding loop 2) revealed decreased enzyme ac-
tivity due to reduced Ca
2+-binding  suggesting that these residues are important for 
Ca
2+-stimulated 5-LO enzyme activity [200]. Ca
2+ was found to bind 5-LO reversibly 
with a kd of ~ 6 µM and the stochiometry of maximum binding averaged  around two 
Ca
2+ ions per 5-LO molecule [203]. In cell-free assays half-maximal activation of en-
zyme activity was reached with 1 - 2 µM Ca
2+ and full activity is reached with 4 -10 
µM Ca
2+. Ca
2+ mediates the interaction with phospholipds and membrane fractions 
[204, 205]. As binding of Ca
2+ occurs at the lipid-water interface and increases hy-
drophobicity of the protein, the concept is currently proposed that Ca
2+ stimulates 5-
LO activity due to promoting membrane association. This is, as aforementioned, me-
diated by the C2ld of the enzyme [200]. Interestingly, Ca
2+ is not required for 5-LO 
activity if high concentrations of phosphatidylcholine (PC) vesicles, displaying natural 
constituents of cellular membranes, arise. Then, 5-LO can be distributed in AA vesi-
cles and product formation proceeds in the absence of Ca
2+ [206]. Furthermore, the 
interaction of Ca
2+, located at the C2ld, renders the enzyme resistant to GP-x1 possi-
bly by increasing the affinity towards lipidhydroperoxides needed for enzyme activa-
tion [207]. Mg
2+ ions, even though with lower affinity compared to Ca
2+, are able to 
bind and activate 5-LO activity in a dose-dependent manner (0.1 – 1 mM) in the 
presence of PC vesicles [208].  
 
Membrane targeting 
C2 domains are Ca
2+-dependent membrane targeting modules found in many cellular 
proteins involved in signal transduction or membrane trafficking [209]. Upon cellular 
stimulation, 5-LO is activated by Ca
2+-mediated binding to nuclear membranes. It is 
suggested that the N-terminal ß-barrel domain of 5-LO functions to facilitate mem-Introduction 
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brane binding which is a prerequisite for 5-LO activation [210, 211]. It is believed that 
the attachement of 5-LO to the nuclear membrane is influenced by non-specific inter-
actions with factors like membrane surface charge or the distinct lipid composition of 
the  nuclear  membrane.  Several  phospholipids,  such  as  phosphatidylethanolamine 
(PE),  phosphatidylinositol  (PI),  phosphatidylserine (PS),  phosphatidylglycerol  (PG), 
diacylglycerol (DAG) and PC have been examined, as in vitro 5-LO activity is rather 
low except in the presence of membrane fractions or phospholipids. Only PC was 
found to increase 5-LO activity, even if 5-LO association has been shown also for PE 
and PS. A higher affinity for zwitterionic PC than for anionic PS or acidic lipids was 
detected leading to the conclusion that this might be due to 5-LO binding to PC-rich 
nuclear membranes [210]. Also, the membrane surface charge seems to play an im-
portant role in the modulation of 5-LO activity. This was inferred from a trend of sup-
pression of 5-LO activity with an increase in negative surface charge of membranes 
[212, 213]. Another important determinant of membrane binding strength of 5-LO, 
enzyme activity and penetration into the hydrophobic core is membrane fluidity.  An 
activity and binding strength increase could be correlated to the dregree of lipid acyl 
chain  cis-unsaturation  and  peaked  with  1-palmitoyl-2-arachidonolyl-sn-glycero-3-
phosphocholine (PAPC). A group of trp-residues was found to penetrate into the hy-
drocarbon region of PAPC membranes and a model of 5-LO bound to phospholipid 
membrane was proposed based on the structure of rabbit reticulocyte 15-LO [214]. 
Therein, trp-13, trp-75 and trp-102 are likely to interact with the membrane and it is 
suggested  that  trp-75  penetrates  deeper  into  the  membrane’s  surface  than  other 
residues. Trp-13 inserts in the hydrophobic part of the membrane and trp-102 is posi-
tioned close to the lipid-water interface. Kulkarni et al. proposed trp-102 as the most 
important trp residues for the 5-LO C2ld and membrane interaction which does not 
show conflicts as trp residues located at the polar headgroup/hydrocarbon borderline 
of membranes are able to facilitate protein interactions via H-bonding and nonpolar 
interactions [215]. The three above mentioned trp residues are also involved in the 5-
LO stimulation induced by 1-oleoyl-2-acetyl-sn-glycerol (OAG). OAG was detected to 
directly bind to the putative PC-binding pocket. Similar to Ca
2+, OAG antagonizes the 
effect of GPx-1 on 5-LO activity [216]. Introduction 
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Fig. 7 Model of 5-LO bound to a phospholipid membrane according to Pande et.al, 2005.  
 
Protein-protein interaction 
C2 domains have been identified to bind a variety of different ligands including other 
proteins  beside  Ca
2+  and  phospholipids  [198].  The  human  coactosin-like  protein 
(CLP), a small 16kDa (142 amino acids) cytosolic protein, affiliated into the group of 
F-actin-binding proteins and similar to coactosin found in Dictyostelium discoideum, 
was discovered to attach to 5-LO and upregulate enzyme activity. This is mediated 
via an interaction with the three trp residues (13, 75,102) located in the regulatory 
domain of 5-LO comprising the PC binding pocket [217, 218]. Ca
2+-induced 5-LO ac-
tivation occurs in the absence of PC indicating a membrane mimicking scaffold func-
tion of CLP. In presence of PC up to 3-fold increase of LTA4 amounts was evident. 
These  facts  point  to  an  intervention  with  the  three  trp  residues  in  the  5-LO  ß-
sandwhich as all effects were abrogated with a 5-LO protein mutant lacking trp-12, 
trp-75 and trp-102 (5-LO 3W-mutant) [218]. Single trp mutants showed 50 % activity 
in presence of low PC and AA on wildtype 5-LO [219]. Thus, all  three trp residues 
seem to contribute equally to PC binding to support 5-LO enzyme activity [220].  Introduction 
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Fig. 8 Zoom into the model of human 5-LO at membrane interaction site 
Model of the 5-LO C2-like domain in purple and the catalytic residue in green.The three trp-residues 
are marked in orange indicating the positions which are responsible for membrane interactions and 
are mutated in case of the 5-LO-3W mutant protein lacking membrane binding capability.Model by 
B.Hoffmann.  
 
Recently, an interaction of 5-LO with a large protein, consisting of 1912 amino acid 
was discovered which belongs to ribonclease III family involved in the biogenesis of 
micro RNAs and is named dicer. Human dicer has been shown to interact with cellu-
lar proteins via its N-terminal domain but it was found that dicer-5-LO interaction is 
provided via its C-terminus and the lipid binding site within the C2ld domain of 5-LO 
as the association of both proteins is interrupted when trp residues are mutated to 
ala. This association may provide a novel link between micro-RNA mediated regula-
tion of gene expression and inflammation [221]. It is also suggested that 5-LO and 
FLAP expression may be involved in the cerebellar LT formation and/or could possi-
bly interfere with the dicer-mediated micro-RNA formation and processes of neuro-
plasticity [222]. Apart from these findings, interactions with transforming growth factor 
type ß-receptor-I-associated-protein 1 (TRAP-1) were reported by screening a hu-
man lung cDNA library and may be involved in the TGF-ß-induced upregulation of 5-
LO expression and activity observed in HL-60- and MM6-cells [217]. Introduction 
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3D model of human 5-lipoxygenase 
 
 
Fig. 9. 3D model of the human 5-LO with structural functionalities (calculated by B.Hoffmann) 
 
1.2.8 Cellular regulation of 5-lipoxygenase activity 
As 5-LO is the key enzyme in LT biosynthesis and lipid mediators play a critical role 
in  inflammatory  processes,  5-LO  expression  and  enzyme  activity  are  tightly  con-
trolled on cellular levels.  
 
Cellular environment 
Given that 5-LO is a non-heme iron containing enzyme which needs initially oxidation 
to the ferric form, protein activity is regulated by the cellular redox tone. The pres-Introduction 
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ence of sufficient lipidhydroperoxides is therefore pivotal. A cellular enzyme involved 
in  redox  events  is  the  selenium  containing Gpx-1,    which  reduces  5-HpETE  and 
thereby governs the actual acitivity of leukocyte 5-LO via regulation of the endoge-
nous tone of hydroperoxides [223]. The addition of Gpx-1 to purified 5-LO prevents 
enzyme  inactivation and  in  presence  of  reactive  Gpx-1 5-LO  product  formation  is 
suppressed by reducing the required hydroperoxides. Adversely, the inhibition of Gpx 
leads to enhanced LT levels and upregulation of 5-LO activity. Subsequently, both 
Gpx-1 and phospholipid-hydroperoxideglutathioneperoxidase (Gpx-4) do affect cellu-
lar 5-LO activity cell-type dependently [224-226]. The B-lymphocytic cell line BL41-
E95A and also immature HL-60-cells display less resistance to Gpx-4 emerging al-
most no 5-LO activity unless diamide or H2O2 was added in contrast to 5-LO pre-
pared from granulocytes [227, 228]. In monocytes and the monocytic cell line MM6 
inhibition of 5-LO is caused by Gpx-1 [229]. To avoid a great loss of 5-LO activity, 
Gpx is also used for protein stabilization under storage conditions [225].  
 
Stimulatory factors 
One of the key determinants stimulating 5-LO activity are Ca
2+-ions. Early studies 
revealed a role of Ca
2+ in  LT biosynthesis as calcium-ionophore (A23187) initiates 
SRS-A production [230]. Interestingly, the concentrations needed for stimulation of 
recombinant 5-LO reaching from 1 - 2 µM  (half-maximal activation) to 4 - 10 µM 
(maximal  activation)  are  considerably  higher  than  the  estimated  intracellular  Ca
2+ 
concentrations required for 5-LO product formation in leukocytes indicating that cellu-
lar events and context adjust the Ca
2+ requirement [145, 231]. In polymorphonuclear 
leukocytes (PMNL) natural agents like N-formyl-leucyl-phenylalanine (fMLP) or plate-
let-activation-factor (PAF) induced cellular Ca
2+ influx and effectively activate cellular 
LT formation when. An increased release in AA and synthesis of LTB4 was detectable 
[232]. However, recent studies indicated reduced Ca
2+ requirements in the presence 
of DAG after cell stimulation with A23187 or thapsigargin. These findings might pre-
dict that Ca
2+ alone without DAGs is not able to activate 5-LO catalysis [233]. Fur-
thermore, OAG is able to stimulate 5-LO activity in a magnitude comparable A23187 
in the presence of exogenously added AA [234].  
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Phosphorylation of 5-lipoxygenase 
The addition of a phosphate group to a protein is a very specific regulatory mecha-
nism and can either result in upregulation of a certain protein function or inhibition 
and the family of kinases play an important role in signal transduction. 5-LO was ob-
served to be phosphorylated at three different serine residues. First, phosphorylation 
of 5-LO was caused by a member of the protein kinase A family, the catalytic subunit 
of protein kinase A (PKA). A correlation of phosphorylation by PKA and 5-LO enzyme 
activity was observed in alveolar and peritoneal macrophages [191, 235]. Mutagene-
sis studies showed that Ser-523 is the key residue for phosphorylation of 5-LO inhib-
iting the catalytic unit of the enzyme and reducing  LT generation in  LT producing 
cells (neutrophils, basophils, mast cells, eosinophils and macrophages) [191, 236-
238]. PKA is usually activated by an increase of cAMP following ligand binding or 
PGE2 binding. Polyunsaturated fatty acids (PUFAs) prevent cAMP-mediated down-
regulaton of 5-LO product synthesis in activated neutrophils [239]. Further, a phos-
phorylation-driven change in subcellular localization was described leading to accu-
mulation of 5-LO protein in the cytoplasm as Ser-523 is part of a nuclear localization 
sequence  (NLS)  [240].  Other  kinase  pathways  impact  on  cellular  LT  formation, 
namely  the  family  of  mitogen-activated-protein-kinases  (MAP-kinases).  Within  this 
family, MK-2 and ERK were found to phosphorylate 5-LO and intervene in 5-LO cata-
lyis. P38 mitogen-activated protein kinase (p38 MAPK) is activated by cellular stress 
like sodium arsenite (chemical stress) in B-cells and human PMNL and in turn phos-
phorylates and activates MAPKAP kinase 2 and 3 (MK2/3). MK-2 then phosphory-
lates 5-LO on Ser-271. 5-LO can be upregulated by the addition of PUFAs suggest-
ing a putative fatty-acid binding site [188, 241-245]. Interestingly, SA and osmotic 
stress were effective also after chelation of Ca
2+ in the medium and inside the cells 
[246]. ERK 1/2 phosphorylates 5-LO at ser-663 and ERK activation was found to 
mediate cellular activation of 5-LO in the presence of unsaturated fatty acid (UFAs) 
[190].  In  MM6-cells,  conditions  leading  to  higher  activity  were  connected  with  in-
creased  5-LO  kinase  activity  and  upregulated 5 -LO  translocation  to  the  nuclear 
membrane [242]. The activity of kinases on 5-LO seems to be responsible not only, 
as mentioned previously, for 5-LO activity and subcellular localization but also for 
Ca
2+-induced membrane association and/or regulation of interaction with other cellu-
lar components [85, 247, 248].  
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5-lipoxygenase: interaction with membranes 
Membrane constituents are important activation factors of 5-LO activity and are es-
sential for 5-LO product synthesis as conversion of endogenously provided AA oc-
curs at the nuclear membrane [145]. In unstimulated cells 5-LO is either located in 
the cytosol (neutrophils, eosinophils or peritoneal macrophages) or in a nuclear solu-
ble compartment associated with chromatin as in alveolar macrophages, Langerhans 
cells or basophilic leukemia cells [146]. Upon stimulation, cytosolic 5-LO translocates 
to the nuclear membrane in the cell [85]. Different patterns have been observed for 5-
LO localization in various cell types, particularly for peripheral blood leukocytes as 
compared to alveolar macrophages [249]. Commonly, A23187 is a prominent stimu-
lus for membrane binding of 5-LO in intact cells and induces 5-LO to produce LTs 
after binding to nuclear membranes [250]. Reversibility in membrane binding could 
be demonstrated using different stimuli of 5-LO, particularly when cells are stimulated 
in  a  weaker  fashion  with  fMLP,  IgE-antigen,  zymosan  or  even  with  A23187  [251, 
252]. It is debatable whether 5-LO first translocates and migrates into the nucleus 
and afterwards binds to the perinuclear membrane from the inside or if 5-LO is at-
tached from the outside of the nuclear membrane. It has been shown that nuclear 
import of 5-LO takes places independently of enzyme activity and LT formation, un-
derlined by findings of elicitation of rat peritoneal neutrophils by glycogen and after 
adhesion of human PMN. It was pointed out that both alveolar macrophages and elic-
ited PMNs show increased capability for 5-LO product formaton [203] but with a rela-
tively high Ca-ionophore activation threshold [253, 254]. The exception are eosino-
phils, where nuclear localization suppresses 5-LO activity. Additionally, LT formation 
can take place in the absence of nuclear membranes when exogenous AA is sup-
plemented as natural substrate in the incubations [255]. 5-LO import into the nucleus 
is assessed by the nuclear localization sequence (NLS) which displays a basic amino 
acid rich sequence and is present in the N-terminal domain as well as close to the C-
terminus of 5-LO which could be determined with GFP-5-LO fusion protein in trans-
fected cells [256-258]. It was concluded that several parts of the protein contribute to 
the nuclear import sequentially, but the ß-barrel domain of 5-LO was found out to be 
essential for membrane association [259]. Also, nuclear export sequences have been 
identified in 5-LO and nuclear export was shown when alveolar macrophages are 
removed from the alveolar milieu [254, 260]. It is still speculated if events leading to Introduction 
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unmasking  of  the  NLS  by  phosphorylation  are  relevant  in  subcellular  localization 
processes of 5-LO [240, 248, 261, 262]. 
 
5-lipoxygenase interacting proteins in leukotriene biosynthesis 
Finally, interaction of 5-LO with other proteins is an important criterium influencing 5-
LO’s enzymatic activity in a cellular environment. CLP, as aforementioned, is colocal-
ized with 5-LO at the nuclear membrane after stimulation of human neutrophils with 
Ca-ionophore and the same distribution pattern for CLP and 5-LO was observed in 
stimulated  MM6-cells  [217].  CLP  was  shown  to  replace  cellular  membranes  as  a 
scaffold for 5-LO but still Ca
2+ was required for LT biosynthesis. This led to the hy-
pothesis that the two proteins form a complex which enables cytosolic formation of 5-
HpETE respectively 5-HETE when triggered by the addition of Ca
2+ and exogenous 
AA. Thus, the mode of binding of 5-LO to CLP might depend on the presence of 
Ca
2+, resembling the “productive” or “non-productive” modes of membrane binding of 
the protein. It was concluded that CLP promotes LTA4 formation catalyzed by 5-LO 
when PC is present. Aside from these facts, CLP regulates the ratio of formed 5-LO 
metabolites, namely 5-HpETE and 5-HETE resulting in a shift in favour to 5-HETE 
[218]. Lastly, FLAP assists 5-LO at the nuclear membrane catalyzing 5-LO metabo-
lite origination. FLAP is a member of the membrane associated proteins in eicosa-
noid  and glutathione  metabolism (MAPEG) and  sequential  identities  of FLAP  and 
LTC4 synthase (also MAPEG member) are 31 % [263, 264]. The three-dimensional 
structure of human FLAP in complex with MK-591 was recently determined by X-ray 
chrystallography [265]. Another compound, MK-886, was found to block membrane 
association of 5-LO in human leukocytes and by radiolabelled MK-886, a 18kDa pro-
tein was designated and then purified in neutrophils [266, 267]. FLAP is a membrane 
bound-protein and protein expression of both FLAP and 5-LO are considered to be 
necessary for Ca-ionophore induced 5-LO catalytic action in transfected human os-
teosarcoma cells in the absence of exogenously added substrate [268]. As MK-886 
did not affect 5-LO membrane association in 5-LO transfected osteosarcoma cells 
lacking FLAP, an accessory role of FLAP as a membrane anchor was assumed [269, 
270]. This is underlined by the suggestion that FLAP may function as a AA transfer 
protein facilitating access to the natural substrate of 5-LO and it became evident that 
FLAP is crucial for conversion of endogenous AA [85]. At this point 5-LO inhibitors Introduction 
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are thought to compete with AA or other fatty acids regarding binding to FLAP [271, 
272]. Recently, another substrate such as 12-(S)-HETE was discovered [273]. Bind-
ing of FLAP to AA was shown, however, no enzymatic activity of FLAP has been re-
ported yet [274]. 
 
Gender-specific aspects 
Recently,  gender-related  differences  in  LT  metabolism  and  5-LO  catalytic  activity 
have been observed on cellular levels (neutrophils) and in the whole blood system. 
Studies indicate that 5-LO and LTs are androgen regulated. Androgens cause nu-
clear localization of 5-LO in an ERK-dependent fashion resulting in decreased 5-LO 
product formation induced by the pathophysiological stimulus fMLP.  LT levels de-
tected were lower in males compared to females [275]. These findings may explain 
recognized gender differences in LT-related diseases which were found to be more 
prominent in females [276].  
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Schematic of cellular LT biosynthesis 
 
Fig. 10: Schematic of the cellular biosynthesis of leukotrienes by 5-LO according to Radmark et al., 
2007. 
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1.2.9  5-lipoxygenase inhibitors 
 As LTs play a prominent role in a great variety of diseases including respiratory dys-
functions, allergic reactions, osteoporosis, cardiovascular diseases and cancer, (see 
section 1.2), great efforts have been made in the development of anti-LT therapy and 
intervention with 5-LO is a challenge in the development of therapeutics. Despite a 
role for LTs in various pathologies, the progress made in the development of 5-LO 
inhibitors is rather moderate. However, novel pharmacological strategies for interven-
tion are of great importance to the field and concepts of inhibition of LT synthesis 
seem to be promising. The following subsection deals with the general pharmacol-
ogical concepts in 5-LO inhibition by currently available compounds and summarizes 
the different molecular approaches to inhibit 5-LO by different intervention strategies 
[276].  
 
Redox-type inhibitors 
Redox-type inhibitors of 5-LO intervene with the enzyme by uncoupling it from its 
catalytic cycle due to reducing the active site iron in the ferric state keeping it in the 
ferrous state (Fe
2+) and by acting as non-selective antioxidants. Mostly, compounds 
display  lipophilic  properties  and  are  derived  from  plant-origin  such  as  nordihy-
droguaraic acid, caffeic acid, flavonoids, coumarins and other polyphenols. The first 
synthetic  compounds  inhibiting  5-LO  were  redox-active  5-LO  inhibitors  such  as 
AA861, L-656,224, phenidone or BW755C [277]. AA861 showed IC50 values of 3 µM 
for LTB4 and 0.1 µM for LTC4.  BW755C inhibited the generation of LTC4 with an IC50 
value  of  100  µM  indicating  that  AA861  is  about  1.000  times  more  potent  than 
BW755C. Aditionally, AA861 did not affect COX or 12-LO. Essentially no antagonistic 
activity to LTD4 or histamine was observed [278, 279].  Despite their great efficiency 
in vitro, all agents lacked suitable oral bioavailability and inhibitor profiles possess 
poor 5-LO selectivity and show adverse side effects as other biological redox sys-
tems are influenced by the drugs such as methemoglobin formation and further, reac-
tive radical species can be formed [280]. Due to these properties the compounds 
were not convincing and failed to enter the market [281]. 
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Iron-chelating compounds 
The development of compounds that are able to chelate the active site iron comprise 
derivatives of hydroxamic-acids and N-hydroxyurea. A very prominent member is the 
compound BWA4C (hydroxamic acid) which potently inhibits 5-LO in intact granulo-
cytes with an IC50 value of 4 nM [282]. BWA4C is a feasible control agent in in vitro 
assays. Further investigations led to the hydrolytic-stable N-hydroxyurea derivative 
zileuton,  a  potent  and  orally  bioavailable  5-LO  inhibitor  (IC50  value  0.5  -  1  µM  in 
stimulated leukocytes) [283, 284]. It leads to therapeutic effects in acute and chronic 
improvement of airway functions and therefore to a reduced need of first-line therapy 
with glucocorticoids or ß-agonists. Zileuton finally entered the market with approve-
ment by the FDA in the United States. It is the first available 5-LO inhibitor for the 
treatment  of  bronchial  asthma,  trade  name  Zyflo®  [285].  Though,  the  drug  only 
showed low therapeutic effects in allergic rhinitis, rheumatoid arthritis and inflamma-
tory bowel disease [286].  Surprisingly, with the exception of zileuton as the only 
marketed iron-ligand inhibitor of 5-LO, no notable efforts concerning the approval of 
drugs have been made in the past five years. One approach accomplished a COX-
inhibitory moiety, preferentially a NSAID, and a covalently linked iron-chelating moi-
ety leading to the dual COX-5-LO inhibition concept. Recently, zileuton was identified 
as inhibitor of PG biosynthesis by interfernce with AA release in macrophages [287].  
 
Non-redox type inhibitors 
Mostly, a lack of selectivity and no appropriate bioavailability are prominent disadvan-
tages of 5-LO inhibitors that initiated the development of the class of non-redox type 
5-LO inhibitors. The designation „non-redox type“ inhibitor implicates only that the 
compounds themselves do not show redox activity [288]. Non-redox-type inhibitors 
are thought to compete with the natural substrate of 5-LO, AA or lipidhydroperoxides 
for binding to 5-LO via the subtrate binding-cleft in the active site. This fact is still 
matter  of  research.  Some  studies  suggest an  additional allosteric  mode  of  action 
[111, 289]. The group comprises structurally diverse molecules. Lead structure opti-
misation led to the orally active potent 5-LO inhibitors ZD-2138 and ZM-230487 (IC50 
values 20 - 50 nM, respectively) tested in human leukocytes and human whole blood 
[290]. Elevated peroxide levels and/ or phosphorylation of 5-LO by MK-2 strongly de-
creased 5-LO inhibitory potency of these compounds in stimulated PMNL and in con-Introduction 
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sequence led to diminished 5-LO inhibition in inflammatory tissues exhibiting a higher 
peroxide level. Furthermore, non-redox type inhibitors require Gpx for efficient inhibi-
tion of 5-LO [289]. A promising candidate, the urea derivative RBx7796, was discov-
ered by Ranbay et al. as a novel type of 5-LO inhibitor. The compound showed 5-LO 
inhibition (IC50 values 3.8 µM (cell-free assay) and 5 µM (cell-based assay)) with a 
characterized competitive, selective mode of action, orally active, stable concerning 
metabolic features and a lack of cytochrome P450 inhibition [291, 292]. Ongoing re-
search led to L-739.010 which possesses the structure of substituted coumarins to 
minimize toxicity and was introduced by the Merck Frost group. Simultaneously, re-
lated fluorophenyl-substituted coumarins where the thioaryl moiety carrying the hex-
afluorcarbinol was replaced by an amino-oxadiazol moiety and therfore displaying 
potent 5-LO inhibition in cell-free assays and human whole blood without acting toxic 
were claimed [276]. Another structural different set of compounds, a potent imidazole 
series, represented by CJ-13.610, was developed by Pfizer. CJ-13.610 is a potent 5-
LO inhibitor in cellular systems (IC50 = 70 nM, neutrophils) and human whole blood 
(IC50 = 230 nM) and its efficacy was not influenced by phosphorylation of 5-LO [293, 
294]. Virtual screening studies identified a novel series of tricyclic thiazole-based de-
rivatives where one compound exerts strong 5-LO inhibition in cell-free assays as 
well as in neutrophils (IC50 values 0.15 µM respectively, 0.17 µM) but failed to show 
inhibitory potency in vivo or in human whole blood. The molecular mechanisms of 
these  compounds  are  unknown  or  only  partly  characterized  but  structure-based 
evaluation  underlines  that  iron-chelating  or  reducing  properties  can  be  excluded 
[276]. 
 
FLAP-inhibitors 
In the late 1980s, MK-886 was discovered, an indole-class compound showing LT 
biosynthesis inhibition both in vitro and in vivo without interfering directly with 5-LO 
[295]. At the same time, BAY X1005, displaying similar properties, was developed at 
Bayer [296]. FLAP was then identified using a photoaffinity analogue of MK-886 with 
which the photoaffinity-labeled protein could be immunoprecipitated from human leu-
kocyte membranes [266, 268]. Further studies identified binding sites for quinoline- 
and indole-based inhibitors like MK-591, also possessing FLAP inhibitory properties.  
Shown by mutagenesis studies, MK-591’s binding site seems to overlap with the AA Introduction 
35 
binding pocket [297]. With these prominent FLAP-inhibiting compounds, phase I and 
II clinical trials were undertaken in the treatment of asthma. Despite good clinical 
safety profiles lacking hepatotoxicity and potent activity against early and late phase 
lung volume decrease after allergene challenge, none of the compounds were further 
developed  [298-301].  As  the  crystal  structure  of  inhibitor-bound  FLAP  was  deter-
mined by X-ray investigations, details of the binding of FLAP to the nuclear mem-
brane could be clarified. FLAP forms homotrimers within the nuclear membrane and 
each monomer is composed of four transmembrane helices that are connected by 
two cytosolic loops and a lumenal loop [302]. Three MK-591 molecules are bound in 
between monomers in three groves which are arranged on the membrane-embedded 
surface of the trimer leading to a binding stoichiometry of 1:1 [267]. 
 
Dual COX-/ 5-LO or COX-/ FLAP inhibitors  
Within the past years, several approaches were made to develop dual inhibiting sub-
stances either affecting related LOs (12-LO, 15-LO) or COX enzymes. This is in line 
with the finding that all these enzymes do have in common that they catalyze reac-
tions with the same substrate, AA. Therefore they might bind to a more or less con-
served AA-binding pocket in the active site of the 5-LO enzyme. Compounds thought 
to interfere with related LOs may have off-target effects that are relevant in terms of 
adverse  side  effects  [276].  A  focus  lies  on  the  development  of  potent  anti-
inflammatory drugs not showing the well-established gastrointestinal toxicity [303]. A 
very prominent representative was licofelone (ML-3000) which was developed until 
clinical trial phase III in 2007 and showed inhibitory potency on both enzymes, COX 
and  FLAP  [111,  304].  Unfortunately,  the  clinical  trial  phase  III  for  ML-3000  was 
stopped due to unpublished reasons.  
 
Other 5-LO inhibitors 
Besides  this  classification  of  so  far  developed  and  characterized  5-LO  inhibitors 
comprising a wide array of different chemical structures, there are many compounds 
derived from plant origin known to inhibit 5-LO enzyme activity and therefore to sup-
press  LT  biosynthesis. As  aforementioned, many phytochemical  compounds  were 
tested on their ability to inhibit 5-LO product formation, exemplified by myrtucommu-Introduction 
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lone from the plant Myrtus communis, boswellic acids originated from Boswellia ser-
rata, namely 11-keto-ß-boswellic acid (KBA) and its acetylic derivative 3-O-acetyl-1-
keto-boswellic acid (AKBA) and as well hyperforin, the major ingredient of St. Johns 
Wort (Hypericum perforatum) [241, 305-308]. All these compounds were identified as 
potent 5-LO inhibitors with corresponding IC50 values ranging from 0.1 – 5 µM tested 
in  intact  cells  and  cell-free assays. Myrtucommulone  and  hyperforin  were  thereby 
verified as dual COX/5-LO inhibitors [111]. Hyperforin’s mode of action is well char-
acterized and a unique molecular mechanism postulating that it interacts with the 
C2ld of the 5-LO enzyme [309]. Recently, inhibition of microsomal PGE2 synthase by 
hyperforin was described [310].  
 
Summary of the current standings in 5-LO inhibitor development 
The previous chapter gives a complex picture of LT bioynthesis suppression by 5-LO 
inhibitors. Despite great efforts which were made in the past und current investiga-
tions, only one 5-LO inhibitor (zileuton) has so far reached the market. More potent 
inhibitors are needed that do not present the typical side effects and that should have 
excellent pharmacokinetic and pharmacodynamic profiles without toxicity.  
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Representatives including chemical structures and potencies for each type of 
5-LO inhibitor 
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Fig.11: Summary of different types of 5-LO inhibitors including their structures and potencies in cellu-
lar and cell-free assays  Aim   
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2  AIM OF THE PRESENT STUDY  
LTs constitue a group of lipid mediators derived from the precursor AA in a two-step 
reaction catalyzed by the 5-LO enzyme. These pro-inflammatory mediators play a 
pivotal role in inflammatory processes and host defense [311]. Beside inflammatory 
diseases like asthma, rheumathoid arhtritis, allergic disorders or atherosclerosis, 5-
LO has been shown to be involved in tumorigenesis and cancer [19]. Other enzymes 
involved in the AA cascade such as COX are upregulated and PG production is in-
creased in tumor tissues [4, 312]. As some NSAIDs show beneficial cardiovascular 
profiles, higher gastrointestinal tolerance and even chemopreventive properties like 
cell cylce arrest and growth inhibition, intense reseach to evaluate possible targets of 
these drugs has been performed over the last years.  
First evidence for a potential role of NSAIDs in the progression and risk reduction of 
cancer was derived from clinical observations in studies of patients suffering from 
FAP and Gardners syndrome who were treated with the well-established NSAID su-
lindac [52, 313]. An increasing body of evidence indicates that there may exist other 
mechanisms of NSAIDs than inhibition of prostaglandin synthesis which are respon-
sible for chemoprevention and higher compatibility in humans [5].  
Ssi, is a well-established NSAID on the market since the 1970s. The drug possesses 
strong  anti-inflammatory,  analgesic  and  anti-pyretic  effects  showing  a  low  ulcero-
genic and cardiovascular profile [59]. Its neoplastic efficacy has been shown by inter-
actions with COX-independent targets preventing precancerous colorectal polyps in 
humans [59].Thus, having in mind the exceptional pharmacological profile of Ssi and 
the pathophysiological effect of LTs, the present studies were undertaken in order to 
determine and characterize a possible influence of Ssi on LT biosynthesis and fur-
thermore  to  identify  the  underlying  mechanisms.  Moreover,  the  studies  aimed  to 
evaluate a possible regulatory effect of Ssi on 5-LO gene expression. The use of NO-
NSAIDs seems to be a promising strategy to inhibit PG biosynthesis. Due to their 
beneficial  chemopreventive  and  gastroprotective  effects,  it  was  additionally  at-
tempted to investigate a possible interaction of NO-NSAIDs and 5-LO as a second, 
potent  target.  Materials and Methods   
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3  MATERIALS AND METHODS 
3.1  Cells and cell culture 
3.1.1 Cell lines 
Mono-Mac-6-cells 
The human cell line MM6 was derived from the peripheral blood of a 64-year-old man 
suffering from acute monocytic leukemia. MM6-cells show a constitutive expression 
pattern of mature monocytes regarding phenotypical and functional tasks [314]. 5-LO 
protein expression and subsequent enzymatic activity can be triggered by treatment 
of the cells with human TGF-ß (1ng/ml) and 1α,25-dihydroxyvitamin D3 (calcitriol) (50 
nM) [315]. 
HeLa-cells 
HeLa cells were cervix carcinoma cells. Due to their 5-LO deficiency, HeLa cells are 
a suitable assay system for elucidating effects which are induced by transfection of 5-
LO plasmids.  
 
3.1.2 Cell culture 
MM6-cells  were  maintained  in  RPMI  1640  medium  supplemented  with  2  mM  L-
glutamine,  10  %  heat-inactivated  (2  hrs  at  56°C)  fetal-bovine-serum,  100  µg/mL 
streptomycin,  100  U/ml  penicillin,  1  mM  oxaloacetic  acid,  1x  MEM  non-essential-
amino acids and 10 µg/mL human insulin. The human insulin was kindly provided by 
Sanofi-Aventis, Frankfurt. HeLa cells were cultured at 37°C in a 5 % CO2 atmosphere 
whereas MM6-cells were maintained at 37°C with a 6 % CO2 atmosphere. 
 
3.2   Isolation of PMNL from buffy coats 
Human polymorphonuclear leukocytes (PMNL) were freshly isolated from leukocyte 
concentrates obtained from the Krankenhaus Höchst (Frankfurt, Germany) or from 
the Blood Center, University Hospital (Tübingen, Germany).  Venous blood was col-
lected from fasted, adult, healthy volunteers, with consent. The subjects had no ap-
parent inflammatory conditions and had not taken anti-inflammatory drugs for at least 
10 days prior to blood collection. The blood was centrifuged at 4.000xg for 20 min at Materials and Methods 
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room temperature for preparation of leukocyte concentrates. PMNL were immediately 
isolated by dextrane sedimentation, centrifugation on Nycoprep cushions (PAA Labo-
ratories,  Linz,  Austria),  and  hypotonic  lysis  of  erythrocytes  [246].  PMNL  (5x10
6 
cells/ml; purity > 96−97 %) were finally resuspended in phosphate-buffered saline pH 
7.4 (PBS) plus 1 mg/ml glucose and 1 mM CaCl2 (PGC buffer). 
 
3.3   Isolation of platelets from buffy coats 
After the densitiy centrifugation step during the isolation of PMNL, plasma containing 
the platelets was centrifuged for 15 min at room temperature at 4.800xg. Pellets were 
resuspended in PBS/NaCl 0.9 % (v/v) and centrifuged again at 4.800xg for 10 min at 
room temperature. Cells were finally diluted into PBS buffer pH 5.9. 
 
3.4  Preparation of microsomal fractions from PMNL 
1x10
7 freshly isolated PMNL were subjected to centrifugation at 4.000xg/20 min and 
pellets  were  resuspended  in  1  ml  homogenization  buffer  (PBS,  sucrose  0.25  M, 
Complete  Mini  Protease  Inhibitor  cocktail  tablette  (Roche  Diagnostics,  Mannheim, 
Germany)). After sonication for 3x20 s and centrifugatioin at 10.000xg/10 min where 
unbroken cells, nuclei and mitochondria are pellete the resulting supernatants con-
taining soluble enzymes and fragmented ER were again centrifuged at 170.000x g/70 
min at 4°C. Microsomal fractions were then kept in 100 µl of homogenization buffer 
and total protein concentration was determined by using the Bradford method [316]. 
 
3.5  Purification of human recombinant 5-lipoxygenase from E.coli 
The proteins 5-LO-wt and 5-LO-3W were expressed in E. coli Bl21 (DE3) cells, trans-
formed with pT3–5LO, and purification of 5-LO was performed by affinity chromatog-
raphy. E. coli were harvested and lysed in 50 mM triethanolamine/HCl, pH 8.0, 5 mM 
EDTA,  soybean  trypsin  inhibitor  (60  µg/ml),  1  mM  phenylmethylsulphonyl  fluoride 
(PMSF), 1 mM DTT and lysozyme (100 mg/ml), homogenized by sonication (3x15 s) 
and centrifuged at 10.000xg for 15 min followed by centrifugation at 100,000xg for 70 
min at 4°C. The supernatant was then applied to an ATP-agarose column (Sigma 
A2767, Deisenhofen, Germany), and the column was eluted as described previously. Materials and Methods 
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Partially purified 5-LO was immediately used for in-vitro activity assays. For some 
studies  5-LO  was  further  purified  by  ion-exchange  chomatography  on  an  ÄKTA-
purifier 100 system (GE Healthcare). 
 
3.6   Determination of protein phosphorylation 
PMNL (1x10
7/100 µl PGC buffer) were preincubated with the indicated concentra-
tions of Ssi, Sso, sul or vehicle for 10 min. Then, 100 nM fMLP was added, the reac-
tion was stopped after 1.5 min at 37 °C by addition of 100 µl of SDS-PAGE sample 
loading  buffer  (20  mM  Tris/HCl,  pH  8,  2  mM  EDTA,  5  %  SDS  (w/v),  10  %  ß-
mercaptoethanol), and heated for 6 min at 95°C. Cell lysates were separated by SDS 
polyacrylamid gel electrophoresis (SDS-PAGE) on a 10 % gel, electroblotted on Hy-
bond ECL nitrocellulose membranes (GE Healthcare, Munich, Germany) and ana-
lysed  for  phosphorylated  ERK1/2  and  phosphorylated  p38-MAPK  using  an  Ettan-
DIGE imaging system (GE Healthcare) as described [275].  
 
3.7  5-lipoxygenase translocation assay 
Freshly isolated PMNL (3x10
7) in 1 ml PGC buffer were pre-incubated with the com-
pounds or vehicle (DMSO) for 15 min at 37°C. Then, 2.5 µM A23187 was added, the 
samples were further incubated for 5 min, and subsequently chilled on ice to stop the 
reaction. Nuclear and non-nuclear fractions were obtained after cell lysis by 0.1 % 
NP-40. Samples were then prepared for SDS-PAGE and Western blotting.  
 
3.8   Determination of 5-lipoxygenase product formation  
5-LO products were either determined in cellular systems such as PMNL, platelets 
and eosinophils or activity of 5-LO was measured by the metabolic rate of 5-LO to its 
natural substrate arachidonic acid with purified, recombinant enzyme. 
 
3.8.1  Cellular 5-lipoxygenase product formation 
PMNL (7x10
6) immediately isolated from leukocyte concentrates and resuspended in 
1 ml PGC buffer were incubated with the test compounds or vehicle (DMSO) at 37°C Materials and Methods 
43 
for 10 min. For the competition assay, cells were first incubated with the FLAP inhibi-
tor  MK-886  (5  µM)  for  10  min  and  then another  10  min for  test  compounds.  For 
stimulation with fMLP, cells were primed with 1 µg/ml LPS/0.2 U/ml Ada 30 min prior 
to the incubation with 1 µM fMLP for 5 min. Test compounds or vehicle (DMSO) were 
added 10 min before treatment with fMLP. 5-LO product formation was started by the 
addition of the stimuli that is either 2.5 µM A23187, 10 µM sodium arsenide (SA) or 
300 mM sodium chloride (SC) together with or without AA as indicated. The reaction 
was stopped after 10 min by addition of 1 ml ice-cold methanol and the formed 5-LO 
metabolites were analyzed by HPLC as described below.  
 
3.8.2  Human recombinant 5-lipoxygenase product formation 
For determination of the activity of recombinant 5-LO, partially purified 5-LO (~ 0.5 µg 
producing ~ 800 -1000 ng 5-LO products in control) was added to 1 ml of a 5-LO re-
action mix (PBS, pH 7.4, 1 mM EDTA, 1 mM  ATP). After incubation with the test 
compounds or vehicle (DMSO) for 15 min at 4°C, samples were pre-warmed for 30 s 
at 37°C and incubated after stimulation with CaCl2 (2 mM) for another 10 min. The 
addition of 1 ml ice-cold methanol stopped the reaction and 5-LO products formed 
were analyzed by HPLC as described in the following section (3.8.3). For the experi-
ments with microsomes and phospholipids, 100 µg or 300 µg microsomes or phos-
pholipids were incubated  for 15 min on ice with recombinant 5-LO enzyme before 
test compounds were added for another 15 min on ice and 5-LO product formation 
was started by adding 2 mM CaCl2 and 20 µM AA (final concentrations) 
 
3.8.3  Solid phase extraction and HPLC analysis of metabolites 
After incubation, samples were then diluted with 500 µl ice-cold PBS buffer, 30 µl 1N 
HCl and 10 µl Prostaglandin B1α as an internal standard for HPLC analysis. Samples 
were  then either  centrifuged  (4000xg)  or  directly  subjected  to  solid  phase  extrac-
tion.Therefore  C18-solid-phase-extraction  columns  (Clean-up®  Extraction  columns 
from UTC, Bristol PA, USA) were used. The columns were preconditioned with 1 ml 
methanol  100  %  (v/v)  and  1  ml  water.  After  sample  application,  columns  were 
washed with 1 ml Milli Q water and methanol (25 % v/v). Subsequently, formed 5-LO 
metabolites were eluted with 300 µl methanol and diluted with 120 µl water. Analysis Materials and Methods 
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of 5-LO products by HPLC allows the detection of leukotriene B4 (only found in intact 
cells), its all-trans isomers and 5-HETE, 12-HETE and 15-HETE. Separation of me-
tabolites was carried out on a C18 reversed phase column (Novapak C18 radial col-
umn 100mm 5mm I.D.4 µM, Waters) with a mobile phase consisting of 76 % metha-
nol  (v/v),  24  %  water  (v/v)  and  0.007  %  (v/v)  trifluoroacetic  acid at  a  flow  of  1.2 
ml/min.  Products  were  detected  for  30  min,  in  the  first  8  min  at  a  wavelength  of 
280nm and for the last 22 min at 235nm. In samples from cell preparations, products 
were  expressed  as  ng/10
6  cells  whereas  recombinant  protein  products  were  de-
scribed as ng products per amount of protein. 
 
3.9  Phospholipase D activity assay 
PLD activity was evaluated using a nonradioactive mass choline assay [317]. Choline 
quantification is based on choline oxidation by exogenous choline oxidase to betain 
and H2O2. In presence of horseradish peroxidase, the formed H2O2 reacts with Am-
plex-red in a 1:1 stoichiometry to generate the fluorescence product resorufin. Briefly, 
human PMNL (2.5×10
6 cells) were preincubated with vehicle (0.1 % DMSO), Ssi (30 
µM) or the PLD inhibitor 5-fluoro-2-indolyl des-chlorohalopemide (FIPI, Sigma, 100 
nM), stimulated with 2.5 µM A23187 (37°C, 3min) and the reaction was stopped on 
ice. After centrifugation (5 min, 1000×g), cells were suspended in 600 µl of 50 mM 
Tris-HCl, pH 8 containing 1 mM PMSF and sonicated at 4°C (3 strokes of 5 s, each). 
Cell  disruption  was  checked  by  phase  contrast  microscopy.  Samples  were  centri-
fuged again (10.000×g, 4°C, 5 min) and supernatants were collected and put on ice. 
Supernatants (250 µl) were diluted with 250 µl Tris-HCl (50 mM, pH 8) containing 1 
mM PMSF. Choline oxidation was performed at 37°C for 1 h after addition of 500 µl 
Tris-HCl (50mM, pH 8), 100 µM Amplex red, peroxidase (2 units/ml), and choline oxi-
dase  (0.2  U/ml).  The  increase  of  resorufin  fluorescence  was  monitored  using  an 
Aminco-Bowman  series  2  spectrofluorometer,  at  excitation  and  emission  wave-
lengths of 530 and 590nm, respectively. Choline content was calculated from calibra-
tion curves obtained with exogenous choline chloride from 5 to 200 pmol.  
 
3.10  Intracellular calcium mobilization 
Freshly isolated PMNL (1x10
7 cells in 1 ml PGC buffer) were incubated with 2 µM Materials and Methods 
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Fura-2/AM for 30 min at 37°C. After washing, cells were resuspended in 1 ml PGC 
buffer, preincubated with Ssi or vehicle (0.1 % DMSO) for 10 min, supplemented with 
1 mM CaCl2, and transferred into a thermally controlled (37°C) fluorimeter cuvette in 
a spectrofluorometer (AB-2) with continuous stirring. Mobilization of intracellular Ca
2+ 
was initiated by addition of fMLP (1 µM). Emission wavelength of the fluorescence 
was 510nm and was measured after excitation at wavelengths 340 and 380nm, re-
spectively. The calculation of intracellular Ca
2+ levels was based on the method of 
Grynkiewicz et al. [318] where the maximal fluorescence (Fmax ) was generated by  
cell lysis  with 0.5 % Triton-X 100 and minimal fluorescence  (Fmin) by treatment with 
the Ca
2+chelating agent EDTA (10 mM). 
 
3.11  SDS PAGE and Western blot  
Aliquots of samples were immediately mixed with the same volume of 2×SDS-PAGE 
sample loading buffer, heated for 6 min at 95°C, and analyzed for 5-LO protein by 
SDS-PAGE and Western blotting using the 5-LO anti-serum 1551, AK-7 (raised in 
rabbit, diluted 1:25) that was kindly provided by Prof. Dr. Olof Rådmark, Stockholm, 
Sweden. Proteins were separated by SDS-PAGE on a 10 % gel and afterwards blot-
ted onto ECL nitrocellulose membrane (GE Healthcare). After blocking with 2 % ECL 
advance blocking agent (GE Healthcare) for 1 h at room temperature membranes 
were incubated with primary antibodies overnight at 4°C. Antibodies were used at 
1:1000 dilutions in TBS containing 2 % advance blocking agent. The membranes 
were then washed and incubated for 1h at room temperature with ECL Plex-CyDye-
conjugated antibodies (Cy5-conjugated anti-rabbit, GE Healthcare) diluted 1:2500 in 
TBS. After washing membranes were dried and then scanned in the Cy5 (excitation 
filter: 635 nm, emission filter: 680 nm) channels by an Ettan DIGE imaging system.   
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Target protein  Primary antibody  source  Purchased from 
5-LO  AK 7  rabbit  Gift from Karolin-
ska Institutet, 
Stockholm 
ERK  1/2  p42/44  MAPK  rabbit  Cell Signalling 
phosphorylated 
ERK 1/2 
Phospho-p42/44  
MAPK 
rabbit  Cell Signalling 
Table 1 Description of Western blot antibodies 
 
3.12  Human whole blood assay 
For analysis of PG or LT biosynthesis products only freshly withdrawn blood from 
healthy volunteers was taken and immediately continued processing. The only re-
quirement for the volunteers was no uptake of NSAIDs for at least two days whereas 
the sex of the volunteers was no knock-out criterion. 
 
3.12.1  Determination of 5-lipoxygenase products in human whole blood 
For whole blood assays, freshly withdrawn blood was obtained by venipuncture and 
collected in monovettes containing 16 IE heparin/ml. Aliquots of 2 ml (A23187) or 3 
ml  (LPS  and  fMLP)  were  pre-incubated  with  the  test  compounds  or  with  vehicle 
(DMSO) for 10 min at 37°C, as indicated, and formation of 5-LO products and 12(S)-
hydroxy-5-cis-8,10-trans-heptadecatrienoic acid (12-HHT) was either started by addi-
tion of fMLP (1 µM) following priming of blood with 1 µg/ml LPS, or by addition of 
A23187 (30 µM). The reaction was stopped on ice after 15 (LPS priming and stimula-
tion with fMLP) or 10 (stimulation with A23187) min and the samples were centri-
fuged (600×g, 10 min, 4°C). Aliquots of the resulting plasma (500 µl) were then mixed 
with 2 ml of methanol and 200 ng PGB1 were added as internal standard. The sam-
ples were placed at -20°C for 2 hrs and centrifuged again (600×g, 15 min, 4°C). The 
supernatants were collected and diluted with 2.5 ml PBS and 75 µl 1 N HCl. Formed 
5-LO metabolites and 12-HHT were extracted and analyzed by HPLC as described 
above. Materials and Methods 
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Alternatively, 450 µl of freshly withdrawn human whole blood from volunteer male 
and female were incubated with drugs or vehicle over a preincubation period of 30 
min  at  37°C.  By  the  addition  of  A23187  (final  concentration  20  µM)  dissolved  in 
autologous plasma, 5-LO product formation was initiated. The final vehicle (DMSO) 
concentration was < 1 %, final volume 0.5 ml). After 15 min the reaction was stopped 
by  rapid cooling of the plate on ice. Samples were then centrifuged at 1.000xg at 
4°C for 15 min and 5-HETE, LTB4, 12-HETE, 15-HETE, and PGE2 in the plasma su-
pernatant were analyzed using LC-MS/MS (liquid chromatography coupled with tan-
dem mass spectrometry). LC-MS/MS analysis was performed on an API 4000 triple 
quadrupole  mass  spectrometer  (Applied  Biosystems,  Darmstadt,  Germany).  The 
mass transitions used were m/z 335.1195.0 (LTB4), m/z 319.2115.0 (5-HETE), 
m/z 319.2178.9 (12-HETE), m/z 319.2219.1 (15-HETE). For internal standardi-
zation  the  following  transitions  were  used:  m/z  339.2196.9  (2H4-LTB4),  m/z 
327.2116.1 (2H8-5-HETE), m/z 327.2184.1 (2H8-12-HETE), m/z 327.2 225.9 
(2H8-15-HETE). Linearity of the calibration curve was proven from 0.5 to 2500 ng 
ml/1 for each eicosanoid. Mean accuracy of the assay was 99.9 +/- 3.25% for LTB4, 
99.85 +/- 4.8% for 5-HETE, 100.2 +/- 4.8% for 12-HETE and 99.76 +/- 4.4% for 15-
HETE. 
 
3.12.2  Determination of cyclooxigenase-2 products in human whole blood 
Aliquots of heparinized human whole blood (500 µl) were incubated with LPS (10 
µg/ml) additionally to the test compound or vehicle (DMSO) for 24 hrs at 37°C. Exist-
ing platelet COX-1 activity was eliminated by the addition of aspirin simultaneously 
with test compounds (100 µM). Plasma was separated by centrifugation at 1.000xg 
and 4°C for 1 min and PGE2 in the plasma supernatant was analyzed by LC-MS/MS 
using the API 4000 triple quadrupole mass spectrometer as described above. 
 
3.13  Determination of human recombinant cyclooxigenase-2 activity 
Human recombinant COX-2 activity was assessed by a competitive enzyme-immuno-
assay with PGF2α as directly measured eicosanoid. COX-2 activity calculation was 
based  on  a  prostaglandin  standard  curve.  All  procedures  were  according  to  the 
manufactors protocoll from Cayman® Chemicals.  Materials and Methods 
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3.14 Saturation-transfer-difference  nuclear  magnetic  resonance  anlysis  of               
5-lipoxygenase 
Wildtype 5-LO was expressed in E.coli and purified by ATP-affinity-chromatography 
following ion-exchange chromatography (Resource Q 6 ml column, GE Healthcare). 
For buffer exchange the protein was dialyzed through a regenerated cellulose mem-
brane with a molecular weight cut-off of 3.5 kDa (Spectra/Por 3, Spectrumlabs, Bre-
dam, Netherlands) against deuterated phosphate buffer (50 mM) pH 7.5 over night at 
4°C under continous stirring. After dialysis the protein solution was concentrated us-
ing membrane filter units (Amicon® Ultra 4, Millipore, Cork, Ireland) where all resid-
ual H2O was finally replaced by D2O. Protein concentration was detemined by Brad-
ford  assay.  Samples  were  incubated  with  vehicle  (DMSO-d6)  or  sulindac  sulfide 
(dissolved  in  DMSO-d6)  and 4.4-dimethyl-4-silapentane-1-sulfonic  acid (DSS)  was 
added for an internal standard. Measurements were performed in a BRUKER Av III-
MHz spectrometer with Txi 
1H-
13C-
15N cryo-sample vial. Suppression of the water 
signal  was  processed  by  the  excitation  sculpting  program.  Irradiation  frequency 
within the ON-resonance experiments was 0.8 ppm, within the OFF-resonance ex-
periments 21.4 ppm with 50 Gaussian pulses with 1 % truncation. For suppression of 
protein signal, 30 ms spinlock was used. Data processing was performed with the 
program Topsin 2.1 (2009). 
 
3.15 Transfection of HeLa cells and reporter gene assay 
24 hrs prior to transfection, HeLa cells were seeded at a density of 4×10
4 cells per 
well. 0.8 µg 5-lipoxygenase luciferase reporter gene plasmid and 0.2 µg pCMVRenilla 
as  internal  standard  were  transfected  using  the  calcium  phosphate  method.  After 
transfection and incubation with Ssi (48 hrs), cells were assayed for reporter gene 
activity with the Dual-Glo™ Stop and Glow Luciferase Assay system following the 
manufacturer’s  protocol  (Promega)  and  measured  with  a  Tecan  infinite®  M200 
reader. Renilla activity was used to normalize the luciferase activity to the transfec-
tion efficacy. Data are shown as relative light units (RLU). Materials and Methods 
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3.16  Quantitative realtime PCR 
MM6-cells were harvested and washed twice with cold PBS buffer, then RNA extrac-
tion was perfomred using the total RNA Mini Kit (Omega) and concentrations of RNA 
were confirmed with a Nanodrop spectrofotometer (Implen GmbH, Munich). 2 µg of 
total RNA were then reverse transcribed into cDNA with the iScript cDNA synthesis 
Kit (Biorad). Quantitative PCR analysis was performed using a MyiQ cycler (Biorad). 
The used 5-LO primers covered the region between -286 to +78kb of the human 5-
LO promotor. 
Results were normalized against actin ct values. Each sample was set up in tripli-
cates and amplified for the indicated cycles. The expression was quantified by the 
comparative DDCT method. 
Table 2: Description of conditions and primers used for quantitative PCR.  
 
3.17 Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (ChIP) assay was performed using the ChIP assay 
kit (Millipore, Billerica, MA). MM6-cells (1×10
7) were treated with the indicated condi-
tions of Ssi for 72 hrs and incubated with 10 µM of MS-275 16 hrs prior to harvest. 
After 72 hrs, cells were fixed with 1 % formaldehyde for 10 min at 37°C and further 
precipitated with antibodies against Sp1 (Millipore) or normal rabbit IgG overnight at 
4°C. Purified DNA samples were used as a template for PCR amplification. The re-
gion between -286 to +78 of the human 5-LO promoter was amplified for 32 cycles. 
 
Target 
gene 
Primer forward  Primer reversed  Tempe-
rature 
[°C] 
Number 
of cycles 
5-LO                  GTTCCTGAATGGCTGCAAC  GTTCCTGAATGGCTGCAAC  60  32 
Sp1  GCTTCAGGCTGTTCCAAACTCT  CTGCCAACTGACCTGTCCATT  60  40 
ß-actin  CGGGACCTGACTGACTACCTC  CTTCTCCTTAATGTCACGCACG  60  32 Materials and Methods 
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3.18  Statistics 
All data are presented as mean + standard error of the mean (s.e.m.). GraphPad 
Prism version 5.0 (GraphPad Software, San Diego, California, USA) was used for 
statistical analysis. Data were subjected to one-way ANOVA coupled with two-sided 
turkey’s post t-test for multiple comparisons. The IC50 values were calculated using 
GraphPad  Prism  version  5.0  and  a  sigmoid  concentration-response  curve-fitting 
model with a variable slope.   Results   
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4  RESULTS 
4.1   Inhibition of leukotriene biosynthesis by sulindac sulfide 
4.1.1   Effect of Ssi on 5-lipoxygenase product formation in intact PMNL 
The effects of sulindac and its metabolites on 5-LO product (LTB4, its all-trans iso-
mers, and 5-H(p)ETE) formation were analyzed in human PMNL, the major 5-LO 
product-forming cells in peripheral blood [319]. The first series of experiments utilized 
A23187 as a stimulus, in order to activate 5-LO directly by an increase in intracellular 
calcium  to  circumvent  receptor  signaling  (e.g.  receptor mediated  MAPK  activation 
leading to phosphorylation of 5-LO). Exogenous AA (2 and 20 µM) as a supplement 
ensured an ample substrate supply for 5-LO. Both measures were taken to exclude 
interference of the compounds with signaling pathways and AA release. Concentra-
tion-response studies revealed that Ssi potently inhibited 5-LO product formation in 
A23187-stimulated PMNL in the absence as well as in the presence of exogenously 
added AA (2 and 20 µM), without significant different potency (IC50 = 9 and 10.6 µM). 
 
Fig. 12: Effect of Ssi on 5-LO product formation in A23187-stimulated intact PMNL in the presence or 
absence of AA 
7x10
6 cells were incubated with Ssi in increasing concentrations in the absence or presence of 2µM or 
20 µM AA, stimulated with A23187 (2.5 µM) and formed 5-LO metabolites were analyzed by HPLC. n 
≥ 3. Values are expressed as mean + SEM.  
 Results 
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Beside Ssi, the related compounds sulindac (Sul) and indomethacin (Ind) which dis-
plays a structural analogue to Ssi, were tested for 5-LO inhibition. Sulindac sulfone 
(Sso), a metabolite of sulindac, was investigated to test the specificity of suppression 
of 5-LO by Ssi. The compounds did not show any inhibiton of 5-LO product formation 
(Fig. 13). Only the well-known potent 5-LO inhibitor BWA4C (BWA), which is an iron-
ligand inhibitor (refer to Fig. 11, section 1.2.9) shows 5-LO inhibition and was used as 
control.  
 
Fig. 13: 5-LO inhibitory effect of Ssi, its  metabolites  and related compounds in A23187-stimulated 
PMNL 
7x10
6 cells were stimulated with A23187 (2.5 µM) and AA (20 µM) after incubation with compounds 
(30 µM) for 10 min at 37°C. Synthesized 5-LO products were detected by HPLC. n ≥ 3.  ***, p ≤ 0.001. 
Values are expressed as mean + SEM. 
  
4.1.2  Effect of Ssi on 5-, 12- and 15-LO product formation  
Since  PMNL  preparations (purity  >95  %)  contain  eosinophils  expressing  15-LO-1, 
also the effects of Ssi on the formation of 15-H(p)ETE were analyzed. In contrast to 
5-LO product synthesis, the formation of 15-H(p)ETE was slightly increased, rather 
than inhibited at SSi concentrations > 10 µM (Fig. 14). In addition, the effect of Ssi on 
platelet-type 12-LO was investigated. 12-H(p)ETE product formation was elicited in 
platelets by 5 µM AA, but no inhibition by Ssi was seen up to 30 µM. In contrast, acti-
vation of 12-LO could be detected. Ssi therefore selectively inhibited cellular 5-LO, 
but not 12- or 15-LO. Results 
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 Fig. 14:  Effect of Ssi on 5-, 12- and 15-LO product formation 
For  analysis  of  12-LO  product  formation,  freshly  isolated  platelets  were  incubated  with  5  µM  AA 
whereas 5- and 15-LO were analyzed in PMNL preparations. 7x10
6 cells were stimulated with 2.5 µM 
A2318 supplemented with 20 µM AA. All formed LO metabolites were detected by HPLC. n ≥ 3. Val-
ues are expressed as mean + SEM. 
 
4.1.3  Effect of Ssi on 5-lipoxygenase product formation of intact PMNL               
   triggered by different stimuli 
Previous studies showed that the type of stimulus and the signal transduction path-
ways  mediating 5-LO  activation  can  lead  to  different  efficacies  of  5-LO  inhibitors. 
Therefore, different stimuli were tested to evaluate the 5-LO inhibition pattern of Ssi. 
Effect of Ssi on 5-lipoxygenase actvitiy in intact PMNL stimulated with physio-
logical stimuli  
In another series of experiments, PMNL were primed with lipopolysaccharide (LPS) 
in the presence of adenosine deaminase (Ada) and then challenged by the natural 
chemoattractant  fMLP.  These  assay  conditions  were  designed  to  closely  mimic 
pathophysiological conditions in the body [319] and therefore offer an estimate of the 
efficacy of 5-LO inhibitors in vivo [308]. Generation of 5-LO products in PMNL follow-
ing stimulation with fMLP (after priming with LPS/Ada, 1 µg/ml/0.2 U/ml) was potently 
suppressed by Ssi with an IC50 = 7.7 µM (Fig. 15). (Data obtained in cooperation with 
C.Pergola, group of Prof. O. Werz, University of Tübingen) Results 
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Fig. 15: Effect of Ssi on 5-LO product formation in intact PMNL triggered by LPS/Ada and fMLP 
Freshly isolated PMNL (7x10
6 cells) were first primed with 1 µg/ml LPS and Ada (0.2 U/ml) for 30 min 
and then incubated with 1 µM fMLP for another 15 min. Quantification of 5-LO products was carried 
out by HPLC analysis. n ≥ 3. Values are expressed as mean + SEM. 
 
Effect of Ssi on 5-lipoxygenase actvitiy in intact PMNL stimulated with  
chemical stimuli  
Previous studies showed that the type of stimulus and the signal transduction path-
ways mediating 5-LO activation can lead to different efficacies of 5-LO inhibitors in 
PMNL [320].  Hence,  we  compared  the  potencies  of  Ssi  in  PMNL  stimulated  with 
A23187 (2.5 µM), hyperosmotic shock (0.3 M NaCl) and genotoxic stress using so-
dium arsenite [321]. All incubations contained exogenous AA (20 µM). IC50 values 
ranged between 8.6 and 14 µM (Fig. 16), but in contrast to A23187-activated cells, 
Ssi failed to completely reduce 5-LO product synthesis in PMNL challenged by cell 
stress, plateauing with approximately 30 % remaining 5-LO activity.  
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Fig. 16: Effect of Ssi on 5-LO product formation in PMNL stimulated with A23187, SC and SA 
5x10
7 cells were pre-incubated with Ssi in increasing concentrations for 15 min at 37°C. SA (10 µM) 
and SC (300 mM) were added 3 min prior to the addition of 20 µM AA, ionophore was added together 
with 20 µM AA. 5-LO metabolites were quantified by HPLC analysis. n=3. Values are expressed as 
mean + SEM. 
 
4.1.4  Effect of sulindac and metabolites on human recombinant 5-lipoxygenase              
  product formation 
As Ssi potently reduced 5-LO product formation in intact PMNL the question was ad-
ressed whether Ssi interferes directly with the catalytic domain of the 5-LO enzyme. 
Therefore, affinity-purified human recombinant 5-LO protein was incubated with the 
compounds indicated and 20 µM AA was added as substrate. Sulindac, which under-
lines oxidative metabolism in the human body to either sulindacsulfone and further 
conversion to Ssi, showed no suppressive effects whereas sulindacsulfone moder-
ately, but not significantly reduced 5-LO activity by ~ 20 %. Only treatment with Ssi 
led to a potent inhibition of 5-LO enzyme activity with an IC50 of 20 µM (Fig. 17) al-
though with a somewhat lower potency compared to intact PMNL (IC50 values 7.7 – 
14 µM). Results 
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Fig. 17: Effect of Sul and metabolites Sso and Ssi on recombinant 5-LO product formation 
Recombinant 5-LO was preincubated for 15 min with the compounds as indicated and then stimulated 
with 2 mM Ca
2+ and 20 µM AA was added. After the reaction 5-LO HPLC analysis of 5-LO products 
followed. n=4. Values are expressed as mean + SEM. 
 
But in contrast to BWA4C, Ssi did not entirely reduce 5-LO activity in the cell-free 
assay and about 30 % residual activity still remained. BWA4C was used as reference 
5-LO inhibitor. Indomethacin (Ind), an unselective COX-inhibitor, was used as nega-
tive control. As expected, Ind did not influence 5-LO product formation in contrast to 
BWA4C. Sso had only weak inhibiting effects (Fig. 18). 
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Fig. 18: Effect of Ssi, Sso, sulindac, indomethacin and BWA4C at the concentrations indicated on 
recombinant 5-LO activity 
5-LO product  formation was determined by HPLC  after incubation with Sul, Sso,  Ssi and controls 
BWA4C and indomethacin and stimulation of recombinant 5-LO protein with Ca
2+ (2 mM) and AA (20 
µM). n ≥ 3. ***, p ≤ 0.001. Values are expressed as mean + SEM. 
 
4.1.5  Effect of Ssi on A23187-induced subcellular redistribution of                      
  5-lipoxygenase in intact PMNL 
Since Ssi was more effective in the context of intact PMNL than with purified recom-
binant 5-LO, the inhibitor may affect additional 5-LO stimulatory mechanisms in intact 
cells, such as FLAP. In fact, sulindac exhibits structural similarity to the FLAP inhibi-
tor MK-886 (refer to 1.2.9). Functional FLAP acts as an anchor for facilitating access 
to the natural substrate AA and FLAP-inhibiting compounds block the translocation to 
the nuclear membrane. FLAP inhibitors share the ability to reverse agonist-induced 
translocation of 5-LO from the cytosol to the nuclear envelope in PMNL [322]. Ssi (10 
-100 µM), but not Sso or Sul, partially reversed 5-LO redistribution from the cytosol to 
the nucleus in PMNL evoked by A23187 with an efficacy comparable to MK-886 (100 
nM). As observed in previous experiments, the 5-LO inhibitor BWA4C did not affect 
A23187-induced 5-LO redistribution at a concentration of 300 nM [309]. (Data ob-
tained in cooperation with C.Pergola, group of Prof. O. Werz, University of Tübingen) 
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Fig. 19: Effect if Ssi and other control agents on A23187-induced subcellular redistribution of 5-LO in 
intact PMNL 
3x10
7 cells were pretreated with the compounds at 37°C for 15 min. A23187 (2.5 µM) were added for 
another 5 min. Nuclear (nuc) and nonnuclear (non-nuc) fractions were obtained by 0.1% NP-40-lysis 
and samples were then subjected to SDS PAGE and Western blotting. A representative out of three 
independent experiments is shown.   
 
4.1.6  Effect of A23187-induced 5-lipoxygenase product formation in PMNL         
   in the presence of MK-886  
To further understand the mode of action of Ssi on 5-LO and to exclude any FLAP-
inhibiting properties of the drug, a competition assay was designed where Ssi’s ability 
to suppress cellular 5-LO product formation in an additive manner to MK 886 was 
investigated. PMNL were incubated with 5 µM MK-886 and subsequently stimulated 
with a mixture of 2.5 µM A23187 and 40 µM AA. In the presence of ample exogenous 
AA (40 µM), the effectiveness of FLAP inhibitors is typically reduced and even high 
concentrations of MK-886 (5 µM) failed to completely inhibit 5-LO product formation, 
and approximately 45% 5-LO activity still remained [323]. This basal activity is con-
sidered a FLAP-independent conversion of AA by 5-LO. In line, the failure of coincu-
bation of MK-886 with the FLAP inhibitor MK-0591 (IC50=3.1 nM) to further reduce 5-
LO  product  formation  demonstrated  this  independence  [324].  By  contrast,  co-
incubation of Ssi (10 µM) together with MK-886 further suppressed 5-LO product syn-
thesis suggesting that Ssi has molecular targets other than FLAP. Co-incubation of Results 
59 
MK-886 with zileuton, a well-known direct 5-LO inhibitor, also reduced activity to a 
near zero level.  
 
 
Fig. 20: Effect of Ssi and related compounds on A23187-induced 5-LO product formation in PMNL in 
presence of MK-886 
Cells were preincubated with MK-886 (5µM) and other compounds for 10min and the reaction was 
started by the addition of 40µM AA and 2.5µM A23187. Activity was assessed by HPLC analysis and 
expressed relatively to vehicle control (100%). n=3-6. *** p ≤ 0.001; * p≤ 0.05. Values are expressed 
as mean + SEM. 
 
4.1.7  Suppression of 5-lipoxygenase product formation by Ssi in human whole  
  blood  
Finally, Ssi was tested for its ability to suppress LT formation in human whole blood. 
Several inhibitors of LT biosynthesis have demonstrated high potency in isolated leu-
kocytes but failed to efficiently interfere with 5-LO product formation in whole blood, 
due to plasma protein binding or to competition with other molecules, such as fatty 
acids [146] . Thus, the ability of a given compound to suppress LT formation in the 
whole  blood  assay may  provide  some perspective  of  its  efficacy in  vivo.  Ssi  was 
therefore added to venous blood from healthy volunteers to concentrations achieved 
under standard oral therapy with sulindac (up to 40 µM [60]). After 10 min, the blood Results 
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was either pre-incubated with LPS for 30 min and then stimulated with 1 µM fMLP or 
stimulated with the Ca
2+-ionophore A23187 alone. The formation of 5-LO products 
was concentration-dependently inhibited by Ssi with IC50 values of 18.7 (fMLP) and 
41.4 µM (A23187) (Fig. 21). Furthermore, the formation of 12-H(p)ETE in the same 
samples of A23187-challenged blood was only moderately inhibited (34.5 ± 14% at 
100 µM SSi, data not shown). (Data obtained in cooperation with C.Pergola, group of 
Prof. O. Werz, University of Tübingen; LC-MS/MS measurements were performed by 
C. Angioni, group of Prof. G. Geißlinger, Hospital of Goethe University, Frankfurt) 
 
 
Fig.21: Effect of Ssi on 5-LO product formation triggered by different stimuli in human whole blood 
Human whole blood was incubated with LPS (1 µg/ml) and fMLP (1 µM) or A23187 (30 µM) and ana-
lysed by LC-MS/MS for 5-LO metabolites. n ≥ 3. *** p ≤ 0.001; * p ≤ 0.05. Values are expressed as 
mean + SEM. 
 
Both sulindac and Sso failed to significantly inhibit 5-LO product formation at concen-
trations up to 100 µM, whereas the 5-LO inhibitor BWA4C (3 µM; control) did sup-
press  5-LO  (Fig.  22).  (LC-MS/MS  measurements  were  performed  by  C.  Angioni, 
group of Prof. G. Geißlinger, Hospital of Goethe University, Frankfurt) 
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Fig. 22: Inhibitory effect of Ssi, Sso, Sulindac and BWA4C on 5-LO product formation in human whole 
blood 
Human whole blood was incubated with the compounds as indicated and the stimulated with A23187 
(30 µM) for 15min and analyzed for 5-LO metabolites by LC-MS-MS. n ≥ 3. *** p ≤ 0.001; *p ≤ 0.05. 
Values are expressed as mean + SEM. 
 
4.1.8  Suppression of cyclooxigenase product formation by Ssi in human whole 
  blood 
Previous studies attributed Ssi’s anti-inflammatory effect to the inhibition of prosta-
glandin synthesizing enzymes, the COX enzymes [325]. In order to compare the in-
hibiting properties of Ssi towards 5-LO and COX enzymes, COX-1 and COX-2 activ-
ity  was  evaluated  in  whole  blood.  Therefore,  blood  samples  were  incubated  with 
drugs and stimulated with LPS 1 µg/ml and incubated 24 hrs at 37°C. Prostanoids 
were then subjected to LC-MS/MS analysis. Lipid mediators analyzed were the COX-
2 derived PGE2, the mainly via the COX-1 pathway obtained 12-HHT and the 5-LO 
derived LTB4 and 5-HETE. Products formed via the COX-pathways are effectively 
suppressed so that PGE2 and 12-HHT production reached almost zero level at Ssi 
concentrations of 100 µM. Calculated IC50 values range from 3 µM (12-HHT) to 3.9 
µM (PGE2). 5-LO activity was affected as well and inhibited at 100 µM Ssi to ~20% 
remaining activity (Fig. 23). (COX-1 derived products were measured by C.Pergola, 
group of Prof. O. Werz, University of Tübingen; LC-MS/MS measurements of COX-2 Results 
62 
and 5-LO products were performed by C. Angioni, group of Prof. G. Geißlinger, Hos-
pital of Goethe University, Frankfurt) 
 
 
 
Fig. 23: Effect of Ssi on eicosanoid formation in human whole blood 
Ssi was added to whole blood in concentrations as indicated. Samples were either stimulated with 
LPS (for 24 hrs) for prostanoid analyses or with A23187 (30 µM) and incubated for 15 min for  LT 
analyses. n ≥ 3. *** p ≤ 0.001; * p ≤ 0.05. Values are expressed as mean + SEM. 
 
Additionally, influence of the prodrug Sulindac and the metabolites Sso and Ssi on 
COX-2 derived PGE2 and COX-1 derived 12-HHT product formation was assessed in 
human whole blood. COX-product formation was not or only moderately influenced 
by Sul and SSo which is in line with the reported lack of inhibition of COX by these 
molecules described in section 4.1 and 4.2. In contrast, Ssi potently suppressed the 
formation of metabolites to almost zero levels (Fig. 24). (COX-1 derived products 
were measured by C.Pergola, group of Prof. O. Werz, University of Tübingen; LC-
MS/MS measurements were performed by C. Angioni, group of Prof. G. Geißlinger, 
Hospital of Goethe University, Frankfurt) Results 
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 Fig. 24: Comparison of inhibition of 12-HHT and PGE2 synthesis by Ssi, Sso and sulindac in human 
whole blood 
Human whole blood was incubated with the inhibitors LPS (1 µg/ml) and either stimulated with A23187 
(30 µM) and analyzed for 5-LO metabolites by LC-MS-MS. n ≥ 3. *** p ≤ 0.001; * p ≤ 0.05. Values are 
expressed as mean + SEM. 
 
4.1.9  Saturation-transfer-difference nuclear magnetic resonance analysis of     
   5-lipoxygenase in the presence of Ssi 
An approach to detect a direct binding of Ssi to 5-LO was undertaken by saturation-
transfer-difference nuclear magnetic resonance (STD-NMR) spectroscopy. 5-LO pro-
tein produced in E.coli was purified first via  ATP-affinity chromatography and in a 
second step via ion-exchange chromatography. For gaining the reference spectrum 
(
1H-NMR spectrum) of Ssi, 160 – 200 µM Ssi were mixed with the additional volume 
deuterated sodium-dihydrogenphosphate buffer to a final volume of 600 µl in a 3 mm 
NMR-sample vial. For the STD-NMR sample spectrum, Ssi was added to a 8 µM 5-
LO protein solution in deuterated buffer. To ensure protein signals, a protein solution 
without inhibitor but with DMSO-d6 as solvent was measured (data not shown).  A 
summary of the obtained data is shown in Fig. 25 below. In red, the inhibitor refer-
ence spectrum revealed clearly the different signals from the Ssi molecule. Numbers Results 
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on the chemical structure of Ssi pointed out the characteristic peaks appearing in the 
spectrum. Residual peaks are artefacts of the difference formation process. The blue 
spectrum which presents the STD-NMR spectrum shows significantly reduced peak 
intensities due to protein binding. Peaks could clearly be allocated to the inhibitor 
profile in the red spectrum. (Data obtained in cooperation with F. Löhr, group of Prof. 
V. Dötsch, Goethe University Frankfurt) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Results 
65 
STD-NMR spectrum  of inhibitor Ssi and  inhibitor Ssi with  5-LO protein     
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Fig. 25: STD-NMR spectrum of Ssi and 5-LO in comparison to a 
1H-NMR spectrum of Ssi 
The red spectrum displays the reference spectrum of the 5-LO inhibitor Ssi (160 - 200 µM, in deuter-
ated 50 mM phosphate buffer). In blue, the spectrum of the inhibitor in the mixture with 5-LO protein (8 
µM, Ssi 160 - 200 µM)) is depicted.  
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4.2   C2-like domain mediated 5-lipoxygenase inhibition by sulindac sulfide  
After description and characterization of Ssi-mediated inhibition of LT biosynthesis in 
different systems such as intact leukocytes, recombinant purified 5-LO and human 
whole blood, this chapter furthermore deals with the characterization of the underly-
ing mechanisms of Ssi-mediated suppression of 5-LO product formation. Results of 
the antecedent section pointed out that reduced 5-LO activity by Ssi did not result 
from suppression of FLAP or competition with its natural substrate AA. Hence, further 
investigations focused on the molecular mechanism possibly mediating the interfer-
ence of the drug with a functional part of the 5-LO enzyme. 
 
4.2.1  Comparison of the 5-lipoxygenase inhibitory potency of Ssi in different 
   cellular systems 
First, it was investigated whether the Ssi’s inhibitory potency is influenced by the type 
of test systems and if the cellular environment and its specific composition impact the 
efficacy of Ssi’s inhibition on LT biosynthesis. Therefore, different cellular prepara-
tions of PMNL beside intact cells, such as cell homogenates and the 100,000xg su-
pernatant (S100) were used. 5-LO product formation was started by the addition of 
CaCl2  (2  mM)  and  exogenously  added  AA  (20  µM).  The  concentration-response 
curves in Fig. 26 revealed a considerable difference in Ssi’s potency to suppress 5-
LO product formation comparing intact cells and the purified recombinant enzyme 
versus  broken  cell  preparations  and  the  S100. Both,  intact  PMNL  and  pure 5-LO 
showed IC50 values ranging from ~ 15-25 µM in contrast to broken cell preparations 
and the S100 where a clear loss of potency of Ssi is detectable. This loss of potency 
is reflected in IC50 values from ~ 30 µM (S100) up to ~ 100 µM (cell homogenates). 
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 Fig. 26: Comparison of Ssi’s 5-LO inhibitory potency in intact PMNL, cell homogenates, S100 and 
with purified 5-LO enzyme 
5-LO activity was measured in intact cells (7x10
6) stimulated with 2.5 µM A23187 and 20 µM AA. In 
PMNL homogenates, S100 and recombinant  enzyme, 5-LO product formation was initiated by  the 
addition of 2 mM Ca
2+ and 20 µM AA. Levels of 5-LO metabolites were assessed by HPLC analysis. 
n=4. Values are expressed as mean + SEM. 
 
Changes of the cellular composition of different cellular systems may interfere with 
the redox tone within the catalytic unit of the 5-LO enzyme which contains a non-
heme iron that needs to be transformed to the ferric state (Fe
3+) during enzyme acti-
vation. Thus, it seemed obvious to evaluate whether the observed loss of potency of 
Ssi in homogenates and S100 depends on a modified oxidation state of the enzyme 
as true for non-redox type 5-LO inhibitors [289]. Therefore, intact cells and cell prepa-
rations were incubated with Ssi or additionally with the reducing agent DTT (5 mM). 
ZD-2138, a non-redox-type inhibitor (refer to Fig. 11, section 1.2.9) which inhibits 5-
LO potently in Ca-ionophore stimulated intact PMNL (IC50 ~ 50 nM) and which was 
reported  to  lose  its  5-LO  inhibitory  potency  in  cell-free  preparations  under  non-
reducing conditions, functioned as internal assay control (Fig. 28) [289, 326]. Inhibi-
tion of 5-LO product formation by Ssi occurred in intact cells whereas Ssi did not 
suppress 5-LO product formation in homogenates and S100 regardless of the pres-
ence or absence of DTT resulting in only ~30 % enzyme inhibition. BWA4C worked 
as control agent and led to ~ 80 % enzyme inhibition (Fig. 27). Results 
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 Fig. 27:  Effect of Ssi and BWA4C on 5-LO product formation in intact cells, homogenates and S-100 
in presence or absence of DTT 
Intact cells (7x10
6) and cell preparations (homogenates and  S100) were either incubated with  Ssi 
alone or in combination with 5 mM DTT, stimulated with Ca-ionophore (2.5 µM, intact cells) or Ca
2+ (2 
mM, homogenates and S100) and AA (20 µM) was supplemented. HPLC analysis for product forma-
tion analysis was performed.n=4. Values are expressed as mean + SEM.   
 
In intact cells, ZD-2138 led to suppression of 5-LO product formation regardless of 
whether DTT was added to the reaction mixture or not. Contrarily, in cell homogen-
ates and S100 its inhibitory potency on 5-LO enzyme was depending on the pres-
ence of DTT and was only effective in DTT-containing samples. 
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Fig. 28 Effect of ZD-2138 and BWA4C on 5-LO product formation in intact cells, homogenates and S-
100 in presence or absence of DTT 
5-LO activity was measured in intact cells (7x10
6), stimulated with 2.5 µM A23187 and 20 µM AA. In 
PMNL homogenates, S100 and recombinant enzyme, 5-LO product formation was started by the addi-
tion of 2 mM Ca
2+ and 20 µM AA. Levels of 5-LO metabolites were assessed by HPLC analysis. n=4. 
Values are expressed as mean + SEM. 
 
4.2.2  Influence of Ssi on phospholipase D activity 
Further  studies  were  undertaken  in  order  to  clarify  possible  cellular  pathways  in-
volved in 5-LO modulation mediated by Ssi. The question was addressed whether 
Ssi shows PLD-inhibiting properties. Cells were preincubated with vehicle (DMSO), 
Ssi 30 µM, 5-fluoro-2-indolyl-des-chlorohalopemid (FIPI, 100 µM), a potent PLD in-
hibitor acting as assay control. Product formation was initiated by 2.5 µM A23187 for 
3 min. After resuspension, sonication and centrifugation of the cells the produced 
choline was continued processing and finally resorufin was detected by fluorescence 
measurements. Results were expressed in three different patterns: choline amount in 
pmol/mio cells, the change of choline in pmol/mio cells and the choline change as 
percentage of control. Neither A23187-stimulated cells nor cells treated with 30 µM 
Ssi, which showed 2-fold excess choline amount over control, were affected com-
pared  to  the  control  inhibitor  FIPI  which  inhibits  PLD  as  expected.  The  relative 
amount of choline decreased to ~ 70 pmol/mio cells whereas cells incubated with Ssi 
only showed moderate loss of choline amount which is in line with the percentual de-
picture  (Fig.  29). (Data  obtained  in  cooperation  with  C.Pergola,  group  of  Prof.  O. 
Werz, University of Tübingen) Results 
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Fig. 29: Influence of Ssi and FIPI in A23187-stimulated PMNL on PLD activity 
2.5x10
6 cells (PMNL) were incubated with vehicle or Ssi (30 µM) and stimulated with A23187 (2.5 µM) 
for 3 min. Formed choline was processed to obtain the fluorescent product resorufin which was finally 
determined. n=3. Values are expressed as mean + SEM. 
 
4.2.3  Effect of Ssi on calcium mobilization in intact PMNL 
Increased Ca
2+ influx triggered by inflammatory stimuli leads to high intracellular Ca
2+ 
levels and is a potent stimulatory factor for the enhancement of 5-LO activity [145]. 
To clarify, whether Ssi shows interactions with a cellular target or is involved in cellu-
lar processes upstream of direct interactions with the 5-LO protein, a possible inter-
ference with intracellular Ca
2+ mobilization was investigated. The Ca
2+ release from 
human PMNL was observed and detected over a time-course of 100 s. Cells (1x10
7) 
were supplemented with 1 mM CaCl2 and the startpoint of Ca
2+ release was the addi-
tion of 1 µM fMLP known as a less vigorous but physiological Ca
2+-related stimulus 
[327]. As notable in Fig. 30, the intracellular free Ca
2+ levels rose upon fMLP stimula-
tion after 25 s and slowly decreased reaching ~ 100 nm intracellular Ca
2+ after 100 s. 
The sample incubated with Ssi behaved similar to the untreated vehicle (DMSO) con-
trol. In the right graph the same picture evoked as it differs only from the depiction 
where the emission at 530 nm wavelength is plotted against time. Obviously, Ssi Results 
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showed no different behaviour compared to control. (Data obtained in cooperation 
with C.Pergola, group of Prof. O. Werz, University of Tübingen) 
 
 
Fig. 30: Interference of Ssi with calcium mobilization in intact PMNL evoked by the stimulus fMLP 
Free Ca
2+-levels were assessed with a fluorospectrometric assay. Incubation of 1x10
7 intact PMNL 
with a fluorophor containing substrate for 30 min was performed. After washing the cells, preincuba-
tion with either DSMO or Ssi for 10 min at 37°C occurred before the Ca
2+ release was started with the 
addition of 1 µM fMLP. Emission was measured at 530 nm with a fluorospectrometer. 
 
4.2.4  Involvement of mitogen-activated protein kinase pathway on Ssi- 
   mediated 5-lipoxygenase suppression in intact PMNL 
As kinase pathways play a regulatory role on cellular LT biosynthesis, one reason-
able approach seemed to evaluate involvement of kinase pathways in Ssi-mediated 
5-LO suppression. It is published that ERK 1/2, a member of the MAP kinase family, 
phosphorylates the 5-LO protein at residue ser-663 and in turn upregulates the en-
zyme’s activity [190]. To achieve insight into possible Ssi-mediated ERK regulation in 
intact PMNL and in turn resulting in downstream modulation of 5-LO activity, cells 
were incubated with Ssi and its metabolites, respectively. U0126 is a potent MK-2 
and MK-3 kinase inhibitor that inhibits the phosphorylation reaction of ERK1/2 and 
therefore displays the inhibitor control. After stimulation of LT product formation the 
reaction was stopped and cells were mixed with 5x loading buffer (5xLB), boiled and 
afterwards proteins were separated by SDS-PAGE and Western blot was performed. 
Increasing concentrations of the active metabolite of Sul, Ssi, did not alter the level of Results 
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phosphorylated ERK-2 protein as demonstrated in Fig. 31. Likewise, Sul and Sso 
showed the same results. As expected, the control inhibitor U0126 assay inhibited 
the phosphorylation of ERK. (Data obtained in cooperation with C.Pergola, group of 
Prof. O. Werz, University of Tübingen) 
 
 
Fig. 31: Effect of Ssi on ERK-phosphorylation in fMLP-stimulated PMNL 
1x10
7 PMNL were incubated with the Ssi and its metabolites concentrations as indicated. U0126 was 
used as control inhibitor. Samples were stimulated with fMLP (100 nm) to induce 5-LO product syn-
thesis. After the reaction, cells were mixed with 5xLB and boiled for cell lysis and preparation for SDS-
PAGE. Western blot analysis followed. A representative of three independent experiments was shown.  
.  
4.2.5  Recovery of Ssi-suppressed 5-lipoxygenase activity by the addition of 
  microsomes to human recombinant 5-lipoxygenase enzyme 
A loss of Ssi’s potency on 5-LO product formation in cell homogenates and S100 of 
PMNL was observed in former experiments. As investigations concerning the under-
lying mechanism revealed that Ssi may interfere directly with the 5-LO enzyme, the 
following studies were designed to mimic the situation present in cell homogenates 
by  addition of  microsomes  from  PMNL  to  the  purified  5-LO  enzyme  [328].  Micro-
somes, for example, are present in broken cell preparations but disappear by cen-
trifugation in the 100.000xg supernatant. Recombinant, human 5-LO was expressed 
in E.coli and purified by ATP-affinity chromatography. Microsomes from PMNL were 
prepared as described in Materials and Methods and preincubated for 15 min on ice 
with recombinant enzyme before test compounds were added. 5-LO enzyme activity 
was started with the addition of Ca
2+ and AA. Ssi alone caused ~ 80 % enzyme inhi-Results 
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bition. Samples coincubated with 100 µg microsomes and Ssi led to only ~ 50 % in-
hibition of 5-LO product formation.The preincubation of 300 µg microsomes with 5-
LO enzyme resulted in a completely restored 5-LO catalytic activity and blocked 5-LO 
inhibition by Ssi. 
       
Fig. 32: Influence of exogenously added microsomes on inhibition of recombinant 5-LO in the pres-
ence of Ssi 
Different amounts of microsomes from PMNL (total protein 100 or 300µg) were preincubated 15 min at 
4°C with recombinant 5-LO and then Ssi was added at the indicated concentrations for another 15 
min. After starting the reaction by the addition of Ca
2+ (2 mM) and AA (20 µM), 5-LO metabolites were 
subjected to HPLC analysis. n=3. * p ≤ 0.05. Values are expressed as mean + SEM. 
 
To  investigate, whether the impaired inhibitory potency induced by microsomes is 
unique to Ssi, two sets of controls were designed. First, as negative control the well-
recognized iron-ligand inhibitor BWA4C was utilized interfering with the non-heme 
iron located in the center of the catalytic unit of the enzyme. The compound is only 
slightly affected in its inhibitory potency by the addition of 300 µg/sample microsomes 
at 1 µM. (Fig. 33). Results 
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Fig. 33: Influence of the addition of PMNL-derived microsomes on inhibition of recombinant 5-LO by 
BWA4C 
Purified 5-LO was investigated for 5-LO product formation by incubation either with BWA4C in differ-
ent concentrations or by BWA4C and microsomes (300 µg) added to the reaction mix. Samples were 
stimulated by the addition of Ca
2+ 2 mM and AA 20 µM. Examination of metabolites was carried out by 
HPLC analysis. n=3. Values are expressed as mean + SEM. 
 
Secondly, hyperforin, the major component of St.John’s wort (Hypericum perforatum) 
and a potent inhibitor of 5-LO which acts by interfering with the C2-like-domain of 5-
LO, was chosen for positive control (refer to Fig.11, section 1.2.9) [309]. Hyperforin 
clearly reduced 5-LO activity down to ~ 20 % product formation at 10 µM. Hence, 
preincubation with microsomal fractions (300 µg) impaired these effects notably and 
restored complete 5-LO enzyme activity.  Results 
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Fig. 34: Influence of the addition of PMNL-derived microsomes on inhibition of recombinant 5-LO by 
hyperforin 
Purified 5-LO was investigated for 5-LO product formation by incubation either with hyperforin in dif-
ferent concentrations or by hyperforin and microsomes (300 µg) added to the reaction mix. Samples 
were stimulated by the addition of Ca
2+ (2 mM) and AA (20 µM). Determination of the formed 5-LO 
metabolites was carried out by HPLC analysis. n=3. Values are expressed as mean + SEM. 
 
4.2.6  Influence of phospholipids on 5-lipoxygenase inhibition by Ssi 
From the data shown on the previous section where microsomes impaired the inhibi-
tory efficacy of Ssi on 5-LO, extended investigations were carried out to obtain more 
detailed information about a possible binding of Ssi to the regulatory domain C2-like 
of 5-LO. The following experiment analyzed the capacity of PC to counteract the in-
hibition of 5-LO activity induced by Ssi. For testing this, purified enzyme was incu-
bated with two different types of phospholipids such as PC and PE at concentration 
of 100 µg/ml in PBS/EDTA buffer and Ssi was directly added to the reaction mixture. 
Stimulated samples (Ca
2+, 2 mM) were supplemented with substrate (AA 20 µM) and 
the  formed  5-LO  metabolites  were  determined  by  HPLC  analysis. In  Fig.  35  Ssi-
suppressed 5-LO product formation was visible in absence of phospholipids. Only in 
the presence of PC and Ssi enhanced 5-LO product formation was detected com-
pared to the data obtained with PE and Ssi. This is reflected in the IC50 values that 
range from ~ 30 µM (100 µg/ml PE +Ssi) to >100 µM (100 µg/ml PC +Ssi).  Results 
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Fig. 35: Influence of PC and PE on Ssi-mediated 5-LO inhibition  
PE (100 µg/ml) and PC (100 µg/ml) were incubated together with increasing concentrations of Ssi and 
puified, recombinant enzyme. Stimulation with Ca
2+ (2 mM) and AA (20 µM) initiated 5-LO product 
formation followed by detection via HPLC. Samples incubated with Ssi were calculated in relation to 
the control with only 10 µg/ml PC, respectively. n=3. Values are expressed as mean + SEM. 
 
Next, dose response characteristics of PC were determined. In line with Fig. 35, puri-
fied 5-LO enzyme was incubated with PC in increasing concentrations. In this mem-
brane-mimicking model an abolition of suppression of 5-LO product formation by 100 
µM Ssi is observed by titrating increasing concentrations of PC to the reaction mix-
ture (Fig. 36). Ssi suppressed the 5-LO activity level to ~ 10 % remaining enzyme 
activitiy which did not differ from samples incubated with 1 µg/ml PC. But at a con-
centration of 3 µg/ml PC 5-LO enzyme activity started to be restored from ~ 30 % - ~ 
60  %. Differences  between  samples  with Ssi  treatment  and  samples  treated  with 
Ssi+100 µg/ml PCl were significant (Fig. 36). Results 
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Fig. 36: Influence of increasing amounts of PC on Ssi-mediated 5-LO inhibition 
Samples containing 5-LO enzyme in buffer were analyzed regarding 5-LO metabolite production after 
incubation with Ssi (100 µM) or Ssi (100µM) and increasing concentrations of PC [µg/ml] as indicated. 
The control was determined in ratio to product formation in samples were enzyme was incubated with 
only PC in the concentrations indicated. * p ≤ 0.05. Values are expressed as mean + SEM. 
 
In order to confirm the monitored effect of PC and to exclude phospholipid mediated 
unspecific effects on Ssi, two further phospholipids, without affinity to the C2-like-
domain of 5-LO enzyme [214] were tested under the same conditions. A concentra-
tion of 100 µg/ml PC counteract the inhibitory effect of Ssi on 5-LO and based on 
that, concentrations of PE and PS were adapted. As control, 5-LO activity assays 
were conducted with only Ssi or with lipids alone. Samples incubated with Ssi+ PC, 
PE or PS (100 µg/ml), respectively were analyzed for 5-LO product formation. Sup-
pression of 5-LO by Ssi was validated by the incubation with 100 µM Ssi and only ~ 
10 % 5-LO activity remained. In contrast, PC increased the 5-LO product formation to 
about 60 % of control which is in line with the previous findings (Fig. 36). This was 
not observed for the samples incubated with PE or PS in the presence of Ssi where 
5-LO activity remained at ~ 20 % and behaved like the Ssi control (Fig. 37).
 Results 
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Fig. 37:  Comparison of the influence of different lipids on Ssi-mediated 5-LO suppression 
Recombinant 5-LO was incubated with Ssi at 100 µM alone, with different phospholipids alone (PC, 
PE, PS, c=100 µg/ml) or with the combination of Ssi and phospholipids. 10 min after starting the reac-
tion by the addition of  2 mM Ca
 2+ and supplementation of 20 µM AA, metabolites were detected by 
HPLC.n=4. ** p=0.01; * p≤ 0.05. Values are expressed as mean + SEM. 
 
To  ensure that the determined effects were not underlying any unspecific mecha-
nisms  of  interactions  between  Ssi  and  the  lipids,  the  following  experiments a d-
dressed whether other 5-LO inhibitors with well-recognized binding modes were in-
fluenced in their inhibition efficacy in presence of PC. BWAC, also used in former 
experiments,  shows the profile of an iron-ligand-inhibitor of 5-LO interfering with the 
non-heme-iron  in  the  enzyme’s  catalytical  domain  [282].  Therefore, e xperiments 
were carried out by incubating 5-LO enzyme with BWAC 1 µM and BWA4C 1 µM in 
addition to 100 µg/ml PC (Fig. 38). Supplementary, Ssi was again tested for 5-LO 
inhibition alone or in addition with PC. As expected, almost completely abolished en-
zyme activity was obtained by incubation of Ssi and BWA4C alone with purified 5-LO. 
But the reversibility of the 5-LO inhibition mediated by PC only occurred in samples 
incubated with Ssi and PC, not with BWA4C and PC. Results 
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Fig. 38: Influence of PC on 5-LO product formation in the presence of Ssi and BWA4C 
Samples were incubated with compounds and with or without PC with concentrations as indicated. 5-
LO product synthesis was started with Ca
2+ (2 mM) and ensured by supplementation of substrate AA 
(20 µM). Afterwards, products were detected by UV-absortion by HPLC. n=3. ** p ≤ 0.01. Values are 
expressed as mean + SEM. 
 
4.2.7  Effect of Ssi on recombinant cyclooxigenase-2 activity in presence of 
   lipid vesicles 
It is known from literature that phospholipid molecules are assumed to ressemble 
biological membranes by the formation of liposome vesicles and to emulate interac-
tions with drugs, they can function as artificial membranes [329]. The following sec-
tion deals with the question whether the observed effect of PC is due to a competition 
with Ssi for the same molecular target or due to the fact that formed liposome vesi-
cles of PC in the reaction mix circumvent the possibility of Ssi to reach 5-LO while 
trapped by liposomes. In order to determine a potential trapping of Ssi by PC vesi-
cles, a COX-2 activity assay was performed as suppression of COX-activity displays 
Ssi’s so far known mode of action. Human recombinant COX-2 was incubated in a 
sample set only with Ssi in several concentrations and together with PC 100 µg/ml in 
a second sample set. The formed product was assessed with an enzyme-linked im-
muno  assay  (ELISA).  As  internal  assay  control,  the  selective  COX-2  inhibitor  ro-
fecoxib  was  used  at  1  µM  concentration,  also  in  presence  or  absence  of  PC Results 
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100µg/ml.  Rofecoxib  suppressed  COX-2  activity  very  potently  (only  20%  residual 
COX-2 activity left) in comparison to Ssi (~ 60 % residual COX-2 activity). However, 
the presence of PC did not change the COX-2 inhibition profile of Ssi in comparison 
to the exclusively Ssi-treated control sample set (Fig. 39). 
 
Fig. 39: Effect of Ssi on recombinant COX-2 activity in presence of lipid vesicles 
COX-2 enzyme was incubated with Ssi in concentrations indicated and in another example PC (c=100 
µg/ml) was added to increasing Ssi concentrations. COX-2 activity was measured by ELISA. n=2. 
 
4.2.8  Identification of the target structure of Ssi within the regulatory 
          C2-like domain of 5-lipoxygenase 
To confirm the data so far obtained suggesting an interaction of Ssi with a lipid bind-
ing  site,  further  studies  were  undertaken  to  elucidate  whether Ssi  shows a  direct 
binding to the regulatory domain of the 5-LO enzyme. It has been demonstrated that 
lipid binding to the C2-like-domain, resulting in augmented 5-LO activity, is mediated 
by  three  tryptophan  residues  (W12,  W75,  W102)  in  the  regulatory  domain  [210]. 
Therefore the existing mutant of the 5-LO enzyme (5-LO-3W), where the three tryp-
tophane residues were changed to alanin by site-directed-mutagenesis PCR [218], 
was incubated with Ssi in different concentrations. Both proteins (5-LO-wt and 5-LO-
3W) were stimulated with CaCl2
 (2 mM) and AA (20 µM) after incubation with Ssi up 
to 50 µM (in relation to the concentrations achieved in humans after oral doses) for 
15 min at 4°C and were analyzed for their amount of formed 5-LO metabolites by 
HPLC. 5-LO activity only moderately differed up to concentrations of 20 µM Ssi if 5-Results 
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LO-wt is compared to the 5-LO-3W. Higher concentrations of Ssi (30 µM) resulted in 
50 % 5-LO-wt enzyme activity while 5-LO-3W showed ~ 80 % remaining enzyme ac-
tivity. 5-LO-wt activity is suppressed to almost zero level at 50 µM Ssi while 5-LO-3W 
remained at ~ 70 % remaining activity (Fig. 40). 
 
Fig. 40: Inhibitory effect of Ssi on 5-LO-wt and -5-LO-3W product formation 
Both proteins, expressed in E.coli and purified by ATP-affinity-chromatography, were incubated with 
the same concentrations of Ssi ranging from 10-50 µM and analyzed for 5-LO product formation after 
addition of 2 mM Ca
2+ and 20 µM AA.n=4. ** p ≤ 0.003. Values are expressed as mean + SEM. 
 
Again, it has to be clarified whether the lack of inhibition of Ssi with the 5-LO-3W mu-
tant is an unspecific side effect or uniquely for the mode of action of Ssi on 5-LO-wt 
enzyme. In order to specify the effect, another inhibitor class (BWA4C) was used. 
Compared to 5-LO-3W, 5-LO-wt enzyme activity is almost completely repressed by 
Ssi and less than 20 % remaining activity is determined in the 5-LO activity assay 
while the 3W-mutant is again not affected at the highest suppressive concentration of 
Ssi used (50 µM). BWA4C potently inhibited 5-LO-wt enzyme activity but led to a 
somewhat higher residual 5-LO product formation of 5-LO-3W (~ 30 %) as shown in 
Fig. 41.  Results 
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Fig. 41: 5-LO inhibition by Ssi or BWA4C on 5-LO-wt and 5-LO-3W 
5-LO product formation was analyzed in both purified, recombinant proteins. Ssi was used at a high 5-
LO-wt suppressive concentration of 50 µM and BWA4C at well-known 5-LO inhibiting concentration of 
1 µM. HPLC analysis was performed after Ca
2+-induced stimulation and supply of enough endogenous 
substrate AA (20 µM).n=3. *** p ≤ 0.005. Values are expressed as mean + SEM. 
 
To further characterize the inhibitory efficacy of BWA4C on 5-LO-3W and to possibly 
evaluate concentration-dependent differences, BWA4C was tested for 5-LO inhibition 
in both protein-mixtures and dose-concentration curves were recorded (Fig. 42). The 
proteins were incubated with increasing concentrations of BWA4C ranging from 0.03 
µM to 1 µM. In Fig. 42, a slight difference in the inhibitory potency between the 5-LO-
wt and the 5-LO-3W could be observed, but 1 µM BWA4C almost completely sup-
pressed the activity of both proteins.  Results 
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Fig. 42: Dose-response-curves of the 5-LO inhibitor BWA4C for 5-LO-wt protein and mutated 5-LO-
3W 
5-LO-wt and 5-LO-3W enzymes were incubated with increasing BWA4C concentrations for 15 min at 
4°C and then stimulated with Ca
2+/AA (2 mM /20 µM) for 10 min at 37°C.Then formed metabolites 
were determined by HPLC. n=3. Values are expressed as mean + SEM. 
 
Finally, studies were undertaken to elucidate the influence of PC and ist effect on the 
activity of wildtype 5-LO and mutated 5-LO-3W.  5-LO-wt enzyme showed almost no 
activity in presence of Ssi (50 µM) alone in contrast to the samples were Ssi and PC 
were present. Here 5-LO activity reached ~ 400 % of relative product formation over 
control. Regarding the mutated 5-LO protein, enzyme activity was still not impacted 
by Ssi 50 µM and even the addition of PC 30 µg/ml did not show any stimulation of 5-
LO-3W enzyme activity to levels obtained for the 5-LO-wt (Fig. 43).
 
 Results 
85 
 
Fig. 43:  Effect of Ssi  and PC on enzyme activity of both 5-LO proteins 
Proteins were analyzed for activity after incubation with Ssi alone (50 µM) or in combination with PC 
(30 µg/ml) and stimulated with 2 mM Ca
2+ and 20 µM AA. Formed 5-LO metabolites were determined 
by HPLC analysis. n=3. Values are expressed as mean + SEM. 
 
4.3  Regulation of 5-lipoxygenase expression by Ssi 
Although the chemopreventive and antitumorigenic activities of NSAIDs against sev-
eral types of cancer are well established, the molecular mechanisms responsible for 
these properties still remain to be elucidated [62]. Inhibition of COX-1 and COX-2 
leading to impaired PG biosynthesis represents the major anti-carcinogenic mecha-
nism of action of NSAIDs. Considerable evidence accounts for a role of partially COX 
independent actions in the drugs chemopreventive activity [61]. Ssi possesses a dis-
tinct chemopreventive activity with molecular mechanisms only partly understood and 
could recently being identified as a potent inhibitor of 5-LO [328]. For the 5-LO en-
zyme obviously playing a crucial role in cancer progression as reported in literature, it 
seemed reasonable to elucidate whether the drug may also modulate 5-LO gene ex-
pression. Though it is known that the promotor region of 5-LO is regulated by Sp1 on 
transcriptional level, the question raised whether Sp1 as a transcriptional regulation 
factor is possibly involved [175]. MM6-cells were chosen for the following expression 
analysis as these monocytes possess an inducible 5-LO after treatment with a com-
bination of calcitriol and the cytokine TGF-ß [315].  Results 
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4.3.1  Analysis of 5-lipoxygenase mRNA levels in Ssi-treated MM6-cells 
First, to get an overview about a possible inhibition of 5-LO expression by Ssi treat-
ment, MM6-cells were examined for 5-LO gene expression after differentiation with 
calcitriol/TGF-ß and incubation with Ssi on mRNA level via qPCR. Cells were differ-
entiated for 72 hrs at 37°C in a 6 % CO2 atmosphere and after that Ssi was added in 
six different concentrations. As nothing was known so far about Ssi’s capacity to in-
fluence 5-LO gene expression, concentrations were chosen likewise on the basis of 
the published data refering to the COX gene regulation [61, 62]. Various incubation 
times with the drug were tested and the most prominent effects were observed after 
an incubation time of 72 hrs with Ssi. Parallel, the same experiment was carried out 
with undifferentiated MM6 cells to monitor whether these effects are differentiation 
related.  After  harvesting and  washing  the  cells,  RNA  was  isolated  using  the  total 
RNA Mini Kit according to the manufacturer’s protocol. RNA concentrations were de-
termined and 2 µg RNA were transcribed into cDNA with the I-script® cDNA synthe-
sis kit. Amplification over the 5-LO proximal promotor region (-286 to +78 base pairs 
relative to transcription initiation site) was performed for 32 cycles. The housekeeping 
gene ß-actin was used as control template and results are presented as 5-LO copy 
numbers per 1000 copies of ß-actin. Fig. 44 shows that treatment with Ssi provoked 
a decrease in 5-LO mRNA levels in a concentration-dependent manner up to 30 µM 
of Ssi in comparison to the untreated control. In undifferentiated cells, a drecrease in 
5-LO mRNA was also visible, but to a somewhat lower extent than in differentiated 
cells. As expected, only a marginal 5-LO mRNA level was achieved in all samples.  
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Fig. 44:  Quantification of 5-LO mRNA levels in MM6-cells after Ssi treatment for 72 hrs 
0.6x10
6 differentiated (calcitriol 50 nM / TGF-ß 1 ng/ml; 72 hrs) and undifferentiated cells were incu-
bated with Ssi in concentrations as indicated for 72hrs. Realtime PCR was performed for 32 cycles 
after cell harvest, mRNA extraction and transcription into cDNA. 5-LO copy numbers were normalized 
to 1000 ß-actin copies. n=3. Values are expressed as mean + SEM. 
 
4.3.2  Analysis of Sp1 mRNA levels in Ssi-treated MM6-cells 
As there exists knowledge in former published data that the transcriptional factor Sp1 
is involved in activation of the 5-LO promoter region by a specific binding site, the so-
called GC4-box, the next experiments dealed with the analysis of Sp1 mRNA levels 
in MM6-cells treated with Ssi for 72 hrs. The same experiments as described in sec-
tion 4.4.1 were carried out to analyse the amounts of Sp1 mRNA in differentiated 
MM6-cells versus undifferentiated cells. In differentiated MM6-cells, Sp1 levels were 
visibly decreased after the addition of increasing concentrations of Ssi. At 10 µM and 
of 30 µM Ssi, the effect is most pronounced leading to 50 % loss of Sp1 mRNA 
amount compared to DMSO control. However, MM6-cells not treated with calcitriol/ 
TGF-ß were not able to show significant differences in Sp1 mRNA amounts.  Results 
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Fig. 45:  Quantification of Sp1 mRNA levels in MM6-cells after Ssi treatment for 72 hrs 
0.6x10
6 differentiated (calcitriol 50 nM / TGF-ß 1ng/ml; 72 hrs) and undifferentiated cells were incu-
bated with Ssi in concentrations as indicated for additional 72hrs. mRNA levels were assessed by 
qPCR using specific primers for Sp1. Results are expressed as x-fold induction over DMSO control. 
 
4.3.3  Cotransfection of Sp1 and 5-LO-pN10 in reporter gene assay in HeLa cells 
So far, investigations concerning the underlying mechanism of 5-LO regulation by Ssi 
on transcriptional level revealed an interaction of Sp1 and Ssi. The following experi-
ment was undertaken to understand if Sp1 is directly involved in Ssi-mediated down-
regulation of 5-LO. In order to confirm this, a reportergene assay model with HeLa 
cells was chosen as an appropriate test system. After 24 hrs of cotransfection of a 5-
LO  promotor  plasmid  (pN10)  and  a  pSG5-Sp1  expression  plasmid,  media  was 
changed and cells were incubated with three different concentrations of Ssi. After 
another 16 hrs, reporter gene activity was measured with to the Dual Glow
® system. 
Values are calculated as reduction of pN10 activity over backbone pSG5. As shown 
in Fig.46, Ssi treatment counteracted the Sp1-mediated 5-LO promotor activation in a 
concentration-dependent manner. Due to maybe reduced capacity of transfected Sp1 
to increase 5-LO promoter activity at 50 ng, a second concentration of 100 ng was 
used.  However,  no  significant  differences  were  detectable  excluding  the  samples 
treated with 3 µM. 10 µM and 30 µM of Ssi led to a clear counteraction of 5-LO pro-
moter activation triggered by Sp1 almost comparable to DMSO controls. Results 
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Fig. 46:  Reporter gene analysis of cotransfection of 5-LO pN10 and Sp1 pSG5 in HeLa cells 
4x10
4 HeLa cells were seeded out 24 hrs prior to transfection. Cotransfection takes places for 24 hrs 
and then media was changed and samples were incubated with Ssi in the indicated. After 16 hrs lu-
ciferase activity was measured and values are calculated by standardization of reportergene luciferase 
to renilla-luciferase.n=3.  
 
4.3.4  ChIP analysis of Sp1 recruitment to the 5-lipoxygenase promoter in Ssi-
   treated HeLa cells 
Furthermore,  another  experiment  dealing  with  the  underlying  mechanisms  of  Ssi-
mediated downregulation of 5-LO mRNA, is now described. Results of the precedent 
section suggest that Sp1 may play a role in the 5-LO downregulation observed in 
MM6-cells by treatment with Ssi. Therefore, ChIP assays should give more detailed 
information  about  a  possible  interplay  between  Ssi  and  Sp1.  In  brief,  cells  were 
grown, either differentiated or undifferentiated, treated with Ssi for 72 hrs and 16 hrs 
prior to harvest, MS-275, a selective histone-1,3-deacetylase-inhibitor (HDAC inhibi-
tor) was added (10 µM) to circumvent possible involvement of HDACs. After cell har-
vest (1x10
7), cells were fixed with 1% formaldehyde-solution and processed for fur-
ther precipitation against Sp1 antibody and normal rabbit IgG.  A sample using no 
antibody served as internal assay control. DNA-templates were then amplified by RT-
PCR. In line with results from qPCR and Western blot analysis (refer to section 4.4.1-
4.4.2), the same regulation pattern of Sp1 resulted after treatment of cells with Ssi in 
the ChIP assay. Reduced Sp1 binding at 3 µM Ssi occured in differentiated MM6 Results 
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cells which is completely abolished at 30 µM Ssi. IgG was used as control antibody. 
Input  was  determined  via  specific  primers  supplied  from  the  manufacturer.  It  can 
clearly be seen that Sp1 is downregulated in MM6-cells whilst treated with Ssi 3 µM 
and 30 µM.  
 
 
 
 
 
Fig. 47: Sp1 ChIP assay of differentiated MM6-cells treated with Ssi for 72hrs 
1x10
7 MM6 cells differentiated with calcitriol/TGF-ß for 72 hrs were incubated with Ssi for additional 72 
hrs and then harvested. ChIP assay was performed against Sp1, rabbit IgG and then templates were 
amplified by RT-PCR. No Ab and input samples were used as internal assay controls.n=1. 
 
The same experimental setup was used for undifferentiated MM6 cells to see if there 
occurs as well Sp1 downregulation. Shown in Fig. 48, a loss of Sp1 is visible at 30 
µM Ssi as well compared to the ChIP analysis in differentiated MM6 cells. But if in-
tensities of 3 µM Ssi treatment are compared, clearly reduced Sp1 binding occurred 
in differentiated MM6-cells whereas undifferentiated cells showed no change in the 
intensitiy of Sp1 lane. Results 
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Fig. 48:  Sp1 ChIP assay of undifferentiated MM6-cells treated with Ssi for 72hrs 
ChIP results in MM6 cells (1x10
7) incubated with Ssi for 72hrs and then harvested. ChIP assay was 
performed against Sp1, rabbit IgG and then templates were amplified by RT-PCR. No Ab and input 
samples were used as internal assay control.    Results   
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4.4  5-lipoxygenase - a potential target for nitrosylated NSAIDs  
In the literature, an increasing body of evidence refers to NO-NSAIDs as compounds 
demonstrating superior effects against a variety of cancer types in cell cultures sys-
tems and animal models.They promise contribution to the control of cancer but the 
molecular  mechanisms  are  not  clear  so  far.  Furthermore,  NO-releasing  NSAIDs 
seem  to  be  able  to  protect  against  NSAID-induced  gastric  damage  in  rats  which 
could be due to the effects of NO [330]. NO-NSAIDs possess a conventional NSAID 
moiety linked, often via a spacer molecule to an NO-releasing moiety [66]. To eluci-
date whether NO-NSAIDs possibly target 5-LO the following section deals with the 
characterization of well-known NSAIDs and their corresponding nitrosylated forms. In 
this  work,  sulindac,  naproxen  and  acetylsalicylic  acid  (ASA)  and  their  NO-
counterparts were chosen as test compounds. 
 
4.4.1  Effect of NO-sulindac and NO-naproxen on 5-lipoxygenase activity in    
   intact PMNL 
To get any knowledge about a possible difference between the conventional NSAID 
and the nitrosylated from, intact PMNL were incubated with both, NO-NSAIDs as well 
as the non-nitrosylated drugs. In order to mimic inflammatory conditions, intact cells 
were  stimulated  with  the  strong  chemical  stimulus  A23187  (2.5  µM).  Sulindac,  at 
concentrations of 10 and 30 µM, did not affect 5-LO activity. The nitrosylated form, 
NO-sulindac suppressed LT biosynthesis at 10 µM to a residual enzyme activity of 20 
% and almost zero at higher drug concentrations (30 µM). Beside, another NSAID 
was tested for potential 5-LO suppression. Naproxen and its nitrosylated derivative 
showed contrasting effects on LT formation.  Naproxen did not influence 5-LO activity 
but NO-naproxen reduced product formation to ~ 40 % of control. There was no dif-
ference in suppression of 5-LO metabolite formation between NO-naproxen used at 
50 µM and 100 µM (Fig. 49). (NO-sulindac and NO-naproxen were synthesized by E. 
Buscato, group of Jun. Prof. E. Proschak, Goethe University Frankfurt)
 Results 
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Fig.49: Influence of NO-sulindac and NO-naproxen on 5-LO activity in intact PMNL 
5x10
6 intact cells (PMNL) were preincubated with NSAIDs respectively NO-derivatives at 4°C with 
concentrations indicated for 15 min. Samples were then stimulated with 2.5 µM A23187 and supplied 
with 20 µM AA. Aanalysis of 5-LO products by HPLC was performed.n=3. Values are expressed as 
mean + SEM. 
 
4.4.2  Influence of NO-sulindac on recombinant 5-LO enzyme 
To further elucidate the potency of NO-sulindac, IC50 values were determined using 
human recombinant 5-LO enzyme. Purified 5-LO was incubated with the compounds 
at the concentrations indicated (refer to Fig. 50) for 15 min on ice. After stimulation of 
5-LO using CaCl2 (2 mM) as a stimulus and supplementation of 20 µM AA, 5-LO me-
tabolites were determined by HPLC analysis. The non-nitrosylated sulindac did not 
influence 5-LO catalysis (~ 100 % enzyme activity). Interestingly, NO-sulindac led to 
full enzyme inhibition at 10 µM and IC50 values can be estimated at ~ 1 µM (Fig. 50). 
 Results 
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Fig. 50:  Influence of sulindac and NO-sulindac on recombinant 5-LO enzyme activitiy 
5-LO protein was incubated with the concentrations indicated of sulindac and NO-sulindac and ana-
lyzed after stimulation with 2 mM CaCl2 and 20 µM AA for 5-LO product formation via HPLC.n=4. Val-
ues are expressed as mean + SEM. 
 
4.4.3  Effect of NO-aspirin and aspirin on 5-lipoxygenase inhibition in intact 
  PMNL 
In the following studies, the effect of NO-aspirin (NO-ASA) on 5-LO activity was as-
sessed compared to the well-known unselective COX-inhibitor aspirin (ASA). In order 
to get insights into the mode of action of novel inhibitors, substrate dependency was 
investigated. Intact PMNL cells were tested for 5-LO actvitiy in the presence of NO-
ASA and ASA, respectively without exogenously added AA. Cells were incubated 
with different concentrations of ASA and NO-ASA. After 15 min 5-LO activity was 
stimulated by the addition of A23187 (2.5 µM). After determination of 5-LO metabo-
lites  by  HPLC  considerable  differences  in  the  obtained  concentration-response-
curves are received (Fig. 51). Incubations with ASA did not lead to any change in 5-
LO product formation whereas NO-ASA suppressed enzymatic activity in a concen-
tration-dependent manner with an approximate IC50 value of ~ 30 µM.  
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Fig. 51: The influence of NO-ASA and ASA on 5-LO activity in intact PMNL in the absence of AA 
PMNL intact (5x10
6) were preincubated with ASA and NO-ASA for 15 min in the indicated concentra-
tions. Cells were stimulated by the addition of 2.5 µM of A23187. Enzymatic activity was measured 
after stopping metabolite formation with cold methanol and extraction of the formed 5-LO metabolites 
followed by HPLC analysis. n=3. Values are expressed as mean + SEM. 
 
In order to circumvent cPLA2 signalling, AA was added as a natural substrate. Prein-
cubation with drugs in indicated concentrations was performed for 15 min and cells 
were stimulated for upregulation of LT biosynthesis by the addition of A23187 (2.5 
µM)  and  AA  (20  µM)  was  added.  After  10  min,  catalytic  activity was  stopped  by 
methanol and products were extracted and analysed by HPLC. In the presence of 
AA, nearly the same profile for both compounds evoked as in the absence of the 
natural substrate (Fig. 52). Again, ASA did not alter 5-LO activity. In contrast, NO-
ASA showed concentration-dependent inhibition of 5-LO activity with an approximate 
IC50 value of ~ 30 µM.  Results 
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Fig. 52: The influence of NO-ASA and ASA on 5-LO activity in intact PMNL in the presence of AA 
5x10
6 intact cells were pretreated with ASA and its NO-derivative for 15 min at 4°C. Stimulation was 
performed by 2.5 µM A23187 and 20 µM AA for 10 min at 37°C. 5-LO product formation was stopped 
yb the addition of methanol and 5-LO metabolites were analyzed by HPLC.n=4. Values are expressed 
as mean + SEM. 
 
4.4.4  Inhibition of 5-LO product formation by NO-NSAIDs in cell free system  
Considering the presented inhibition profiles of NO-sulindac and NO-ASA in the cell-
based assay in the previous section, possible interactions of the other NO-NSAIDs  
were now assessed in a cell-free assay using purified human recombinant 5-LO. To 
identify probable interferences with the 5-LO enzyme and nitrosylated NSAIDs, drugs 
were incubated with the appropriate amount of protein leading to ~ 800 -1000 ng 5-
LO products. Induction of 5-LO metabolites was elicited by the addition of Ca
2+ (2 
mM) and substrate was supplied exogenously (20 µM AA). The reaction was stopped 
after 10 min by the addition of methanol and analysis of 5-LO products was deter-
mined by HPLC. Interestingly, sulindac showed 5-LO enzyme inhibition of 50 %, but 
the nitrosylated derivative showed a more pronounced 5-LO suppression as only 20 
% 5-LO actvitiy remained at 50 µM NO-sulindac. NO-derivatives of naproxen and 
ASA suppressed 5-LO product formation as well but less potent as compared to in-
tact PMNL. Both compounds reduced 5-LO product formation levels only to ~ 40 % 
enzyme activity. Non-nitrosylated drugs lead to 5-LO activity between 60 % and 80 
%. BWA4C was used as internal assay control (Fig. 53). Results 
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Fig. 53:  NO-NSAIDs and their influence on recombinant 5-LO activity 
Recombinant  5-LO  protein  was  incubated  with  the  indicated  concentrations  of  sulindac,  naproxen, 
ASA and their NO-derivatives for 15 min at 4C°. 5-LO activity was started by the addition of 2 mM Ca
2+ 
and 20 µM AA. After product extraction, 5-LO metabolite levels were analyzed by HPLC.n=3. Values 
are expressed as mean + SEM. 
 
4.4.5  5-lipoxygenase activity in human whole blood 
Regarding suppressive capacities of 5-LO inhibitors, the question arises whether po-
tential compounds with in vitro activity do show the ability to inhibit LT biosynthesis in 
vivo. Therefore, whole blood assays were performed. First experiments were carried 
out using the physiological stimulus LPS 10 µg/ml and fMLP 1 µM mimicking patho-
physiological inflammatory conditions in the body. Freshly withdrawn venous blood 
was taken from healthy volunteers and studies were started immediately. After prein-
cubation with substances for 30 min, samples were stimulated with the LPS/fMLP 
combination as described in the material and methods section. 15 min later, the reac-
tion was stopped by placing samples on ice and plasma was obtained by centrifuga-
tion. Analysis by LC-MS-MS followed to quantify the formed LTs. All used drugs were 
applied at higher concentrations (100 µM) as tested before to exclude a possible lack 
of inhibition due to plasma protein binding or metabolism in the whole blood system. 
For determination of inhibtion pattern of the chosen compounds the 5-LO metabolites Results 
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LTB4 and 5-HETE were detected and calculated. For all NO-derivatives almost the 
same suppressive efficacy occured as shown in Fig. 54. 5-LO product formation was 
inhibited by 50 %. Zileuton served as control inhibitor. 
 
Fig. 54: Effect of NO-NSAIDs on 5-HETE and LTB4  formation in human whole blood 
Venous  whole  blood  freshly  gained  from  healthy  volunteers  was  preincubated  (30  min)  with  com-
pounds at the concentrations indicated at 37°C. After the addition of the stimulus consisiting of LPS 
10mg/ml and fMLP 1 µM reaction was performed for 1 h at 37°C and stopped by cooling the samples 
on ice. After obtaining plasma by centrifugation, LT levels were assessed by LC-MS-MS.Preliminary 
results, n=1. 
 
4.4.6 Comments on future studies  
Given  the  results  from  the  previous  section,  it  has  clearly  come  out  that  NO-
derivatives of certain NSAIDs could display a novel strategy for 5-LO modification 
and the released NO might directly interfere with the 5-LO enzyme. Further studies 
are needed to elucidate the molecular mechanisms involved in 5-LO suppression by 
NO-NSAIDs  Discussion   
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5  DISCUSSION 
The present results revelaed that Ssi is a novel 5-LO inhibitor with clinical relevance. 
5-LO inhibition occured in stimulated leukocytes as well as with human recombinant 
purified 5-LO protein. Moreover, Ssi convinced in human whole blood assays via a 
potent suppression of 5-LO product formation. The molecular mechanism of the drug 
on 5-LO inhibition was investigated. The studies comprised elucidations of a possible 
influence of Ssi on 5-LO gene expression. Lastly, NO-releasing drugs were tested 
and evaluated on their 5-LO inhibitory potency. The following chapter therefore criti-
cally discusses the obtained data and places the findings into the so far published 
scientific background.        
         
5.1  Suppression of 5-lipoxygenase product formation by Ssi 
Sulindac is a well-studied NSAID and the general opinion is that sulindac’s mode of 
action constitute an unselective COX-inhibitory activity, slightly preferential for COX-
1. The drug also possesses analgesic, anti-pyretic and chemopreventive properties 
and is classified as a low-ulcerogenic NSAID that causes markedly less gastrointes-
tinal toxicity as compared to related unselective COX inhibitors, such as diclofenac, 
indomethacin or naproxen [331]. Interestingly, sulindac exerts extraordinary proper-
ties among the class of NSAIDs concerning the overall severe side effect profile and 
leads  therefore  to  less  typical  unwanted  effects  during  continuous  NSAID  intake, 
such as dyspepsia, gastric ulcers or gastrointestinal bleedings. From the structural 
point of view the drug is ranked to the group of indene-acetates regarding its chemi-
cal profile und shows relations to the structure of indomethacin which is a strong in-
ducer of gastrointestinal disorders.  
Since the 1970s, more and more evidence evoked that the use of NSAIDs is linked to 
chemopreventive  events  and  numerous  experimental,  epidemiologic  and  clinical 
studies suggest NSAIDs to play a promising role as anticancer drugs as they show 
induction of apoptosis and inhibition of angiogenesis, two strategies helping to sup-
press malignant tumor growth [332-335]. Several studies inidicated the chemopre-
ventive use and their efficacy especially in colorectal cancer, but also in esophagus, 
stomach, breast,  lung  urinary  bladder  and ovary  carcinomas  where  they may  de-
crease  the  incidence  of  these  types  of  cancer  [333].  These  findings  have  been Discussion 
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documented  by four lines of evidence such as epidemiological studies, animal stud-
ies, in vitro experiments and clinical trials [336]. Liu et al. were among the first to 
show the involvement of COX-2 in tumorigenesis by observing an overexpression of 
COX-2 protein in colorectal and other tumors. It could be shown that the deletion of 
the COX-2 gene led to a decreased incidence of carcinomas in transgenic mice and 
so the rationale for the development of selective COX-inhibitors was born [337]. The 
link  between  COX-inhibition  and  chemoprevention  was  made  as  the  unselective 
COX-inhibitor sulindac and the selective COX-2 inhibitor celecoxib confirmed their 
beneficial chemopreventive profile as they inhibited effectively the growth of adeno-
matous polyps and caused regression of existing polyps in randomized clinical trials 
[338-341]. However, there seemed to be COX-2-independent targets being responsi-
ble for the behaviour of these inhibitors, exemplified by celecoxib. Additional pharma-
cologic activities were employed and among various targets there seemed to be cel-
lular  components  responsible  for  the  drug’s  molecular  mechanism  [12].  As  AA-
produced eicosanoids have been implicated to a variety of diseases including differ-
ent  forms of  cancers,  the  focus  shifted  then  more  from  COX-derived  PGs  to  LO-
derived LTs and the hydroxyeicosatetraenoic acids (HETE’s) as they exert also pro-
found  biological effects on the development of cancers and recent lines of evidence 
suggest that 5-LO products are especially involved in colon carcinogenesis [37, 38]. 
Two studies found that 5-LO inhibitors act chemopreventively in animal lung carcino-
genesis when the FLAP inhibitor MK-886 and the 5-LO inhibitor A79175 were used in 
a mouse model [342, 343]. Anderson et al. showed reduced DNA synthesis and cell 
growth in human prostate cancer cells [344]. In this regard and having in mind the 
above mentioned, it was shown that increased  LTC4 production in gastrointestinal 
tissues was present and also a determinant for NSAID-induced ulcerogenicity and 
concomitant application of a 5-LO inhibitor abolished the indomethacin-induced gas-
trotoxicity in pigs [345]. As the molecular mode of action of chemopreventive-acting 
NSAIDs is only partly understood, it seemed most reasonable to elucidate further 
targets of the NSAID sulindac and molecular mechanism considerations evoked in-
terference with the 5-LO pathway. The literature provides indirect evidence that 5-LO 
is inhibited by Ssi in humans. On the one hand, Ssi displays strong chemopreventive 
activities against colorectal cancer, which may be only partly attributed to inhibition of 
PG synthesis [346]. Moreover, 5-LO products participate in crucial tumor develop-
ment events and pharmacological inhibition of 5-LO attenuates the growth of adeno-Discussion 
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matous colonic polyps in animals and potently induces antiproliferation and apoptosis 
of cultured tumor cells [347-349]. Thus, also the favourable gastrointestinal profile of 
sulindac may relate to its 5-LO inhibitory activity. In addition, the superior efficacy of 
Ssi against acute gout [350] may be associated with the drug’s 5-LO suppressive 
activity since urate crystals stimulate the release of LTs from PMNL and may thereby 
contribute to the pathogenesis of the inflammatory reaction [351].  
The first result section showed indeed potent inhibition of 5-LO product formation by 
sulindac’s active metabolite, Ssi, in intact PMNL with calculated IC50 values of ~ 10 
µM. In line with findings in literature, where Ssi displays the efficient compound, only 
Ssi inhibited 5-LO in PMNL, neither the prodrug sulindac nor the formed metabolite 
sulindac sulfone showed inhibitory potency on 5-LO. On cellular level natural sub-
strate concentrations are important for enzyme performance as a competition may 
occur whilst inhibitors are tested. However, Ssi inhibited 5-LO product synthesis in 
PMNL  equipotently  regardless  of  whether  AA  was  provided  from  endogenous 
sources via cPLA2 or exogenously added to the reaction mixture. This leads to exclu-
sion of an interference of Ssi with AA supply (refer to 4.1.1). 5-LO activation induced 
by intracellular Ca
2+ influx was performed by challenging the leukocytes by A23187, 
one of the strongest chemical stimuli, capable of inducing 5-LO product biosynthesis 
circumventing receptor signalling [250, 352]. In terms of selectivity and regarding 12- 
and 15-LO it was found that Ssi only inhibits 5-LO very potently but did not affect 12- 
and 15-HETE production which is eligible as 15-HETE  might interfere with the pro-
gression of malignancy  and promotes the anticarcinogenic metabolism of AA [353, 
354]. 12-LO products are connected to pro-carcinogenic events in the AA pathway 
and promote tumor progression and upregulation of synthesis in different types of 
adenocarcinomas are related to increased tumor growth [355-357]. Actually, inhibi-
tion of 12-LO products seemed preferable but as many different reports assign con-
trary properties to 12-HETE in the past years, 5-LO inhibition by Ssi is more favour-
able. In this regard, Ssi displays a selective inhibition profile on 5-LO. 
5-LO is a tightly controlled enzyme with multiple regulatory mechanisms. Hence, in 
addition  to  direct  inhibition  of  5-LO, c ellular  components  or  mechanisms  such  as 
cPLA2, FLAP, MAPKs, Ca
2+ mobilization, interaction with coactosin-like protein and 
nuclear membrane association modulate 5-LO activity and may represent potential 
targets for Ssi [145]. Suppression of cellular product formation by an inhibitor could 
be caused by interactions at any of the multiple regulatory nodes on cellular 5-LO Discussion 
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activation and have to be considered and investigated when characterizing a novel 
inhibitor of 5-LO. Stress inducing stimuli like the pathophysiologically GPCR ligand 
fMLP in combination with bacterial LPS or SC and SA are mediating cellular LT acti-
vation  by  interference  with  MAPK  pathway (activation  of  ERK 1/2  and p-38 MAP 
kinases) and are valuable conditions for a test system as the situation in the human 
body is closely mimicked. Ssi shows stimulus-independent efficacy to inhibit 5-LO in 
cells stimulated with fMLP 1 µM after priming with LPS 1 µg/ml and Ada 0.2 U/ml 
possibly excluding interference with the kinase signalling pathways. Different stress 
situations did not lead to siginificant differences in IC50 values of Ssi in cellular based 
assays, only a slight increase is visible while treated the cells with SA and SC com-
pared to A23187. Seemingly, Ssi does not target any cellular regulating factors such 
as AA-providing cPLA2 or MAPK pathways. As the next promising test system, as-
says with the purified 5-LO protein emerged reasonable. In line with previous results 
suggesting no interference of Ssi with any cellular components, the obtained results 
showed that purified recombinant human 5-LO is affected by Ssi as the efficient me-
tabolite  tested  in  cell-free  assays  showing ~   80  %  enzyme  inhbition.  Additionally 
tested sulindac and sulindac sulfone produced a maximal enzyme inhibition of ~ 20 
%. This leads to the conclusion that only Ssi directly interferes with the 5-LO protein. 
As many factors influence cellular LT biosynthesis and 5-LO activity, further targets 
had to be adressed in a cellular context.  In terms of the results in intact cells and 
cell-free assays, Ssi acted more potent in intact leukocytes with an IC50 of ~ 10 µM  
compared  to  purified  5-LO  where  50  %  inhibition  was  observed  at  ~  20 µM Ssi. 
Therefore, as interference with different 5-LO activating pathways are unlikely for Ssi, 
inhibition of FLAP remains an alternative mechanism. Ssi exhibits structural similarity 
to the FLAP inhibitor MK-886 and Ssi suppressed the translocation of 5-LO in PMNL 
from the cytosol to the nuclear envelope which is an established property of FLAP 
inhibitors [322]. A similar inhibiton pattern can be as well recognized with the first in-
troduced  dual  COX-FLAP  inhibitor,  licofelone  (ML-3000),  which  prevented the  nu-
clear  redistribution  of  5-LO  in  ionophore-activated  PMNL  as  observed  for  other 
FLAP-inhibitors. The literature provides evidence that FLAP-inhibition was concluded 
after transfection experiments in HeLa cells were 5-LO inhibition was detectable only 
with co-transfected FLAP [323]. However, when FLAP was efficiently blocked by MK-
886 in PMNL, Ssi still inhibited (FLAP-independently) 5-LO product formation in intact 
PMNL. Moreover, FLAP-dependent 5-LO inhibiton could be excluded since competi-Discussion 
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tion of Ssi with the FLAP-inhibitor MK-591 did not result in enhanced suppression of 
5-LO enzyme activity. This leads to the conclusion that FLAP is not target of Ssi. 
Many inhibitors tested in isolated leukocytes with high efficacy in vitro, unfortunately 
failed to efficiently interact with LT biosynthesis in vivo. As the success and the bene-
ficial profile of a newly discovered inhibitor for a potential application in humans de-
pend on its efficacy and safety in vivo, studies imitating human body conditions are 
inevitable.Therefore, tests on Ssi’s influence on LT production in human whole blood 
system were undertaken with freshly withdrawn blood from healthy volunteers and 
Ssi  showed  potent  inhibition  regardless  which  stimulus  was  used  (LPS/fMLP  or 
A23187). IC50 values of ~ 25 µM may appear high compared to inhibitors adressing 
their target in the nanomolar range. Thus, concentrations of Ssi achieved in humans 
with a bis daily intake of 400 mg Ssi peak at 36.8 µM and steady state concentrations 
as well range at ~ 25 - 30 µM. Results showed promising effects [358]. 5-LO inhbition 
of Ssi in human whole blood is almost comparable to COX-inhibition as the potency 
of Ssi to suppress COX-2 (IC50 ~ 4 µM) in whole blood was verified [359]. Namely, 
IC50 values differ from ~ 4 µM for COX isoformes, COX-1 and COX-2, and ~ 20 µM 
for 5-LO enzyme in human whole blood. Notably, inhibition of cellular 5-LO product 
synthesis occurred at lower Ssi concentrations with an IC50 ~ 8 -10 µM. This value is 
similar to IC50 values of Ssi for COX-2 (11 -14 µM) in transfected COS-1 cells [360]. 
Accordingly, 5-LO is a target of Ssi with almost equivalent susceptibility as COX-2 
supported by the whole blood results, where Ssi suppressed the LPS-induced 5-LO 
product formation with an IC50 of 18.7 µM closely to the published IC50 value for COX-
2 (10.43 µM) [359]. Despite these differences, almost full enzyme inhibition of both 
AA metabolizing enzymes COX and 5-LO is visible leading to a comparable efficacy 
at high Ssi concentrations (100 µM Ssi) in LPS-stimulated leukocytes. These findings 
of maximal suppression of 5-LO product synthesis by Ssi 100 µM display relevance 
for  the  previously  hypothesized  COX-independent  mechanism  of  Ssi.  Numerous 
COX-independent molecular mechanisms of Ssi have been observed in vitro, which 
may explain the drug’s peculiar and beneficial pharmacological profile. Mechanisms 
like inhibition of the NF-κB activation by 200 µM Ssi, disruption of PPAR-δ signalling 
by 100 µM Ssi are described and the in vivo relevance of these mechanisms is de-
bated  because  Ssi  plasma  concentrations  >100  µM  are  not  achieved  in  humans 
[361]. After ingestion of 400 mg (the recommended dose for treatment of arthritis), 
plasma drug concentrations reach a maximum of 38.6 µM, depending on the dosing Discussion 
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procedure [60]. The inhibition data in conjunction with the pharmacokinetic data sug-
gest that standard dosage regimes of sulindac could reduce 5-LO product formation 
by more than 50 %. Importantly, pharmacokinetic studies demonstrated a prominent 
accumulation  of  Ssi  in  colonic  epithelial  cells  raising  the  possibility  of  still  even 
greater 5-LO suppression in these tissues [362].  
 
Summary of 5-lipoxygenase inhibition by Ssi 
To preliminary summarize Ssi’s inhibitory mechanism on 5-LO, the presented results 
demonstrate that clinically relevant concentrations of Ssi suppress 5-LO product syn-
thesis in different cellular assays including human isolated PMNL, triggered by either 
the physiological stimuli LPS/fMLP, but also by A23187 or cell stress, as well as in 
LPS/fMLP- and ionophore-stimulated human whole blood. Currently, according to the 
described  data, sulindac  represents  the  first  functional  COX/5-LO  inhibitor  on  the 
market with 5-LO suppressive efficacy in whole blood at clinically relevant concentra-
tions and a favourable tolerability in humans. In conclusion, it could be shown that 
the pharmacologically active metabolite of sulindac, Ssi, suppresses 5-LO product 
synthesis in leukocytes and in human whole blood at clinically relevant concentra-
tions by direct interference with 5-LO. Suppression of 5-LO product formation may 
contribute to the pharmacodynamic profile of sulindac in animals and humans. Clini-
cal studies that address the effects of sulindac on LT biosynthesis in patients at stan-
dard  dosage  regimes  for  prolonged  periods  would  be  a  helpful  expansion  of  the 
pharmacological actions of this drug. The obtained data suggest that Ssi suppresses 
cellular 5-LO product formation via direct inhibition of 5-LO, with the possible contri-
bution of additional mechanisms, such as inhibition of 5-LO translocation.  
 
5.2  Interference of Ssi with the regulatory domain of 5-lipoxygenase 
Considerable efforts have been made in order to develop safe and efficient 5-LO in-
hibitors. However, many compounds failed under in vivo conditions either due to ad-
verse effects (interference with other biological processes or production of reactive 
radicals) or a loss of efficacy due to increased oxidative state and/or phosphorylation 
of 5-LO in inflamed tissues [281, 288]. Elucidation of the binding mode of Ssi to 5-LO 
is of high interest and warrants investigations from which may emerge high affine, Discussion 
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selective and safe inhibitors of 5-LO with in vivo efficacy. In successive studies the 
mechanism on Ssi on 5-LO enzyme was investigated.  Previous results made a di-
rect 5-LO inhibition by Ssi most evident and it was obvious that Ssi’s inhibitory po-
tency varied dramatically in different test systems regarding intact leukocytes and 
their 100.000xg supernatants, homogenates and recombinant purified 5-LO protein 
[328]. Comparing the IC50 values of intact cells (~ 10 µM) and purified, recombinant 
5-LO enzyme (~ 25 µM) to cell homogenates of PMNL (~ 100 µM) and S100 (~ 70 
µM) it seems that these differences in inhibitory potency of Ssi on 5-LO are signifi-
cant and are eventually due to a regulating factor or naturally occurring constituents 
in cell homogenates. It was speculated that in pure enzyme preparations Ssi is able 
to reach its target and does not have to compete with this factor. First, experiments 
were undertaken to gain detailed information about any other cellular targets which 
could potentially be affected by Ssi in a cell which is activated by an inflammatory 
stimulus. As described previously, the cellular redox tone is of great importance for 
the enzyme’s catalytic acitivity and can be modified by certain specific inhibitors [145, 
294].  Furthermore,  the  intervention  with  or  generation of  reactive  oxygen  species 
(ROS) may play an important role. Ssi is thought to sensitize cells to oxidizing agents 
and drugs that affect mitochondrial functions, resulting in the production of ROS and 
death by apoptosis [363]. However, compared to ZD-2138, a non-redox type inhibitor 
of 5-LO which requires reducing agents such as DTT in broken cell preparations or 
S100  of  PMNL  to  perform  inhibition,  5-LO  inhibition  by  Ssi  is  Gpx-independent. 
Thereupon, other pathways leading downstream to the 5-LO signalling or procuring 
pre-cursors were elucidated. PLD is an enzyme responsible for processing phosphol-
ipids  to  PA  and  choline.  Inhibition  of  PLD  leads  to  diminished  amounts  of  DAGs 
which usually, in an agonistic way, stimulate 5-LO [233, 364]. Therefore, PLD could 
represent a potential target of Ssi. However, PLD was not inhibited by Ssi. Another 
mechanism of 5-LO activation being possibly repressed by Ssi and resulting in dimin-
ished 5-LO product formation could be interference with intracellular Ca
2+ levels. In-
tracellular Ca
2+ increase is a very rapid process and signal transduction follows im-
mediately. Upon stimulation with various stimuli like A23187 or fMLP, intracellular 
Ca
2+ levels increase significantly in cells participating in the inflammation process. 
However,  analysis  of  Ca
2+  release  in  fMLP  stimulated  PMNL  by  a  fluorescence-
based assay showed no difference between Ssi-treated and untreated cells. Thus, 
interaction  with  Ca
2+  mobilization  and  subsequently  reduced  5-LO  activity  is  not Discussion 
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likely. Another assumption may be an interaction with cellular 5-LO product synthesis 
by blocking the activation of MAPK, which phosphorylates and thereby stimulates 5-
LO [145]. Interference with MAPK signalling by Ssi is unlikely since PMNL activation 
with  A23187  widely  circumvents  receptor-coupled  signalling  and  thus  employs 
MAPK/phosphorylation-independent  5-LO  activation  [321].  On  the  other  hand,  Ssi 
was  most  potent  against  5-LO  when  product  synthesis  was  induced  by  receptor-
coupled  pathways  (using  fMLP  and/or  LPS  as  a  stimulus)  mediated  by  MAPK. 
Hence, under these conditions, an interference of the drug with the downstream re-
ceptor signaling pathways or the release of AA can not be excluded. In Western blot 
analysis,  a  possible  Ssi-mediated  ERK  regulation  was  investigated  from  PMNL 
preparations.  It was demonstrated that 5-LO activation by phosphorylation via MAPK 
is not affected by Ssi as ERK- and phosphorylated ERK protein patterns did not dif-
fer. Then other strategies were followed focusing on the purified protein and its struc-
tural features. As shown before, Ssi directly inhibits purified 5-LO enzyme and inhibi-
tion seems to be mediated by an interaction with the C2-like domain of the protein. 
This was first supported by the observation of Ssi’s different potencies on 5-LO inhi-
bition depending on the cellular environment where a loss of inhibitory potency oc-
curred  in  reaction  mixtures  containing  cellular  membrane  constituents  (PMNL  ho-
mogenates and S100). On the basis of these findings, an interference of 5-LO with 
the lipid binding site of 5-LO was suggested. The 5-LO enzyme, which translocates 
to the nuclear envelope upon cellular stimulation, forms  LTs at the nuclear mem-
brane where AA is provided by cPLA2 and FLAP facilitates access to its natural sub-
strate [148]. Membrane binding is mediated by trp residues within the C2-like domain 
of  5-LO  and  this  lipid  binding  site,  moreover  responsible  for  the  binding  of  PC 
liposomes, displays a possible target motif for Ssi. [211]. As inhibition of 5-LO by Ssi 
was supposed to occur via the mentioned trp amino acids, a competitive effect of the 
5-LO inhibition and the addition of microsomal preparations consisting of membrane 
particles was explored. Microsomes, prepared of leukocytes and mimicking cellular 
membranes, were able to reverse Ssi induced 5-LO inhibition when added to crude 
5-LO incubations. As there is evidence for hyperforin’s binding mode via the lipid-
binding sites, microsomes should occupy the predicted binding site and in conse-
quence inhibition of 5-LO should fail. Presented results could support this hypothesis. 
It has been shown in the published literature that phospholipids like PC can stimulate 
5-LO by interfering with the regulatory C2-like-domain of the enzyme [210]. These Discussion 
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interactions are mediated by an interference with the PC selective, membrane asso-
ciation modulating, three amino acid residues located on position 13, 75 and 102 of 
the regulatory domain of 5-LO [205, 213]. These binding properties are distinguished 
by the activation factor Ca
2+ thus stimulation of the enzyme can occur [205]. PE and 
PS function as constituents of natural biomembranes but lack the ability of binding to 
conserved regions of C2 domains or C2-like domains [211]. In present investigations, 
uniquely significant interactions with PC were detectable whereas other lipids (PE or 
PS) did not show considerable impact on 5-LO inhibition by Ssi. These findings could 
not be observed with the control inhibitor BWA4C. Hyperforin displayed the same 
profile as found for Ssi so far. It seemed reasonable, that a 5-LO protein mutant lack-
ing three trp residues which are essential for intact functionality and target the 5-LO 
enzyme to nuclear membranes, should not be affected by Ssi. Due to the mutation 
within the regulatory domain of the 5-LO enzyme, the binding properties of 5-LO-3W 
should account for reduced lipid binding. Subsequently, diminished stimulation of en-
zyme activity should be observable [216]. The mutated protein (5-LO-3W) where trp 
residues are replaced to ala is known to show lower response to PC liposomes in-
duced activity enhancement [210]. Given that binding of Ssi is mediated via the three 
corresponding amino acids, it was expected that Ssi would not induce decreased 5-
LO product formation whilst added to the 5-LO-3W mutant. Indeed, in the present 
work almost no influence of Ssi on this 5-LO-3W mutant was observed while the 5-
LO-wt was inhibited in a concentration-dependent manner. This leads to the conclu-
sion that these amino acids are required for accessibility and inhibition of 5-LO by 
Ssi.  BWA4C  potently  suppressed  the  3W mutant  5-LO  protein  supporting the hy-
pothesis identifying Ssi as a novel approved drug inhibiting 5-LO by interference with 
the lipid binding site within the regulatory C2 like domain. For 5-LO inhibitor categori-
zation (refer to section 1.2.9 for details) three groups can be built up: redox-active 
compounds interfering with the non-heme iron of 5-LO in the catalytic domain, iron-
chelating substances and fatty acid mimetics, the so called non-redox type inhibitors, 
which act in a competitive manner with the natural substrate of 5-LO [146]. However, 
Ssi did not show iron-chelating properties and a direct interaction for example reduc-
ing the iron atom or radical scavenging could not be demonstrated (data not shown). 
A competitive mode of action could be excluded as previous studies indicated an un-
competitive mode of inhibition of 5-LO [328]. Results obtained with purified, isolated 
5-LO seemed to confirm a direct interaction with the 5-LO protein. Efforts to deter-Discussion 
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mine a selective binding via a linking with the putative binding site holding the three 
essential trp residues located in the C2-like domain were carried out using the satu-
ration-transfer-difference NMR approach. The studies showed clearly binding of Ssi 
to  the  5-LO-wt  but  unfortunately  affected  the  5-LO-3W  as  well  (data  not  shown), 
probably due the high Ssi concentrations (160 - 200 µM) needed for NMR analysis 
and therefore resulting in unspecific binding. However, a second possible binding site 
on 5-LO possibly occupied at higher concentrations of Ssi will lack physiological rele-
vance  for  the  drugs  application  as  only  38.6  µM  plasma  drug  concentrations  are 
achieved  after  standard  uptake  and  concentrations  used  lastly  for  NMR  studies 
ranged from 100 – 200 µM [60].  
 
Concluding remarks on Ssi’s molecular mechanism on 5-lipoxygenase 
Thus, Ssi potently inhibited purified 5-LO enzyme but lost efficacy when assays are 
performed in different cellular systems, especially differences in inhibitory potencies  
in intact cells and isolated 5-LO compared to cell homogenates and S100 prepara-
tions are evident. Microsomes, added to isolated 5-LO protein diminished the efficacy 
of  Ssi  presuming  a  competitive  action  of  the  inhibitor  with  lipid  particles.  PC 
liposomes  were  capable  of  counteracting  of  Ssi’s 5-LO  inhibitory  effect.  All  these 
facts led to the presumption of an interference of Ssi with the membrane targeting 
site located in the C2-like domain of the 5-LO enzyme. This could be supported by 
inhibition patterns of Ssi on a 5-LO protein mutant lacking the responsible trp resi-
dues. As increasing evidence suggests a role for 5-LO products found in a variety of 
cancer tissues, inhibition of 5-LO enzyme activity presents a strategy for chemopre-
ventive intervention [4, 38]. Ssi possesses certain chemopreventive properties and 
by unknown mechanisms inhibits tumor cell growth and reduces polyp development 
in colorectal cancer which maybe attributed to reduced LT biosynthesis in these tis-
sues [347, 349]. Other COX-2 selective inhibitors where COX-independent effects 
have been attributed did only show modest reduction regarding polyp growth in FAP 
patients in contrast to Ssi [365].  As Ssi lacks severe side effects manifesting in lower 
allergenic toxicity and beneficial cardiovascular profiles, the mechanistic analysis of 
the inhibition mode of Ssi in 5-LO product formation is of great importance and may 
provide answers explaining the peculiar and beneficial profile of the drug [331]. Col-
lectively, the present work displays a novel strategy inhibiting LT formation by block-Discussion 
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ing the early step in LT biosynthesis by Ssi targeting the C2ld of 5-LO. The identifica-
tion of Ssi’s target structure on 5-LO offers the possibility of designing potent com-
pounds showing even more promising chemopreventive efficacy and favorable pro-
files in the treatment of cancer. Taken together, Ssi is the first approved drug on the 
market exhibiting 5-LO inhibition by blocking the regulatory domain of the enzyme by 
a direct interaction. Therefore Ssi could represent a novel lead structure for 5-LO in-
hibitors. 
 
5.3  Ssi’s influence on 5-lipoxygenase expression 
In the early 1990ies, the role of COX-2 expression was evaluated and correlated to 
enhanced tumor growth using a transgenic mice model. Furthermore, it was con-
cluded  that  overexpression  of  COX-2  alone  was  sufficient  to  induce  tumorigenic 
transformation in a tissue-specific manner [337]. It was possible to establish a strong 
correlation between the use of NSAIDs and the decreased incidence of colorectal, 
breast and lung cancers [334, 366, 367]. Carcinomas of different origins have been 
investigated and a COX-2 upregulation was found to occur in 85 % of all human co-
lon carcinomas and 50 % in colon adenomas, supported by gene deletion studies 
[61, 368-370]. However, there is a considerable body of data supporting the hypothe-
sis of COX-independent targets of NSAIDs being responsible for chemopreventive 
and  antitumorigenic  actions  [61].  The  literature  provides  evidence  that  molecular 
mechanisms of several NSAID-mediated anti-cancer effects can be attributed to in-
terference with inhibition of COX-2 as target gene [371, 372]. It is well established 
that other genes are described to be altered by drugs and chemicals by increased or 
decreased gene expression and are as well involved in mechanisms of cancer pre-
vention independent from PG formation. One example is the NSAID-activated-gene-1 
(NAG-1) which belongs to the TGF-ß superfamily of growth factors and is regulated 
by  several  NSAIDs  [373].  Both,  COX-selective  and  COX-unselective  inhbitors  in-
crease NAG-1 expression. Structural characteristics for COX inhibition seemed to be 
different from the regulation of NAG-1 and prevention of cancer activity. In former 
publications it was reported that Ssi possessed the most prominent properties to in-
duce NAG-1 gene expression as ample inductions were observed at concentrations 
at 1 - 50 µM, a physiological concentration achieved in vivo [373]. It has not been 
published  yet  that  5-LO  expression  is  downregulated  by  chemopreventive-acting Discussion 
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NSAIDs. As a working hypothesis it was speculated whether 5-LO displays such a 
target gene for NSAIDs and if Ssi contributes to the regulation of 5-LO on transcrip-
tional level. Therefore, the studies comprised first analysis of a primary effect of Ssi 
on 5-LO gene regulation in the monocytic cell line MM6 after induction of cell differ-
entiation and concomitantly cellular 5-LO synthesis. Cells were treated with Ssi and 
the  obtained  qPCR  data  showed  a  concentration-dependent d ecrease  of  5-LO 
mRNA in differentiated MM6 cells after 72 hrs of incubation with Ssi. This decrease 
did not occur, as expected in control cells (undifferentiated). ß-actin was used as 
housekeeping gene control. Low concentrations (0.3, 1, 2 µM) of Ssi were able to 
suppress 5-LO mRNA formation to amounts half of the control, but higher concentra-
tions led to only 20 % of initial copy numbers. These findings argue for an influence 
of 5-LO m-RNA formation which could be mediated by a regulating element such as 
a transcriptional factor. As refered to in previous sections (1.2.6), the 5-LO promoter 
region consist of five repeated GC-rich sequences, discovered as transcription factor 
binding  region,  where  Sp1,  a  common  transcriptional  regulatory  factor,  can  bind  
[173].  Sp1 regulates basal transcription of NAG-1 gene through certain GC-boxes 
[374]. As Sp1 is known to show cabability to bind on these promoter fragments resid-
ing in the 5-LO promotor and is also required for 5-LO expression in monocytes, a 
possible interplay of Sp1, 5-LO and Ssi could be conceivable. Realtime PCR results 
from the same experimental approach as aforementioned showing a reduced mRNA 
level of Sp1 while treated with Ssi underlined the possible involvement of Sp1 in Ssi-
induced mRNA regulation of 5-LO [175, 179]. More information about Sp1’s involve-
ment in the downregulation of 5-LO mRNA by Ssi was gained in reporter gene assay 
where Sp1 was cotransfected and its promoter activating property was at least partly 
counteracted by increasing concentrations of Ssi. A ChIP assay could underline Sp1 
as a possible binding partner involved in the Ssi-mediated downregulation of 5-LO at 
a concentration of 30 µM Ssi which is physiologically relevant. Recently, p53, a tumor 
suppressor gene, responsible for the induction of NAG-1 which is linked to cell death, 
could be another probable player in the outlined scenario, but this remains to be elu-
cidated [375]. 
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Concluding remarks 
A shift in AA metabolism by the use of COX-inhibitors may be a mechanism warran-
ting further consideration for contribution to the prevention of cancer. The reported 
findings support the conclusion that the chemopreventive activity of unselective COX-
inhibitors such as sulindac and its active metabolite Ssi, is mediated by alterated 
gene expression. For example, COX-2 and NAG-1 gene are well documented genes 
involved in cancer preventive activities of COX - inhibitors. The description of the 5-
LO gene as a novel target being downregulated by Ssi may, with the view to 5-LO 
and its target functions in general concerning several types of cancer, demonstrate a 
novel strategy for screening potential anticancer drug candidates. Ssi may stand for a 
novel structure of 5-LO inhibiting compounds additionally showing gene regulatory 
functions and therefore possesses highly beneficial profiles for the use in humans. 
 
5.4  Modulation of 5-lipoxygenase enzyme activity by NO-NSAIDs 
Chemoprevention is a wide spread field and great efforts have been made to gain 
more understanding of the behind lying molecular mechanisms. New drug develop-
ment strategies have been made to produce safer and more efficient drugs, ideally 
combining  two  modes  of  action  or  operating  simultaneously  at  two  targets.  Even 
though NSAIDs are promising cancer chemopreventive agents and long-term use of 
aspirin and other NSAIDs have been shown to reduce the risk of cancer of the colon 
and as well as of other cancers of the breast, prostate, lung and skin, disadvantages 
like  gastrotoxicity  still  persist.  Despite  the  exploration and  knowledge  provided by 
continous research and substantial insights into the mechanism by which NSAIDs 
modulate these events, questions still need to be answered with regard to safety, 
efficacy, optimal treatment regimen and mechanism of action [376]. In search of all 
these matters, discovering NO as a molecule with gastroprotective properties and the 
ability to mimick the effects of PGs, this emerges the rationale for the development of 
NO-releasing NSAIDs. Synergistic effects were suspected from the COX-inhibition on 
the one hand and the gastroprotective effect in terms of ulcerogenicity on the other 
hand. It seemed of major relevance to investigate and to compare possible inhibition 
patterns of compounds and their NO-releasing partners on 5-LO activity and there-
fore maybe to identifiy the molecular mechanism of these drugs. Several NO-NSAIDs 
were currently under investigation such as NO-naproxen, the first agent of this novel Discussion 
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class of drugs named COX-inhibiting nitric oxide donators (CINOD) [75]. NO-asprin 
and NO-sulindac can also be classified into this group of drugs [66]. In search of new 
concepts of 5-LO inhibiton, a third working hypothesis was therefore based on the 
previous results, where Ssi as a conventional NSAID showed the ability to inhibit LT 
biosynthesis  by  direct  interference  with  the  5-LO  enzyme.  It  was  assumed  that 
thereby  NO-NSAIDs  justify  their  chemopreventive  activity  in  certain  tumors.  As 
shown in previous sections, sulindac, a prodrug, did interfere with 5-LO activitiy nei-
ther in cellular systems nor in cell free assays. In the case of NO-sulindac, it was 
suspected that an appropriate inhibition of 5-LO enzyme activity can only take place 
if NO, released from the nitrosylated sulindac, interferes in any mode of action with 
the  protein  structure. E xaminations  with  NO-sulindac  and  NO-naproxen  in  cellular 
systems such as PMNL evoked inhibition of 5-LO only by the NO-derivative, but not 
by the non-nitrosylated parent NSAID. A dose-response curve of NO-sulindac exerts 
the most potent inhibitory profile (IC50 ~ 2 µM) which could be confirmed in studies on 
the recombinant purfied enzyme where NO-sulindac acts even more potent than Ssi. 
The obtained results led to the conclusion that NO may be a key factor involved in LT 
biosynthesis suppression. As NO-NSAIDs were developed, a straightforward mecha-
nism was outlined which involved the release of cytoprotective NO being responsible 
for the decreased mucosal damage in the stomach usually caused by the regularly 
intake of NSAIDs from NO-NSAIDs [63]. This concept is widely discussed in the lit-
erature and NO is appreciated to play a double role being able to protect, but also to 
promote cancer [377]. The question raised whether it is NO that brings the cytopro-
tective and/or anticancer effect. It was thought that NO is being released in the upper 
gastrointestinal tract to elicit its protective properties [378, 379]. The strongest evi-
dence against this hypothesis is found in the fact that NO-aspririn, the most promi-
nent NO-NSAID, passes the stomach without breakdown as the drug was detected in 
the duodenum after intake [72, 73]. Indeed, a possible explanation could be that NO 
reaches the mucosa via the circulation site as it is speculated that NO is cleaved by 
breakdown of the drug when it reached the circulating blood stream  and additionally 
elevated NO levels have been reported after NO-NSAID administration using NO-
flurbiprofen in a rat modell [72, 380]. The obtained inhibition pattern of NO-ASA be-
side the use of ASA as control, which is known to show no interaction with the 5-LO 
pathway, however evoked almost the same picture. Only the NO-derivative was ac-
tive  on  5-LO  enzyme.  Suppression  by  NO-ASA w as  rather  potent  and  substrate-Discussion 
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independent  with  IC50  values  of  ~  30  µM  in  the  cellular  assay  provoking  a  non-
competitive mode of action. A slight increase in the IC50 values (~ 50 µM) was found 
in cell-free assays presuming additional cellular components supporting 5-LO inhibi-
tion by NO-ASA. In literature, mechanistical studies are mostly found about NO-ASA 
proposing effects on MAPK pathway, inhibition of iNOS and inhibition of NF-kB acti-
vation [81-83]. To complete the preliminary data, whole blood studies showed sup-
pression of LT biosynthesis products LTB4 and 5-HETE as well but rather low sup-
pressive potential was observed as all compounds used (NO-sulindac, NO-naproxen, 
NO-ASA) only inhibited 5-LO enzyme activity up to 40 - 50 % residual enzyme activ-
ity.  Extensively  higher  concentrations  were  needed  to  gain  this  inhibition  pattern 
compared to cellular-based and cell-free assays. As an explanantion could serve ei-
ther an insufficient NO-release into the blood stream or that the amount of NO is not 
sufficient to achieve 5-LO inhibition. Probably, these findings are due to the fact that 
released NO is promptly bound by plasma proteins in the circulation blood stream. 
However, a direct intereference with one of the regulating parts of the 5-LO protein 
seems likely for the NO-derivatives NO-ASA, NO-sulindac and NO-naproxen as all 
drugs together show the ability to suppress the purified recombinant 5-LO enzyme. 
As mentioned in the future comments of the result section 4.3, a broad spectra of 
experiments has to be carried out to clarifiy the detailed mechanism underlying the 
interaction of NO-NSAIDs and 5-LO.  
 
Concluding remarks 
The last section should verify, whether a link between the chemopreventive efficacy 
and beneficial gastrointestinal profiles of NO-NSAIDs and 5-LO as a molecular target 
can be built up. NO-NSAIDs such as NO-sulindac, NO-aspirin or NO-naproxen were 
able to inhibit 5-LO enzyme activity, whereas NO-sulindac showed the most potent 
inhibition pattern regardless whether tests were performed in cellular assays or cell-
free  assays.  Only  in  human  whole  blood  systems  all  compounds  showed  almost 
equipotent inhibitory potency on 5-LO. It is still a matter of debate whether the NO 
molecule is required for the chemopreventive, antitumorigenic and gastroprotective 
properties which is ascribed to NO-NSAIDS. The present results link NO-NSAIDs to 
the 5-LO pathway and could provide evidence for 5-LO as a novel target of NO-
NSAIDs.   Summary   
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6  SUMMARY 
During the last years, chemopreventive activity of NSAIDs against a great variety of 
tumors was highly investigated. COX-2 seemingly plays a major part in tumorigensis 
and tumor development, underlined by several studies in animals and humans. At 
first, NSAIDs were thought to accomplish chemoprevention by inhibition of COX-2 as 
their so far known mode of action comprises unselective inhbition of COX-enzymes. 
However, further studies revealed COX-independent mechanisms. Sulindac is known 
as a well established drug used to treat inflammation and pain exerting the most 
prominent chemopreventive action, mainly in colorectal cancer or FAP and can be 
classified into the group of NSAIDs inhibting both COX-isoformes. As interference 
with the AA metabolism is evident, it was speculated whether Ssi has targets other 
than COX-enzymes providing evidence and explanation of its beneficial side effect 
profile and its ability to reduce tumor growth. 5-LO is another master enzyme in the 
AA cascade which produces inflammatory lipid mediators (LTs) upon stimulation in 
inflamed tissues. The present work should answer the question if Ssi targets the 5-
LO pathway and should examine the molecular mechanisms behind Ssi-mediated 5-
LO inhibiton. As COX-2  is upregulated during carcinogenesis and is inhibited by Ssi, 
further investigations should show regulatory effects of Ssi on 5-LO gene expression 
in MM6-cells and whether Sp1 as a common transcriptional factor is involved in such 
a regulation. As the use of NO-NSAIDs seem to be a promising strategy concerning 
their chemopreventive and gastroprotective effects compared to the parent NSAIDs, 
a possible interaction with the 5-LO pathway as a second, potent target should addi-
tionally be elucidated. In the first section it was demonstrated that the pharmacologi-
cally active metabolite of sulindac, Ssi, targets 5-LO. Ssi inhibited 5-LO in ionophore 
A23187- and LPS/fMLP-stimulated human PMNL (IC50 ≈ 8 -10 µM). Importantly, Ssi 
efficiently suppressed 5-LO in human whole blood at clinically relevant plasma levels 
(IC50 = 18.7 µM). Ssi was 5-LO-selective as no inhibition of related lipoxygenases 
(12-LO, 15-LO) was observed. The sulindac prodrug and the other metabolite, sulin-
dac sulfone, failed to inhibit 5-LO. Mechanistic analysis demonstrated that Ssi directly 
suppresses 5-LO with an IC50 of 20 µM. Together, these findings may provide a novel 
molecular basis to explain the COX-independent pharmacological effects of sulindac 
under therapy. In the second part of the work dealing with the analysis of Ssi’s inhibi-
tory mechanism on 5-LO it was presented that Ssi shows a lack of potency in cellular 
systems where membrane constituents are existent. The addition of microsomal frac-Summary 
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tions of PMNLto crude 5-LO enzyme were able to recover enzyme activity to ~ 100 
%. Selectively 5-LO activity stimulating lipids like PC, participating in 5-LO membrane 
interactions  within  the  regulatory  C2-like  domain  of  5-LO,  counteracted  the  Ssi-
mediated inhibition on 5-LO-wt in a concentration-dependent manner. Lastly, a pro-
tein  mutant  lacking three  trp resudies  essential  for  linking  the  enzyme  to  nuclear 
membranes and deploying catalytic activity was not influenced by Ssi and shows en-
zyme activity in a cell-free assay. Ssi displays the first 5-LO inhibitor on the market 
interacting with the C2-like domain of the enzyme and therfore can stand for a novel 
lead structure of 5-LO inhibitors. An influence on 5-LO gene expression by Ssi could 
be detected in differentiated MM6-cells, described in the results chapter 3 (4.3). Ssi 
downregulated the 5-LO mRNA level after 72 hrs of incubation in differentiated MM6-
cells to ~ 20 % of output control at concentrations of 10 µM. Concomitantly, mRNA 
levels of Sp1 were suppressed. Reporter gene studies revealed Sp1 most probably 
as a regulating agent involved in the Ssi-mediated 5-LO mRNA downregulation as 
co-transfection of increasing amounts of Sp1 could abrogate the effect. A ChIP assay 
could identify Sp1 as a critical transcriptional factor as Sp1 binding to the 5-LO pro-
moter decreased in presence of Ssi. Lastly, three NO-NSADIs (NO-sulindac, NO-
naproxen, NO-aspirin) were tested for the ability of 5-LO product inhibition. In intact 
PMNL, all compounds showed effective inhibition of 5-LO activity and NO-sulindac 
was most potent with an IC50 value of ~ 3 µM. NO-ASA inhibited 5-LO with IC50 val-
ues of ~ 30 µM and showed a non-competitive mode of action in cell-based assays. 
On  human r ecombinant 5 -LO  all  compounds  again  showed  inhibitory  potency 
whereas NO-sulindac again suppressed LT biosynthesis with an IC50 vaue compara-
ble to intact cellular systems. Unfortunately, all inhibitors showed a loss of potency 
when tested for inhibition of 5-LO product synthesis in human whole blood as higher 
concentrations up to 100 µM were needed to reach at least 55 % enzyme inhibition. 
However, this strategy of 5-LO inhibition seems promising and needs further experi-
mental approaches to gain more insight into the mechanism of 5-LO inhibition by NO-
NSAIDs.  Zusammenfassung   
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7  ZUSAMMENFASSUNG 
Die chemopräventiven Wirkungen von nichtsteroidalen Antirhheumatika (NSAR)  er-
fuhren in den letzten Jahren reges Interesse und waren Gegenstand einer Vielzahl 
von Studien. In diversen Untersuchungen in Tiermodellen, aber auch in Humanstu-
dien konnte gezeigt werden, dass das Enzym Cyclooxigenase-2 (COX-2) eine we-
sentliche  Rolle  bei  der  Tumorentstehung  sowie  in  der  Tumorentwicklung  spielte. 
Durch Umsetzen des natürlichen Substrates Arachidonsäure (AA) entstehen im so-
genannten Eicosanoid-Stoffwechsel die Prostaglandine (PG). In Tumorgeweben, vor 
allem bei kolorektalen Karzinomerkrankungen, sind eine Überexpression der COX-
Enzyme  sowie  dementsprechend  eine  erhöhte  PG-Synthese  zu  beobachten.  Die 
durch enzymatische Aktivität der COX-2 synthetisierten PG stellen Trigger der tumor-
assoziierten Angiogenese dar, wirken modulatorisch auf das Immunsystem und regu-
lieren Zellmigration und Zellinvasion. Die COX-2 stellte somit ein vielversprechendes 
Targetmolekül  für  die  Krebsforschung  dar.  Da  NSAR  als  primär  bekannten  Wir-
kungsmechanismus  über  eine  unselektive  Hemmung  beider  Isoformen  der  COX-
Enzyme  wirken,  erklärte  man  sich  auch  die  chemopräventiven  Wirkungen  dieser 
Substanzen über die Inhibition der COX-2-Aktivität. Jedoch lieferten viele Untersu-
chungen auch Hinweise auf COX-unabhängige Mechanismen. Sulindac, einzuord-
nen in die Gruppe der NSAR, stellt einen schon lange am Mark befindlichen und un-
tersuchten  Wirkstoff  dar,  der  zur  Behandlung  von  Schmerzen  und  entzündlichen 
Erkrankungen eingesetzt wird. Der bisher bekannte Wirkmechanismus des aktiven 
Metaboliten von Sulindac, Sulindac-Sulfid (Ssi), ist die unselektive COX-Hemmung. 
Unter  den  NSAR  stellt  Sulindac  den  potentesten  Vertreter  der  chemopräventiven 
Wirkstoffe dar und wird hier vor allem zur Behandlung von familiärer adenomatöser 
Polyposis (FAP) und bei kolorektalen Karzinomerkrankungen eingesetzt. Da NSAR 
respektive Sulindac über die COX-Hemmung in den AA-Stoffwechsel eingreifen, war 
eine naheliegende Vermutung, dass Ssi auch andere Enzyme in diesem Stoffwech-
selweg beeinflusst. Dies könnte das nebenwirkungsarme Profil bezüglich gastroin-
testinaler Schädigungen sowie auch die chemopräventiven Wirkungen erklären. Die 
5-Lipoxygenase (5-LO) stellt ein weiteres Hauptenzym im AA-Metabolismus dar und 
synthetisiert proinflammatorische Lipidmediatoren, die sogenannten Leukotriene (LT) 
nach erfolgter Stimulation der Zelle bei Entzündung. Die vorliegende Arbeite sollte 
nun  untersuchen,  ob  Ssi  mit  dem  5-LO-Signalweg  interagiert  und  möglicherweise 
einen Einfluss auf die LT-Biosynthese hat. Des Weiteren sollten mögliche zugrunde-Zusammenfassung 
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liegende molekulare Mechanismen aufgeklärt werden. Da die COX-2 in Tumorgewe-
ben hochreguliert ist und durch NSAR eine Regulation der Expression erzielt werden 
kann, sollte anschliessend auch ein etwaiger Einfluss von Ssi auf die Expression des  
5-LO Enzyms untersucht werden. Es stelle sich die Frage, ob Sp1, ein bekannter 
Transkriptionsfaktor, bei einer etwaigen Regulation im zellulären System in Mono-
Mac-6 (MM6) Zellen beteiligt sein könnte. Eine neue, vielversprechende Strategie im 
Hinblick auf gastroprotektive als auch chemopräventive Eigenschaften stellt die Ent-
wicklung der sogenannten Nitro-NSAR dar (NO-NSAR), welche im Vergleich zu den 
herkömmlichen NSAR einen NO-freisetzende Substituenten und die Struktur eines 
NSAR  kombinieren,  verbunden  durch  ein  Spacermolekül.  Da  aufgrund  der  PG-
Hemmung  deren  zytoprotektive  Eigenschaften  wegfallen, war  es  naheliegend,  die 
vorteilhaften PG-Wirkungen durch im Gastrointestinaltrakt lokal freigesetztes NO zu 
imitieren. NO-NSAR zeigten im präklinischen Modell der Zellkultur und auch im Tier-
modell  chemopräventive  Eigenschaften  bei  verschiedenen  Krebsarten.  Vorliegend 
sollte hier evaluiert werden, ob verschiedene NO-NSAR die 5-LO als Zielstruktur ad-
ressieren.  
Im ersten Teil der Arbeit konnte gezeigt werden, dass das NSAR Ssi als ein potenter 
Hemmstoff der 5-LO agiert. Es stellte sich heraus, dass nur Ssi als der pharmakolo-
gisch wirksame Metabolit von Sulindac einen Einfluss auf die LT-Biosynthese auf-
wies, nicht jedoch das Prodrug Sulindac und der Metabolit Sulindac-Sulfon. Weitere 
getestete Verbindungen, die der Klasse der NSAR zuzuordnen sind (Diclofenac und 
Indomethacin)  hatten  keine  inhibitorische  Wirkung  auf  die  Aktivität  der  5-LO.  Die 
Hemmwirkung von Ssi auf die 5-LO wurde werder durch die Abwesenheit noch durch 
steigende Mengen an natürlichem Substrat des Enzyms, der AA, in Konzentrationen 
von 2µM und 20µM verringert. Des Weiteren zeigte sich in der Produktanalyse frt 15-
Lipoxygenase (15-LO), die auch in Granulozyten vorkommt, eine Selektivität von Ssi 
für  5-LO.  Die  in  Plättchen  vorkommende  12-Lipoxygenase  (12-LO)  wurde  in  ihrer 
Aktivität eher durch eine Behandlung der Zellen mit Ssi stimuliert, während Ssi kei-
nerlei Einfluss auf die Produktbildung der 15-Lipoxygenase (15-LO) aus Granulozy-
ten hatte. Ssi hemmte die 5-LO in sowohl mit Calcium-Ionophor (A23187) als auch 
mit LPS/fMLP (physiologischer Stimulus) stimulierten humanen Leukozyten (IC50 8-
10µM). Weitere Stimuli der 5-LO-Produktbildung, die zum einen osmotischen Stress 
der Leukozyten hervorrufen (Natriumchlorid) und zum anderen chemischen Stress 
der Zellen verursachen (Natriumarsenit) führten nicht zu signifikanten Unterschieden Zusammenfassung 
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der Inhibitorpotenz von Ssi. Auf Proteinebene konnten mechanistische Studien eine 
potente Hemmung der 5-LO-Aktivität nach Inkubation mit Ssi und anschliessender 
Stimulation des humanen, rekombinanten 5-LO-Proteins nachweisen (IC50 = 20µM). 
Hier zeigte sich wieder die bereits im zellulären System beschrieben Wirkung des 
aktiven Metaboliten Ssi an 5-LO, Sulindac und Sulindac-Sulfon und auch Indometha-
cin führten nicht zu einer Inhibition der 5-LO-Produktbildung. In Versuchen, die die 
subzelluläre Lokalisation des 5-LO-Proteins untersuchen sollten, stellt sich heraus, 
dass  Ssi  eine  Hemmung  der  Translokation  des  5-LO-Proteins  zur  Kernmembran 
vermittelt. Die Schlussfolgerung, dass dies in einer Hemmung des 5-Lipoxygenase-
aktivierenden-Proteins  (FLAP)  durch  Ssi  begründet  liegt,  konnte  jedoch  in  einem 
Kompetitionsassay  mit  einem  bekannten  FLAP-Inhibitor  (MK-886)  nicht  bestätigt 
werden. Weiterhin supprimierte Ssi wirksam die 5-LO-Produktbildung im humanen 
Vollblutversuch in klinisch relevanten Konzentrationen (IC50 = 18.7µM) unabhängig 
vom verwendeten Stimulus (A23187 oder LPS/fMLP). Auch in diesem  Testsystem 
erwies  sich  Ssi  als  wirksame  5-LO-inhibitorische  Substanz  während  Sulindac  und 
Sulindac sulfone keine suppressive Wirkung auf die 5-LO-Aktivität zeigten. 
Im zweiten Teil der vorliegenden Arbeit, der sich mit der mechanistischen Aufklärung 
der Hemmung von Ssi an 5-LO befasste, wurde ein Verlust der Inhibitorpotenz in 
Abhängigkeit von der zellulären Umgebung festgestellt. In intakten Zellen und am 
Reinenzym erreichte Ssi IC50-Werte von 15-25µM während in Zellhomogenaten und 
dem 100.000xg Überstand (S100) IC50-Werte von 30-100µM vorlagen. Waren Memb-
ranbestandteile  im  Reaktionsansatz  vorhanden,  so  wie  etwa  in  Zellhomogenaten,  
verlor Ssi deutlich an inhibitorischer Potenz. Die Vermutung, dass die zelluläre Zu-
sammensetzung einen Einfluss auf den Redoxzustand der 5-LO und somit auch für 
eine Hemmung verantwortlich ist, konnte nicht bestätigt werden. Zunächst wurden 
zelluläre Signalwege untersucht, auf die der Arzneistoff Ssi Einfluss haben könnte. 
Daher wurde ein potentieller Einfluss von Ssi auf die Phospholipase D (PLD) unter-
sucht. Es zeigte sich jedoch keine durch Ssi verursachte Enzymhemmung. Da Calci-
um ein starker Stimulus für eine Aktivierung des 5-LO-Enzyms darstellt, wurde als 
nächstes die Freisetzung von Calcium in Leukozyten evaluiert, jedoch zeigte sich 
hier auch keine Veränderung durch Ssi im Vergleich zur unbehandelten Kontrolle. Im 
zellulären Kontext wurde eine Phosphorylierung und nachgeschaltet eine Aktivierung 
der  5-LO  durch  die extracellular-regulated-kinase  (ERK  1/2), eine  Kinase aus  der 
mitogen-activated-protein-kinase  (MAPK) Familie, beschrieben. Eine Hemmung von Zusammenfassung 
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ERK 1/2 durch Ssi wurde im Western Blot-Experiment jedoch nicht beobachtet. Da-
her fokusierten sich die folgenden Versuche auf Interaktionen von Ssi mit dem aufge-
reinigtem 5-LO-Enzym. Die Zugabe von aus PMNL gewonnen mikrosomalen Frakti-
onen,  die  membranäre  Bestandteile  in  der  Zelle  immitieren  sollten,    zu  5-LO-
Reinenzym in Gegenwart von Ssi konnte die Enzymaktiviät nahezu wieder auf 100% 
herstellen.  Phospholipide,  die  ebenfalls  Bestandteile  von  Membranen  darstellen, 
vermitteln die für die 5-LO-Aktivität essentielle Membranbindung durch Interaktion mit 
der regulatorischen C2-ähnlichen Domäne des Enzyms.  Insbesondere Phosphati-
dylcholin (PC) ist in der Lage, die 5-LO-Aktivität selektiv zu stimulieren und konnte 
die  Ssi-vermittelte  5-LO-Hemmung  konzentrationsabhängig  aufheben.  Andere 
Phospholipide wie Phosphatidylethanolamin (PE) und Phosphatidylserin (PS) zeigten 
weder einen stimulatorischen Einfluss auf die rekombinante 5-LO noch ließ sich die 
durch Ssi hervorgerufene Enzymhemmung aufheben.  Um die Interaktion von Ssi mit 
der C2-ähnlichen Domäne der 5-LO zu verifizieren, wurde eine 5-LO-Proteinmutante 
generiert, bei der drei Tryptophanreste, die  essentiell für die Membranbindung der 5-
LO sind, gegen Alanin ausgetauscht wurden. Das mutierte Protein wurde von Ssi 
nicht beeinflusst und zeigte unverändert katalytische Aktivität. Dies spricht für eine 
Interaktion  von  Ssi  mit  den  drei  die  Membranbindung  vermittelnden  Tryptophan-
resten. Ssi ist der erste 5-LO-Inhibitor auf dem Markt, der an der C2-ähnlichen Do-
mäne des 5-LO-Enzyms angreift  und stellt daher eine neue Leitstruktur für 5-LO-
Inhibitoren dar, die chemopräventive Eigenschaften und ein verbessertes gastroin-
testinales Profil besitzen. Es lässt sich feststellen, dass die 5-LO-Hemmung durch 
Ssi  einen  neuen  molekularen  Ausgangspunkt  für  die  Erklärung  der  COX-
unabhängigen pharmakologischen Effekten von Ssi in der Therapie bietet. 
Im  dritten  Teil  der  Arbeit  wurde  ein  möglicher  Einfluss  von  Ssi  auf  die  5-LO  Ge-
nexpression untersucht. Es konnte im quantitativen PCR  Versuch eine Regulation 
von Ssi auf die 5-LO mRNA-Menge in MM6-Zellen beobachtet werden. Der Effekt 
trat in differenzierten Monozyten (Differenzierungsdauer 72h mit Calcitriol und trans-
forming-growth-factor-ß (TGF-ß) nach 72h Behandlung mit Ssi auf. Die 5-LO mRNA- 
Menge wurde in differenzierten MM6-Zellen auf ~20% der Kontrolle herunterreguliert. 
Da in der Literatur die Beteiligung des Transkriptionsfaktors Sp1 bei der Herabregu-
lation der COX-Genexpression durch NSAR publiziert wurde, lag die Untersuchung 
der Sp1 Expression nahe. Simultan zur Abnahme der 5-LO mRNA Menge ließ sich 
eine Abnahme der Sp1 mRNA Menge feststellen. Daher sollte anschließend festge-Zusammenfassung 
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stellt werden, ob sich der durch Ssi-vermittelte Effekt auf die 5-LO-mRNA durch Ü-
berexpression  von  Sp1  supprimieren  lässt. In  der  Reportergenanalyse  konnte  ge-
zeigt werden, dass Sp1 bei der Ssi-vermittelte Herabregulation der 5-LO mRNA eine 
Rolle zu spielen scheint, da steigende Mengen an Sp1 den durch Ssi hervorgerufe-
nen  Effekt teilweise aufheben konnten. Ein Chromatin-Immunopräzipitationsversuch 
(ChIP-Versuch) lieferte dann bestätigende Ergebnisse, da in Anwesenheit von Ssi in 
der höchsten eingesetzten Konzentration von 30µM nahezu keine Bindung mehr von 
Sp1  an  5-LO  detektierbar  war.  Ssi  zeigt  offenbar  auch  auf  der  Ebene  der  Ge-
nexpression regulatorische Effekte am 5-LO Enzym.  
Als letztes beschäftigte sich die vorliegende Arbeit mit der Testung von NO-NSAR 
(NO-Sulindac,  NO-Naproxen,  NO-Aspirin)  im  Hinblick  auf  eine  eventuelle  5-LO-
Hemmung, da die chemopräventiven Wirkungen dieser Verbindungen möglicherwei-
se auch über eine Hemmung des 5-LO-Proteins erklärbar sind. In intakten Granulo-
zyten zeigten alle Verbindungen effektive Inhibition der LT-Biosynthese wobei NO-
Sulindac am potentesten agierte (IC50 ~3µM). Die entsprechenden analogen Verbin-
dungen ohne NO-Gruppe wurden als Kontrollsubstanzen ebenfalls getestet und hat-
ten keinen Einfluss auf die 5-LO-Aktivität. NO-Aspirin hemmte mit einem IC50-Wert 
von ~30µM. Weiterhin wurde das Verhalten von NO-Asprin in Anwesenheit und Ab-
wesenheit des natürlichen Substrates AA untersucht. Die resultierenden ähnlichen 
Dosis-Wirkungskurven mit oder ohne AA ließen auf ein nicht-kompetitives Verhalten 
von NO-Aspirin im zellulären Testsystem schliessen. Versuche mit rekombinantem, 
aufgereinigtem  5-LO-Enzym  ergaben  wiederum  eine  Hemmung  der  5-LO-
Produktbildung durch alle drei Verbindungen.  NO-Sulindac unterdrückte am  poten-
testen  die 5-LO-Produktbildung. Daraufhin wurden Tests im humanen Vollblutsys-
tem durchgeführt. Es zeigte sich in diesem Testsystem jedoch eine deutlich schlech-
tere  Inhibition  bezüglich  der  Produktbildung  von  Leukotrien  B4  (LTB4)  und  5-
Hydroxyeicosatetraensäure (5-HETE) durch NO-NSAR. Es waren höhere Konzentra-
tion der Substanzen im Vergleich zu den vorherigen Experimenten nötig (100µM), 
um  mindestens  55%  Enzymhemmung  hervorzurufen.  Die  Strategie  der  5-LO-
Hemmung durch NO-NSAR ist von pharmakologischer Relevanz und es bedarf wei-
terer Untersuchungen, um den genauen molekularen Mechanismus der Hemmung 
der 5-LO durch NO-NSAR aufzuklären.   
 References 
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